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Cardiovascular disease (CVD) is one of the leading causes of deaths and is responsible 
for approximately 30% of all deaths worldwide [1]. CVD is the term used to encompass a 
wide range of diseases of the cardiovascular system, such as coronary heart disease (CHD), 
stroke and heart failure. Tobacco use, physical activity and diet are major modifiable risk 
factors for CVD [2]. For example, dietary components such as cocoa and tea are associated 
with a lower risk of CVD. A meta-analysis of cohort studies showed that cocoa/chocolate 
intake was associated with a 37% lower risk of CVD and 29% lower risk of stroke [3]. Meta-
analyses of tea showed that those who drank 1-3 cups of green tea per day had a 36% 
lower relative risk of stroke [4], and that those who drank 3 cups of green or black tea per 
day had a 21% lower risk of stroke [5]. An increase in green tea consumption of 1 cup/d 
was also associated with a 10% lower risk of CHD [6].
Pathophysiology of Cardiovascular Disease
Atherosclerosis is a chronic disorder characterized by the accumulation of lipids and 
fibrous elements in large arteries and is one of the main underlying causes of CVD [7]. The 
endothelium, a thin layer of cells that line the interior of blood vessels in the circulatory 
system, plays an important role in the development of atherosclerosis [7]. 
Hyperlipidaemia, smoking and hypertension, classic risk factors for atherosclerosis, lead 
to an increase in oxidised products of lipoproteins such as LDL, and angiotensin II [8]. This 
stimulates endothelial cells to produce inflammatory cytokines such as TNF-α, C-reactive 
protein (CRP), and interleukins (IL-1β, IL-6, and IL-8). In response to these cytokines, 
adhesion molecules such as soluble endothelial selectin (sE-selectin), soluble vascular cell 
adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and 
von Willebrand factor (vWf) are synthesized by endothelial cells and induce adhesion of 
leukocytes to the endothelium. After adhesion, monocyte chemoattractant protein-1 (MCP-
1) induces the transendothelial migration of monocytes into the intima [9]. Once in the 
intima, monocytes may differentiate into macrophages and scavenge oxidized LDL. This 
leads to the formation of foam cells, resulting in chronic inflammation and progression 
into fatty streaks and fibrous plaques, which in turn leads to atherosclerosis. Studies have 
shown that inflammatory cytokines (e.g. CRP, TNF-α, and IL-6) and adhesion molecules (e.g. 
sVCAM-1, sICAM-1, and sE-selectin) are predictors of CVD risk [10-12]. 
Chronic inflammation is not only heavily involved in the development of atherosclerosis, 
but is also linked to the development of insulin resistance [13-15]. It is suggested, for 
example, that cytokines such as TNF-α may induce insulin resistance [16]. Insulin resistance 
is associated with an increased risk of type II diabetes mellitus and atherosclerosis [17], as 
well as CVD [18, 19].
Inflammatory processes and insulin resistance play a role in maintaining normal endothelial 
and vascular function. By controlling the release of vasoactive compounds such as nitric 
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oxide (a vasodilator) and endothelin-1 (a vasoconstrictor), the endothelium helps to control 
vascular tone and normal endothelial function. An imbalance in vasoactive compounds 
can lead to a deterioration in the flexibility of the vascular wall, causing a progressive 
increase in blood pressure. As such, endothelial dysfunction is positively associated with 
hypertension [20]. A widely used measure of endothelial function is flow- mediated dilation 
(FMD), which measures the change in arterial diameter in response to reactive hyperaemia 
[21]. Prospective cohort studies showed that every 1% increase in FMD is associated with 
an 8-13% lower risk of future cardiovascular events [22, 23]. Likewise, the risk of CVD 
mortality doubles with every 20 mm Hg increase in systolic blood pressure [24].
Cardiometabolic health encompasses the underlying processes involved in developing 
type II diabetes and CVD [25, 26]. Endothelial dysfunction, inflammation, insulin resistance 
and hypertension are all major determinants of cardiometabolic health [22, 23, 27]. 
There is evidence that cocoa and tea protect against CVD by positively influencing these 
cardiometabolic risk factors [28-32].
Cocoa, Tea and Cardiometabolic Health
Interest in the cardioprotective effects of cocoa stems, in part, from observations of an 
ecological study carried out in Central America. The Kuna Indians who live on the San Blas 
Islands, off the coast of Panama, have low blood pressure which does not rise with age [33]. 
Interestingly, the Kuna Indians who migrate to mainland Panama do see an age-dependent 
increase in blood pressure. This excludes the possibility that Kuna Indians are genetically 
protected against hypertension and suggests that the protective factor is local to the island 
environment, for example the diet. The most striking difference in diet between the two 
populations is what they drink. On the islands, there is little drinking water and the supply 
from the mainland is unpredictable. For this reason, the Kuna Islanders consume up to 5 
cups per day of a raw cocoa drink whereas the mainland Kuna Indians consume only 0.5 
cups per day [34]. 
The effect of cocoa on blood pressure has been demonstrated since then in a number of 
randomised, placebo-controlled, clinical trials (RCTs). A meta-analysis of these cocoa RCTs 
showed that cocoa consumption reduced systolic blood pressure (SBP) by 3.2 mmHg and 
diastolic blood pressure (DBP) by 2.0 mmHg [35]. 
RCTs have also investigated the effects of cocoa on other markers of cardiometabolic 
health. A meta-analysis by Hooper et al. showed that cocoa consumption improved FMD 
chronically (2-18 weeks) by 1.3%, as well as acutely (2 hours) by 3.2% [28]. Based on this 
evidence, the European Food Safety Authority (EFSA) approved a health claim that cocoa 
flavan-3-ols help to maintain normal endothelial function [36]. In the meta-analysis of 
Hooper et al, chronic cocoa consumption was also related to improvements in insulin 
resistance [28]. 
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Similar to cocoa, results from RCTs also showed that chronic tea consumption (median 
daily intake of 500 mL/d) improved FMD by 2.6% [31]. Likewise, green tea or green tea 
extracts reduced SBP/DBP by 2.1/1.7 mmHg in healthy subjects [37], and improved insulin 
resistance in obese type II diabetes patients [29]. 
There is some evidence from RCTs that cocoa and tea can favourably influence biomarkers 
of endothelial function and inflammation, however, studies are still limited and  results are 
conflicting. For example, consuming a cocoa beverage decreased plasma levels of sVCAM-1, 
but did not change sICAM-1 [38]. In contrast, another cocoa study found no change in 
sVCAM-1, but found a decrease in sICAM-1 [39]. Other biomarkers of endothelial function 
changed after cocoa consumption – NO increased [40, 41], and endothelin-1 production 
decreased [42]. To our knowledge, inflammation markers have only been studied in one 
cocoa study, which did not find an effect on IL-6 or CRP [39]. Black tea had no effect on 
E-selectin, P-selectin, sICAM-1 and sVCAM-1 [43], as well as CRP, IL-1β, IL-6, and TNF-α [44]. 
Other studies did show, however, that chronic tea consumption reduced the levels of MCP-
1 and CRP [30, 32].   
Flavonoids in Cocoa and Tea 
Cocoa and tea are both rich sources of flavonoids. Flavonoids are a group of secondary 
plant metabolites that belong to the larger group of polyphenolic compounds (Figure 
1). The first research into flavonoids began in the 1930’s when Szent-Gyӧrgyi reported 
a substance in citrus fruits that was thought to influence the permeability of capillaries, 
and called it vitamin P [45]. Later on, this substance proved to be a mixture of flavonoids 
[46]. No deficiency disease was ever linked to vitamin P, and hence it lost its vitamin 
status. Nowadays, over 4000 different flavonoids have been identified, and based on their 
chemical structure they can be divided into 6 subclasses; flavan-3-ols, flavonols, flava-
nones, flavones, isoflavones and anthocyanidins. As shown in Figure 2, flavonoids are 
characterised by two benzene rings (A and B rings) that are linked by a heterocyclic pyran 
ring (C ring). Differences in saturation and oxidation states of the C ring and the position of 
the B ring determine the subclass.
Flavonoids can be found in a wide range of plant-based foods, including cocoa, tea, apples, 
citrus fruits, red wine, berries and legumes (Figure 1). The average intake of all flavonoids 
together, in a French population, was approximately 500 mg/d [47]. Tea is the major dietary 
source of monomeric flavan-3-ols as well as flavonols. In the Netherlands, tea contributes 
more than 65% of monomeric flavan-3-ol intake as well as 50% of flavonol intake [48, 49]. 
Of the flavonols in tea, quercetin (Figure 2) is the most abundant – approximately 50% of 
the flavonol content of black tea is from quercetin [50]. 
Cocoa is a rich source of flavan-3-ols and contains both monomeric and oligomeric flavan-
3-ols. Because oligomeric flavan-3-ols have a much lower bioavailability than monomeric 
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flavan-3-ols [51], they are not thought to contribute directly to the cardioprotective effects 
of cocoa. Of the monomeric flavan-3-ols in cocoa, epicatechin (Figure 2) is by far the most 
abundant. A bar of 100 g dark chocolate (54% cocoa) provides 33 mg of epicatechin – more 
than twice the mean daily intake in the Netherlands [48]. Interestingly, epicatechin is also a 
major monomeric flavan-3-ol in tea [52], and tea is its major dietary source [48].
Epicatechin is the major monomeric flavan-3-ol in cocoa, and tea is not only the major 
dietary source of epicatechin, but also the flavonol quercetin (Figure 3). For this reason, 
we highlighted epicatechin and quercetin as two dietary flavonoids which could mediate 
the cardioprotective effects of cocoa and tea. Evidence of the effects of epicatechin and 
quercetin on CVD incidence, as well as markers of CVD risk, is limited. Hence, it remains 
unclear if, and how, the dietary flavonoids epicatechin and quercetin protect against CVD. 
Epicatechin, Quercetin and Cardiovascular Disease
Cohort Studies on Cardiovascular Disease
Associations between the intake of flavonoid subclasses and CVD have been investigated. 
McCullough et al. showed that the highest quintile of monomeric flavan-3-ol intake was 
significantly associated with a 17% lower risk of CVD mortality in 98,469 American men 
and women [53]. Likewise, in the Zutphen Elderly Study, a higher intake of monomeric 
flavan-3-ols was associated with a 51% lower risk of CHD mortality in 805 elderly Dutch 
Examples Quercetin
Kaempferol
Proantho-
cyanidins
Epicatechin
Hesperetin
Naringenin
Daidzein
Gensitein
Delphinidin
Malvidin
Apigenin
Luteolin
Main 
dietary 
Sources
Tea
Apples
Onion
Tea
Apples
Cocoa
Grapefruit
Orange
Soy
Legumes
Blackberry
Blackcurrant
Chicory
Artichoke
Olive
FIGURE 1. Categorisation of polyphenol subclasses, with examples and main dietary sources of all 
flavonoid subclasses.
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men [54]. Other studies, however, showed no significant association. In the European 
Prospective Investigation into Cancer and Nutrition, monomeric flavan-3-ol intake was 
not significantly associated with CVD mortality in 40,622 Spanish [55], or 24,885 British 
men and women [56]. Likewise, flavan-3-ol intake was not significantly associated with 
CVD mortality or ischaemic stroke in 1,950 Finnish men [57], or with CVD, CHD or stroke 
mortality in 34,489 post-menopausal women [58]. For flavonols, McCullough et al. showed 
that the highest quintile of intake was associated with a 16% lower risk of CVD mortality 
[56]. In the Zutphen Elderly Study, the highest tertile of flavonol intake was also associated 
with a 58% lower risk of CHD mortality [59].
Cohort studies have not assessed the association between epicatechin intake and CVD 
mortality. A number of cohort studies have, however, investigated the association between 
quercetin and CVD mortality. One study reported that a higher quercetin intake was 
significantly associated with a 12% lower risk of CHD mortality in 10,054 Finnish men and 
women [60]. Other cohort studies, however, reported no significant association between 
FIGURE 2. Structures of flavonoids. i) Flavonoid skeleton, ii) (-)-epicatechin, iii) Quercetin. The various 
R-groups of the flavonoid skeleton can be: H, OH, OCH3 or O-Glycoside. The A and B rings are linked by 
a heterocyclic pyrane ring (C ring). Differences in saturation and oxidation states of the C ring and the 
position of the B ring determine the subclass.
i) ii)
iii)
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quercetin intake and stroke incidence in 9,208 Finnish men and women [61], or with CHD 
mortality in 66,289 women [62], or CHD incidence in 34,789 male health professionals [63].
Randomised-Controlled Trials on Cardiometabolic Health
A  number of trials have investigated the effects of pure quercetin, and to a lesser extent 
epicatechin, on markers of CVD risk. Chronic supplementation of quercetin dihydrate (150 
mg/d) for 8 weeks did not improve endothelial function in 49 healthy male subjects [64]. 
It is important to note that in this study, endothelial function was measured by means 
of reactive hyperemia with finger plethysmography using the Endo-PAT2000 system, 
instead of the more commonly used measure of endothelial function; FMD. An acute study 
showed that pure epicatechin (70 – 140 mg) improved FMD, however, this was only tested 
in a small sample of 6 healthy individuals [41]. This effect could be explained by changes in 
vasoactive compounds as the increase in FMD coincided with an increase in NO. Relatively 
high dosages of pure epicatechin (200 mg) and quercetin (200 mg) supplementation 
augmented NO products and reduced endothelin-1 acutely in 12 healthy men [65]. 
FIGURE 3. Dietary sources of epicatechin and quercetin intake. Mean epicatechin intake = 15.1 mg/d, 
mean quercetin intake = 15.5 mg/d. Based on data from the Zutphen Elderly Study (Chapter 2).
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Three RCTs reported positive effects of pure quercetin supplementation on blood pressure. 
Egert et al. showed that 150 mg/d of pure quercetin for 6 weeks reduced systolic blood 
pressure in 93 overweight/obese men and women [66]. Likewise, Edwards et al. showed 
that 730 mg/d of quercetin for 4 weeks reduced systolic and diastolic blood pressure in 
hypertensive subjects, but not in prehypertensive subjects [67]. Chronic supplementation 
of quercetin dihydrate (150 mg/d) for 8 weeks decreased systolic blood pressure in healthy 
male subjects [64]. Other studies investigated the effects of quercetin supplementation 
on markers of inflammation. Supplementation of quercetin-3-glucoside (1000 mg/d) for 1 
week did not attenuate IL-6 levels after sprint exercise in recreationally active adult men 
[68]. In contrast, supplementation of 4x500 mg of quercetin over a period of 24-hours did 
lower markers of inflammation in sarcoidosis patients [69].
Molecular Mechanisms of Epicatechin and Quercetin
Due to recent developments and reductions in cost, gene expression analyses have 
become more feasible and reliable. It has been suggested that cocoa flavan-3-ols may 
protect against CVD via the inhibition of mitogen-activated protein kinases (MAPKs) and 
transcriptions factors NF-kB and AP-1 [70], as well as activation of the Nrf2 transcription 
factor [71]. 
NF-kB is a transcription factor involved in normal cell function and helps regulate the 
expression of genes involved in inflammation, innate immunity and cell survival [72]. 
Interestingly, NF-κB is mediated by the stimulation of TNF-α and IL-1β. In vitro studies 
showed that cocoa flavan-3-ols modulated the secretion and transcription of IL-1β and 
TNF-α in peripheral blood mononuclear cells (PBMCs) collected from healthy volunteers 
[73, 74]. In an animal study, Morrison et al. showed that pure epicatechin supplementation 
prevented diet-induced activation of aortic NF-κB in ApoE*3-Leiden mice fed an atherogenic 
diet [75]. 
Nrf2 is a transcription factor which protects cells against oxidative stress by maintaining 
active antioxidant pathways [72]. To our knowledge, there is no current evidence of the 
effects of pure flavonoids on Nrf2 activation in humans. Animal studies did, however, show 
that epicatechin increased the activation of Nrf2 and Nrf2 target genes in aortas from rats 
[76], and that the cardioprotective effects of epicatechin were abolished in mice lacking the 
Nrf2 transcriptional factor [77]. The activation of Nrf2 has also been linked to an increased 
PI3K/Akt activity [78]. Interestingly, improvements in insulin resistance as a result of cocoa 
flavan-3-ol consumption is thought to be mediated through the induction of the PI3K/Akt 
and ERK1/2 pathways [72]. 
Peripheral blood mononuclear cells are a mixture of T-cells, B-cells and monocytes which 
are relatively easy to collect. Human nutrition studies also show that they are sensitive 
to diet-induced changes in gene expression [79].  Nevertheless, evidence of the effects 
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of flavonoids or flavonoid-rich foods on PBMC gene expression in humans is lacking. 
One RCT did, however, report that acute cocoa consumption significantly decreased NF-
κB activation in PBMCs [80]. To our knowledge, no human study has yet investigated the 
effects of pure flavonoids on gene-expression in PBMCs, specifically looking at endothelial 
function and inflammation.
Thesis Outline
Cohort studies showed a lower risk of CVD mortality with higher intakes of flavonoid-rich 
foods such as cocoa and tea. Results from RCTs showed that cocoa and tea consumption 
improved vascular and endothelial function, as well as insulin resistance. Cocoa and tea 
are complex mixtures of many flavonoids and other substances. The effects of specific 
flavonoids in cocoa and tea on cardiovascular health are, therefore, unclear. A major 
favan-3-ol in cocoa is epicatechin, whereas tea is a major dietary source of epicatechin and 
quercetin. We hypothesize that epicatechin and quercetin are major contributors to the 
cardioprotective effects of cocoa and tea. The aim of this thesis is to gain insight into the 
effects of epicatechin and quercetin on cardiovascular health and disease. 
Since we are not aware of any cohort studies that have studied the association between 
epicatechin intake and CVD mortality, we first carried out an epidemiological analysis. In 
Chapter 2, the association between epicatechin intake and cardiovascular mortality was 
investigated using data from the Zutphen Elderly Study – a cohort of 744 elderly Dutch 
men who were followed for a period of 25 years.
Whether epicatechin and quercetin affect cardiometabolic health was investigated in a 
clinical trial with the pure compounds. First, the effects of pure epicatechin and quercetin-
3-glucoside supplementation on cardiometabolic risk factors were evaluated by means 
of a double-blind, randomised, crossover trial in 37 healthy adults (Chapter 3). To gain 
more mechanistic insight, the effects of epicatechin and quercetin supplementation on 
a comprehensive set of biomarkers of endothelial dysfunction and inflammation were 
evaluated (Chapter 4). In the same study, the effects of pure epicatechin supplementation 
on PBMC gene expression were also studied (Chapter 5). 
In Chapter 6 the contribution of epicatechin to the vascular effects of dark chocolate 
was investigated by comparing the acute effects of dark chocolate and pure epicatechin 
supplementation on vascular function. This was done by means of a, randomised-
controlled trial in 20 healthy adult men. Finally, in Chapter 7 the main findings of this 
thesis are summarised and discussed in a broader context in the general discussion.
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ABSTRACT
Background
Prospective cohort studies showed that the consumption of cocoa and tea was associated 
with a lower risk of cardiovascular diseases (CVD) and cocoa and tea improved cardiovascular 
risk factors in randomised-controlled trials. Cocoa and tea are major dietary sources of the 
flavan-3-ol epicatechin. We investigated the associations of dietary epicatechin intake with 
25-year CVD mortality in elderly Dutch men. 
Design
We used data from the Zutphen Elderly Study, a prospective cohort study of 774 men aged 
65-84 years in 1985. Epicatechin intake was estimated with the cross-check dietary history 
method four times in 15 years. Time-dependent Cox proportional hazards models were 
used to investigate repeated measures of epicatechin intake in relation to 25-year CVD 
mortality.
Results
The mean intake of epicatechin was 15.2 ± 7.7 mg/d, and the major dietary sources were 
tea (51%), apples (28%) and cocoa (7%). During 25 years of follow-up, 329 men died from 
CVD, 148 from coronary heart disease (CHD) and 72 from stroke. The risk of CHD mortality 
was 38% lower in men in the top compared to the bottom tertile of epicatechin intake (HR: 
0.62; 95% CI: 0.39, 0.98). Similar results were found for men with and without prevalent 
CVD at baseline, although they were not statistically significant. Epicatechin intake was 
significantly associated with a 46% lower risk of CVD mortality in men with prevalent CVD 
(HR: 0.54; 95% CI: 0.31, 0.96) but not in men free of CVD. 
Conclusions
We showed for the first time that epicatechin intake was inversely related to CHD mortality 
in elderly men and to CVD mortality in prevalent cases of CVD. More studies are needed 
before conclusions can be drawn. 
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death and is responsible for ap-
proximately 30% of all deaths worldwide [1]. Diet is an important determinant of CVD 
[2]. Consumption of plant-based foods, which are a rich source of flavan-3-ols, was 
inversely associated with CVD risk [3]. Flavan-3-ols are a subclass of flavonoids and cocoa 
(Theobroma cacao), tea (Camellia sinensis) and apples are their major dietary sources.
A meta-analysis of 7 observational studies (n=114 009) showed that the highest level of 
chocolate consumption was associated with a 37% (HR: 0.63; 95% CI: 0.44, 0.90) lower risk 
of CVD and a 29% (HR:0.71; 95% CI:0.52, 0.98) lower risk of stroke [4]. In a meta-analysis of 
14 cohort studies, 3 cups of black or green tea consumption per day was associated with 
a 13% (HR: 0.87; 95% CI: 0.81, 0.94) lower risk of stroke [5]. A meta-analysis of 5 additional 
observational studies (n= 35 808) showed that those who drank 1-3 cups of green tea per 
day had a 36% (HR: 0.64; 95% CI: 0.47, 0.86) lower risk of stroke [6]. Black tea consumption 
was not associated with CHD [7]. 
Clinical trials showed that chocolate/cocoa improved endothelial function, blood pressure 
and insulin resistance [8]. Likewise, meta-analyses of tea trials showed that black or 
green tea consumption improved endothelial function [9] and that black [10] and green 
tea reduced blood pressure [11]. Randomized controlled trials also found that green tea 
reduced fasting glucose and insulin concentrations [12], thus reducing insulin resistance 
- an important risk factor for type 2 diabetes and CVD [13-15]. Indeed, a meta-analysis 
of prospective cohort studies showed that tea consumption was inversely related to the 
incidence of type 2 diabetes [16]. 
Epicatechin is the most abundant flavan-3-ol in cocoa. Black and green tea are also rich 
in epicatechin, and contribute approximately 40% of the epicatechin intake in European 
populations [17]. Recently, we showed that a supplement of pure epicatechin of 100mg/d 
decreased sE-selectin, a marker of endothelial dysfunction [18], and improved insulin 
resistance [19]. These results suggest that epicatechin contributes to the cardioprotective 
effects of chocolate/cocoa. 
Previously we showed in the Zutphen Elderly Study that cocoa intake was inversely associated 
with CVD mortality [20] and that tea intake was inversely related to CHD mortality [21]. In 
the present study, we investigated the associations of repeated measures of epicatechin 
intake with 25-year CVD mortality risk also in the Zutphen Elderly Study. 
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METHODS
Study population
The Zutphen Elderly Study is a prospective cohort study that investigated risk factors of 
chronic diseases in elderly men. It is an extension of the Zutphen Study that started in 1960 
as the Dutch contribution to the Seven Countries Study. In 1985, 555 men of the original 
cohort were still alive and were invited to participate in the Zutphen Elderly Study. A 
random sample of all other men of the same age group also living in Zutphen, but who did 
not take part in the original Zutphen Study, were also invited to participate. This resulted 
in a total target population of 1266 men aged 65-84 years. Of these 1266 men, 939 (74%) 
agreed to participate in the study. After excluding subjects with missing information on 
diet (n=63) and/or risk factors (smoking: n=53; physical activity: n=75), complete data was 
available for 807 men. After excluding prevalent cancer cases (n=63), a study population of 
744 remained (Supplemental Figure 1).
The study was conducted according to the guidelines of the Declaration of Helsinki and 
was approved by the medical ethics committees of the University of Leiden (1985 and 
1990) and of the Netherlands Organisation for Applied Scientific Research (1995 and 2000). 
All participants provided written informed consent. 
Dietary assessment
The habitual diet during the month preceding the interview was assessed between March 
and June in 1985, 1990, 1995 and 2000, using the cross-check dietary history method, 
adapted for the Dutch setting [22]. Participants were interviewed by trained dieticians 
about their usual pattern of food intake during weekdays and weekends, with the person 
usually preparing the meals also present. Based on these patterns, the dieticians asked the 
respondents to indicate the frequency of consumption and serving size of each food using 
a checklist. This information was used to estimate the average weekly food consumption, 
which was checked against the quantities of foods bought each week. The food intake 
data were encoded by the dieticians and converted into energy and nutrient data using 
time-specific food composition tables as well as flavan-3-ol data. The monomeric flavan-
3-ol content of 120 commonly consumed plant foods and beverages were determined by 
Reverse Phase HPLC with ultraviolet and fluorescence detection. For each food product, the 
(-)-epicatechin, (+)-catechin, (-)epigallocatechin, (-)-epicatechin gallate, (-)-epigallocatechin 
gallate and (+)-gallocatechin concentrations were determined [23, 24]. Epicatechin intake 
in 1985 correlated strongly with epicatechin intake in 1990 (r=0.59), in 1995 (r=0.51) and in 
2000 (r=0.46).
 
Risk factors and lifestyle factors
Body Mass Index (BMI) was calculated as weight (kg) divided by height squared (m²), which 
were measured at baseline according to standardised protocols. Blood pressure (BP) was 
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measured at baseline while participants were in the supine position, and was calculated 
as the mean of two measurements. Subjects were considered hypertensive if they had a 
systolic BP greater than 160 mmHg, diastolic BP greater than 95 mmHg or were prescribed 
anti-hypertensive medication. Non-fasting blood samples were collected to determine 
serum total and HDL-cholesterol enzymatically [25, 26]. A medical history was used to 
collect information about diagnosis of myocardial infarction, stroke, heart failure, cancer 
and diabetes, as well as use of aspirin, antihypertensive and lipid-lowering medication at 
baseline and in follow-up surveys. A lifestyle questionnaire was used to collect information 
about social economic status (professionals, non-manual workers, small business owners 
or manual workers) at baseline (1985), and smoking status (former, current or never) at 
repeated intervals (1985, 1990, 1995, 2000). Physical activity was also assessed at repeated 
intervals using a validated questionnaire designed for retired men [27], and was categorised 
according to the average time spent per week doing physical activities with an intensity of 
at least 3 metabolic equivalents (METs). Men were called physically active if they spent at 
least 150 minutes/week on activities of at least moderate intensity.  
Case ascertainment
Participants were followed until death or censored on 30 June 2010. Causes of death 
were determined based on official death certificates, medical histories collected by the 
examining physician or by interviewing relatives of the deceased person, and abstracts of 
medical records from the hospital and general practitioners in Zutphen. Primary causes 
of death were coded according to the ninth edition of the International Classification of 
Diseases by a clinical epidemiologist. ICD-codes 390-459 refer to CVD, codes 410-414 refer 
to CHD and codes 430-438 refer to stroke mortality. Sudden death (ICD-code 798.2) was 
also included as a cause of death for CVD and CHD. After 25 years of follow-up, 32 (4%) of 
the men were still alive. Two subjects were lost to follow-up and censored at the date of 
their last examination. 
Statistical analysis
Baseline characteristics were compared among tertiles of epicatechin intake. One-way 
analysis of variance was used for normally distributed variables, Kruskal-Wallis test for 
skewed variables and Chi-square test for categorical variables. The individual contributions 
of tea, cocoa and apples to total epicatechin intake were calculated. To better represent 
long-term intake, the cumulative mean of epicatechin intake was calculated. Morta- 
lity between 1985 and 1990 was related to epicatechin intake estimated in 1985; mortality 
between 1990 and 1995 was related to the mean epicatechin intake of 1985 and 1990; 
mortality between 1995 and 2000 was related to the mean epicatechin intake of 1985, 
1990, and 1995; and mortality between 2000 and 2010 was related to the mean epicatechin 
intake of 1985, 1990, 1995 and 2000. 
Processed on: 9-6-2016
503508-L-bw-Dower
28
Hazard ratios of cardiovascular mortality were estimated with Cox proportional hazard 
models using the SAS PHREG procedure (SAS 9.3, SAS Institute, North Carolina, USA). 
Proportional hazard assumptions were examined by a log–minus–log plot and the 
assumptions were met. Model 1 was adjusted for age. Model 2 was additionally adjusted 
for prevalence of myocardial infarction, stroke, heart failure or diabetes at baseline as well 
as aspirin use, anti-hypertensive medication, smoking status, alcohol intake and physical 
activity. Model 3 was additionally adjusted for dietary factors that are related to CVD (energy, 
saturated fat, trans fat, n-3 fatty acids, n-6 fatty acids, dietary fibre, potassium, β-carotene 
and coffee). A stratified analysis was conducted for prevalence of CVD. Additionally, hazard 
ratios of CVD mortality for total flavan-3-ol monomer intake as well as intake of catechin, 
epicatechin gallate (ECg) and epigallocatechin gallate (EGCg) were calculated. Associations 
were considered statistically significant if p<0.05. 
RESULTS
The mean age of the study population at baseline was 71.9 ± 5.2 years. In total, 56% of 
the men had a BMI of at least 25kg/m², 31% were current smokers, 25% did not consume 
alcohol and 26% were physically active. At baseline, 22% had a history of CVD and 10% 
had diabetes, 50% were hypertensive, 1% used lipid-lowering medication and 10% aspirin.
The cumulative mean of epicatechin intake was 15.2 ± 7.7 mg/d (range: 0.01-60.6 mg/d). 
The major dietary sources of epicatechin intake were tea (51% = 7.8mg/d), apples (28% 
= 4.3 mg/d ) and cocoa (7% = 1.1 mg/d). Subjects with higher epicatechin intake were 
generally more physically active, less likely to be smokers and drank less coffee (Table 1). 
Total energy intake and intake of protein, carbohydrates, potassium and fibre were also 
higher in subjects with higher epicatechin intake.
The median survival time over the 25-year period was 10.7 years (IQR: 5.9-16.0). Of the 712 
men who died, 329 died from CVD, 148 from CHD and 72 from stroke. CVD mortality was 
inversely associated with epicatechin intake in the age-adjusted model (Table 2, model 1). 
This association was no longer statistically significant after adjustment for lifestyle and 
dietary factors, with a hazard ratio of 0.79 (95% CI: 0.58, 1.08) in the top compared to the 
bottom tertile. CHD mortality was inversely associated with epicatechin intake in all three 
models. The hazard ratio of CHD mortality was 0.62 (95% CI: 0.39, 0.98) in the fully-adjusted 
model (Model 3). Although not statistically significant, similar associations were obtained 
for men with and without prevalent CVD at baseline (Table 3). For men with prevalent CVD, 
epicatechin intake was associated with a 46% lower CVD mortality risk (HR: 0.54; 95% CI: 
0.32, 0.96). 
Besides epicatechin, also the intake of other flavan-3-ol monomers was investigated 
in relation to CVD mortality (Table 4). The mean intake of catechin was 4.2 ± 2.5 mg/d. 
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TABLE 1. Baseline characteristics of 744 men in the Zutphen Elderly Study, by tertile of epicatechin 
intake in 1985.
Characteristics T1 T2 T3 P-value1
Range of epicatechin intake, mg/d < 11.1 11.1 – 18.0 > 18.0
Number 248 248 248
Age, y 71.7 ± 5.2 72.4 ± 5.3 71.7 ± 5.1 0.27
BMI, kg/m² 25.6 ± 3.5 25.8 ± 3.2 25.4 ± 2.8 0.41
Physical activity ≥ 3 METs, n (%)
    0 mins/week
    1-150 mins/week
    > 150 mins/week
152 (61)
42 (17)
54 (22)
131 (53)
49 (20)
68 (27)
109 (44)
66 (27)
73 (29)
0.003
Social economic status, n (%)
    Professionals
    Non-manual workers
    Small business owners
    Manual workers
18 (7)
102 (42)
56 (23)
70 (28)
21 (9)
108 (44)
49 (20)
68 (28)
32 (13)
108 (44)
44 (18)
64 (26)
0.37
Smoking Status, n (%)
     Never                                              
     Former
     Current
34 (14)
114 (46)
100 (40)
35 (14)
132 (53)
81 (33)
44 (18)
158 (64)
46 (19)
<0.001
Alcohol intake, n (%)
g/d
     >0–20 g/d
     >20 g/d
64 (26)
110 (44)
74 (30)
65 (26)
133 (54)
50 (20)
55 (22)
134 (54)
59 (24)
0.07
Systolic blood pressure, mm Hg 151.2 ± 21.5 150.8 ± 21.2 150.4 ± 21.0 0.93
Diastolic blood pressure, mm Hg 84.3 ± 11.1 86.3 ± 11.8 85.7 ± 11.2 0.13
Serum total cholesterol, mmol/L 6.2 ± 1.1 6.2 ± 1.2 6.0 ± 1.0 0.16
Serum total/HDL cholesterol 5.7 ± 1.6 5.8 ± 1.60 5.7 ± 1.6 0.51
Total energy, kcal/d 2010   ± 496 2147 ± 493 2283 ± 505 <0.001
Protein, g/d 79.8 ± 20.6 82.2 ± 16.3 84.9 ± 17.9 0.009
Total carbohydrates, g/d 211.1 ± 59.4 235.3 ± 64.8 258.3 ± 65.2 <0.001
Total fat, g/d 94.1 ± 31.3 97.4 ± 28.8 101.2 ± 29.8 0.03
Saturated fatty acids, g/d 40.9 ± 14.8 42.9 ± 13.9 44.4 ± 14.3 0.03
Trans fat, g/d 10.2 ± 5.8 10.8 ± 6.4 10.8 ± 6.0 0.38
n-3 fatty acids, g/d 1.4 (1.1-1.8) 1.3 (1.1-1.7) 1.4 (1.0-1.7) 0.88
n-6 fatty acids, g/d 10.5 (7.1-16.0) 11.0 (7.4-15.8) 11.7 (8.6-16.9) 0.07
Calcium, mg/d 991 ± 410 1028 ± 376 1043 ± 364 0.31
Potassium, mg/d 3394 ± 911 3520 ± 726 3676 ± 743 <0.001
β-carotene, mg/d 1.4 (1.0-1.9) 1.5 (1.0-2.0) 1.5 (1.1-2.2) 0.11
Dietary fibre, g/d 22.2 ± 6.9 24.2 ± 6.2 28.1 ± 7.0 <0.001
Coffee, ml/d 456 (300-660) 427 (300-560) 346 (215-480) <0.001
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Catechin intake was inversely related to CHD mortality and the strength of the association 
was similar to that of epicatechin. The intake of catechin was strongly correlated with that of 
epicatechin (r=0.80). Therefore the intake of catechin and epicatechin was combined. The 
daily intake of epicatechin gallate (ECg) was 24.4 ± 16.7 mg/d and that of epigallocatechin 
gallate (EGCg) was 18.2 ± 12.4 mg/d. These two flavan-3-ols were very strongly correlated 
(r=0.99). For this reason, the intake of these two flavan-3-ols was also combined and 
related to CVD mortality. The intake of ECg plus EGCg was not significantly associated with 
CVD mortality.
The major dietary sources of epicatechin, tea, apples and cocoa were not associated with 
CHD mortality (data not shown). 
 
Characteristics T1 T2 T3 P-value1
Tea, ml/d 175 (0-297) 425 (271-542) 620 (464-861) <0.001
Cocoa, g/d 0.4 (0-1.9) 0.9 (0-3.0) 2.0 (0-4.8) <0.001
Apple, g/d 8 (0-48) 56 (8-112) 112 (64-148) <0.001
Data are mean ± SD or median (IQR).
1 Test for differences among tertiles of epicatechin intake. Chi-square test for categorical variables, 
one-way analysis of variance for normally distributed variables and Kruskal-Wallis test for skewed 
variables (n-3 fatty acids, n-6 fatty acids, β-carotene, coffee tea, cocoa and apple intake).
Abbreviations: BMI: body mass index; HDL: high density lipoprotein.
TABLE 1. Continued
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TABLE 2. Tertiles of epicatechin intake and 25-year cardiovascular mortality, in 744 elderly Dutch men 
free of cancer at baseline.
Tertiles of Epicatechin Intake (mg/d)
T1 T2 T3
Number 227 266 251
Median survival time, y 1 8.8 (5.1-13.7) 11.8 (6.3-16.1) 11.9 (6.5-22.9)
Median epicatechin intake, mg/d 1 7.5 (5.1-9.4) 14.5 (12.5-15.9) 21.9 (19.5-25.6)
CVD
Cases 106 116 107
Model 1 1.00 0.78 (0.60, 1.02)2 0.72 (0.55, 0.95)
Model 2 1.00 0.88 (0.67, 1.15) 0.75 (0.56, 0.99)
Model 3 1.00 0.90 (0.68, 1.19) 0.79 (0.58, 1.08)
CHD
Cases 47 57 44
Model 1 1.00 0.76 (0.52, 1.12) 0.59 (0.39, 0.89)
Model 2 1.00 0.81 (0.55, 1.20) 0.57 (0.37, 0.87)
Model 3 1.00 0.85 (0.57, 1.27) 0.62 (0.39, 0.98)
Stroke
Cases 25 23 24
Model 1 1.00 0.81 (0.45, 1.46) 0.88 (0.49, 1.58)
Model 2 1.00 0.92 (0.50, 1.67) 0.93 (0.51, 1.70)
Model 3 1.00 0.81 (0.43, 1.51) 0.78 (0.40, 1.53)
1 Values are median (IQR).
2 Values are hazard ratios with 95% confidence intervals, obtained by Cox proportional hazard analysis, 
using the lower tertile as the reference (all such values).
Model 1: Adjusted for age 
Model 2: Adjusted for model 1 plus prevalence of myocardial infarction, stroke, heart failure or diabetes 
at baseline as well as anti-hypertensive medication, aspirin, smoking status (categories), alcohol intake 
(categories) and physical activity (categories).
Model 3: Adjusted for model 2 plus, total energy, saturated fat, trans fat, n-3 fatty acids, n-6 fatty acids, 
dietary fibre, potassium, β-carotene and coffee.
Abbreviations: CVD: cardiovascular disease; CHD: coronary heart disease
Processed on: 9-6-2016
503508-L-bw-Dower
32
TABLE 3. Tertiles of epicatechin intake and 25-year cardiovascular mortality in 744 elderly Dutch men 
free of cancer at baseline, stratified by prevalence of cardiovascular diseases.
Mortality case Epicatechin Intake (mg/d)
Yes / No (n) T1 T2 T3
CVD mortality
Prevalent CVD    93 / 73 1.00 0.56 (0.31-1.03) 0.54 (0.31-0.96)
CVD-free   236 / 342 1.00 1.03 (0.73-1.43) 0.90 (0.61-1.33)
CHD mortality
Prevalent CVD 46 / 120 1.00 0.34 (0.14-0.84) 0.46 (0.20-1.05)
CVD-free 102  /476 1.00 1.08 (0.67-1.75) 0.63 (0.34-1.16)
Stroke Mortality
Prevalent CVD 17 / 149 1.00 1.17 (0.25-5.46) 0.50 (0.11-2.27)
CVD-free 55 / 523 1.00 0.70 (0.34-1.44) 0.92 (0.41-2.05)
Values are hazard ratios with 95% confidence intervals, obtained by Cox proportional hazard analysis, 
using the lower tertile as the reference; adjusted for age, physical activity (categories); anti-hypertensive 
medication; aspirin; smoking status (categories); alcohol intake (categories); prevalent diabetes at 
baseline; total energy; saturated fat; trans fat; n-3 fatty acids; n-6 fatty acids; dietary fibre; potassium; 
β-carotene and coffee.
Abbreviations: CVD: cardiovascular disease; CHD: coronary heart disease
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TABLE 4. Tertiles of intake of different flavan-3-ol monomers and 25-year cardiovascular mortality in 
744 elderly Dutch men free of cancer at baseline.
Tertiles of Intake (mg/d)
T1 T2 T3
CVD Mortality
Catechin 1.00 0.84 (0.63-1.13) 0.78 (0.57-1.05)
Catechin + epicatechin 1.00 0.92 (0.69-1.21) 0.77 (0.56-1.05)
ECg + EGCg 1.00 0.93 (0.70-1.23) 0.92 (0.68-1.23)
Total flavan-3-ols 1.00 0.87 (0.66-1.15) 0.80 (0.59-1.08)
CHD Mortality
Catechin 1.00 0.76 (0.50-1.15) 0.60 (0.38-0.93)
Catechin + epicatechin 1.00 0.94 (0.63-1.41) 0.62 (0.39-1.00)
ECg + EGCg 1.00 0.94 (0.62-1.43) 0.95 (0.61-1.47)
Total flavan-3-ols 1.00 0.95 (0.63-1.43) 0.74 (0.47-1.16)
Stroke Mortality
Catechin 1.00 0.88 (0.48-1.63) 0.68 (0.35-1.31)
Catechin + epicatechin 1.00 0.84 (0.45-1.55) 0.72 (0.37-1.41)
ECg +EGCg 1.00 0.80 (0.44-1.46) 0.80 (0.42-1.50)
Total flavan-3-ols 1.00 0.75 (0.40-1.38) 0.73 (0.39-1.38)
Values are hazard ratios with 95% confidence intervals, obtained by Cox proportional hazard analysis, 
using the lower tertile as the reference; adjusted for age;  prevalence of myocardial infarction, stroke, 
or diabetes at baseline;  anti-hypertensive medication; aspirin; smoking status (categories); alcohol 
intake (categories); physical activity (categories); total energy; saturated fat; trans fat; n-3 fatty acids; 
n-6 fatty acids; dietary fibre; potassium; β-carotene and coffee.
Abbreviations: CVD: cardiovascular disease; CHD: coronary heart disease; ECg: epicatechin gallate; 
EGCg: epigallocatechin gallate.
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DISCUSSION
In this study of elderly Dutch men, the risk of long-term CHD mortality was 38% lower in 
men in the highest tertile of epicatechin (median intake 22 mg/d) compared to the lowest 
(median 8 mg/d). In men with prevalent CVD, the highest tertile of epicatechin intake was 
associated with a 44% lower long-term CVD mortality risk compared to those in the low- 
est tertile.
Major strengths of the present study are the long duration (25 years) and the complete 
mortality follow-up. Using repeated measures of dietary assessment and covariates (every 
5 years between 1985 and 2000) provided a more accurate assessment compared to a 
single baseline assessment because of reduction in intra-individual variation. Furthermore, 
the epicatechin intake was assessed with the cross-check dietary history, a reproducible 
dietary survey method [22]. Although, the strength of validity for assessing epicatechin 
intake is currently unknown, the 5-year repeated estimate of epicatechin intake was 
strongly correlated (r=0.59). A limitation of our study is the relatively small study population, 
resulting in a limited power for the studied associations. Furthermore, our cohort included 
only elderly Dutch men and is, therefore, not generalisable to younger men and women. 
Finally, although we adjusted for a wide range of risk factors related to cardiovascular 
disease, we cannot exclude the possibility of residual confounding. 
To our knowledge, this is the first prospective cohort study to examine specifically the 
association between dietary epicatechin intake and CVD mortality. Previous cohort studies 
focused on total flavan-3-ol monomer intake and showed conflicting results [28-31]. An 
explanation could be that individual flavan-3-ol monomers differ in their metabolic effects. 
Epicatechin is of particular interest because it is the major flavan-3-ol monomer of cocoa, 
and a meta-analysis of randomised controlled cocoa trials showed that cocoa/chocolate 
improved blood pressure and endothelial function in adults [8].
Tea, apples and cocoa are rich in both epicatechin and catechin. The strong correlation 
between epicatechin and catechin intake in our study (r=0.80) could explain the association 
between catechin and CHD mortality. A study in rats showed that the vasodilatory 
effect of catechin was only 20% of that of epicatechin, suggesting that epicatechin is the 
most biologically active compound of the two [32]. There was also a strong correlation 
between epicatechin and tea intake (r=0.75). This makes it difficult to separate the effects 
of epicatechin from that of tea in observational studies due to multi-collinearity. Ideally, 
RCTs using pure flavonoids are needed to fully elucidate the role of flavonoids in the 
cardioprotective effects of tea. The correlation between ECg and EGCg intake was also 
extremely high (r>0.99), because both are exclusively present in tea. For this reason, 
we combined the intake of ECg and EGCg and found that these compounds were not 
associated with CHD mortality risk.
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The inverse association of epicatechin with CVD mortality could be mediated through 
changes in endothelial function. Chocolate/cocoa RCTs have consistently shown 
improvements in flow-mediated dilation (FMD), a measure of endothelial function [8]. In 
addition, pure epicatechin (200 mg) acutely (after 2 h) increased nitric oxide bioavailability 
and decreased endothelin-1 [33], two important mediators of endothelial function. 
However, in our previous clinical trial, supplementation of 100mg pure epicatechin per 
day for four weeks did not affect these markers [19], suggesting that dose and duration 
of exposure are critical. A link of FMD with future CVD events was firmly established in 
prospective studies, and there were indications for a stronger association in diseased 
populations [34]. This is consistent with the results of the present study which suggested 
that epicatechin intake was more strongly inversely related to CVD mortality risk in 
prevalent cases of CVD compared to those free of CVD. 
The inverse association of epicatechin with CVD mortality could also be mediated through 
changes in insulin resistance, a risk factor for diabetes and CVD [13-15]. A meta-analysis 
of RCTs showed that chocolate/cocoa improved insulin resistance [8]. In addition, a meta-
analysis of cohort studies showed that tea was inversely associated with type 2 diabetes 
[16]. We showed in a double-blind crossover RCT that pure epicatechin improved insulin 
resistance (19). These results point to a protective role of epicatechin in the aetiology of 
diabetes and CVD.  
In the present study, elderly men with a median epicatechin intake of 22 mg/d had a 38% 
lower risk of CHD mortality compared to those with a median intake of 8 mg/day. This 
suggests that the beneficial effects of epicatechin on CHD mortality may be achieved 
at relatively low levels of intake. A daily intake of 22mg of epicatechin is equivalent to 
approximately 6 cups of black tea (1 cup = 125ml), 54g of dark chocolate (54% cocoa) or 2-3 
apples (1 apple = 120g) (24, 25). 
In conclusion, our findings suggest that a higher epicatechin intake is associated with a 
lower risk of long-term CHD mortality, in a population-based study of elderly men, and to 
CVD mortality in men with prevalent CVD. More and larger studies are needed to confirm 
these associations before statements can be made about the strength of the association 
of epicatechin with CVD mortality.
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SUPPLEMENTARY FIGURE 1. Flow-chart of participants included in the analysis.
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ABSTRACT
Background
Prospective cohort studies showed inverse associations between the intake of flavonoid-
rich foods (cocoa and tea) and cardiovascular disease (CVD). Intervention studies showed 
protective effects on intermediate markers of CVD. This may be due to the protective effects 
of the flavonoids epicatechin (in cocoa and tea) and quercetin (in tea). We investigated the 
effects of supplementation of pure epicatechin and quercetin on vascular function and 
cardiometabolic health.
Methods 
Thirty-seven apparently healthy men and women aged 40–80 years with a systolic blood 
pressure (BP) between 125 and 160 mm Hg at screening were enrolled in a randomised, 
double-blind, placebo-controlled, crossover trial. CVD risk  factors were measured before 
and after 4 weeks of daily flavonoid supplementation. Participants received (-)-epicatechin 
(100 mg/d), quercetin-3-glucoside (160 mg/d), or placebo capsules for 4 weeks, in random 
order. The primary outcome was the change in flow-mediated dilation from pre- to post-
intervention. Secondary outcomes included other markers of CVD risk and vascular 
function.
Results
Epicatechin supplementation did not change flow-mediated dilation significantly (1.1% 
absolute; 95% CI: -0.1, 2.3; p=0.07). Epicatechin supplementation improved fasting 
plasma insulin (∆ insulin: -1.46 mU/L; 95% CI: -2.74, -0.18; p=0.03) and insulin resistance (∆ 
homeostasis model assessment of insulin resistance (HOMA-IR): -0.38; 95% CI: -0.74, -0.01; 
p=0.04) and had no effect on fasting plasma glucose. Epicatechin did not change BP (office 
BP and 24-h ambulatory BP), arterial stiffness, nitric oxide, endothelin-1, or blood lipid 
profile. Quercetin-3-glucoside supplementation had no effect on flow-mediated dilation, 
insulin resistance, or other CVD risk factors.
Conclusions
Our results suggest that epicatechin may in part contribute to the cardioprotective ef-
fects of cocoa and tea by improving insulin resistance. It is unlikely that quercetin plays 
an important role in the cardioprotective effects of tea. This study was registered at 
clinicaltrials.gov as NCT01691404.
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INTRODUCTION
Prospective cohort studies showed inverse associations between the intake of flavonoid-
rich foods (cocoa and tea) and cardiovascular disease (CVD). Meta-analyses of observational 
studies showed a 37% lower risk of CVD with increasing chocolate consumption [1], a 21% 
lower risk of stroke with increasing tea consumption [2], and a 15% lower risk of diabetes 
with higher tea consumption [3].
Cocoa and tea may change CVD risk factors, including vascular function, insulin sensitivity, 
blood pressure (BP), and blood lipids. Cocoa/chocolate consumption improved flow-
mediated dilation (FMD), a measure of endothelial function, by 1.34% relative to controls 
in a meta-analysis of 11 randomised-controlled trials (RCTs) and also insulin resistance 
(HOMA-IR) [4]. Similarly, 13 RCTs found a reduction of 3.2 mm Hg in systolic BP (SBP) and of 
2.0 mm Hg in diastolic BP (DBP) relative to controls after cocoa or chocolate consumption 
[5]. Few studies have investigated cocoa and arterial stiffness, a novel marker of CVD risk 
[6–8]; only improvements in augmentation index were reported [9, 10]. In 10 RCTs, cocoa/
chocolate reduced serum LDL and total cholesterol compared with controls [11].
Similarly, 9 RCTs found an increase in FMD of 2.6% (absolute) after tea consumption [12]. 
Consuming decaffeinated green tea extract improved HOMA-IR in obese patients with type 
2 diabetes, despite no change in body weight [13]. Following consumption of green tea or 
green tea extracts, 13 RCTs showed a reduction in SBP of 2.08 mm Hg and DBP of 1.71 mm 
Hg [14], and 19 RCTs showed improvements in total and LDL cholesterol [15].
Cocoa is high in flavan-3-ols (a subclass of flavonoids) and in particular epicatechin. A bar 
of 100 g dark chocolate (54% cocoa) provides 33 mg of epicatechin - 3 times the mean 
daily intake in The Netherlands [16, 17], but the main dietary source of epicatechin is 
tea [16]. Besides epicatechin, tea is also a major source of flavonols (another subclass of 
flavonoids), of which quercetin is the most abundant [18]. For Dutch males, tea provides 
16 mg quercetin/d (47% of the mean daily intake) as well as 11.5 mg epicatechin/d (69% of 
the intake) [18–20]. 
The above-mentioned cardioprotective effects were only demonstrated with cocoa and 
tea, complex mixtures of many flavonoids and other substances. The specific role of 
flavonoids remains unclear until the effects of pure flavonoids are studied. Only a few 
studies investigated the effects of high doses of pure flavonoids on a limited number of 
cardioprotective markers [21–24]. We, therefore, investigated whether pure epicatechin 
and quercetin could account for the cardioprotective effects of cocoa and tea by performing 
an intervention study in 37 subjects who ingested supplements with a relatively low dose 
of pure (-)-epicatechin or quercetin-3-glucoside daily for 4 weeks.
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METHODS
Subjects
Apparently healthy men and women aged 40–80 years were recruited from Wageningen 
and  surroundings, in The Netherlands. Eligible for participation were non-smoking men 
and women, with a BMI (in kg/m2) between 20 and 40 and SBP between 125 and 160 mm 
Hg on 2 separate occasions. Exclusion criteria included the presence of diabetes mellitus; 
cardiovascular, gastrointestinal, or liver disease; usage of antihypertensive or cholesterol-
lowering medication or corticosteroids; adherence to a prescribed diet; unstable weight 
in the past 2 months; ≥10 h/week moderate to vigorous physical activity (≥3 metabolic 
equivalent tasks); and pregnancy or lactation. All participants (Table 1) gave written 
informed consent, and the study was approved by the Medical Ethics Committee of 
Wageningen University.
Intervention
The study was conducted as a randomised, double-blind, placebo-controlled, crossover 
study between October 2012 and March 2013 (Figure 1). After enrolment, subjects were 
randomly allocated into 6 intervention sequences using computer-generated block rando-
misation by a staff member not involved in the study. All supplements were encapsulated in 
non-transparent capsules that were identical in appearance and coded A, B, or C. Encoding 
was performed by an external pharmacist not involved in the study. Encoding was broken 
after all data analysis had been performed. Participants ingested (-)-epicatechin (n = 35), 
quercetin-3-glucoside (n = 35), and placebo capsules (n = 35) for 4-week periods, separated 
by 4 weeks of washout. Outcome variables were measured at the research centre at the 
start and end of each 4-week intervention period. Measurements of endothelial function 
(FMD), BP, arterial stiffness, body weight (wearing minimal clothing), and blood samples 
were taken in the morning following an overnight fast (from 22:00). To assess acute-on-
chronic effects of flavonoid supplementation, FMD measurements were repeated on the 
final day of each intervention period, 2 hours after ingestion of the total daily dosage of 
the supplements. For the 24 hours before each measurement day, subjects were asked to 
avoid physical activity and alcohol consumption. The day before each measurement day, 
subjects underwent 24-hour ambulatory BP monitoring (24-h ABPM), collected 24-hour 
urine samples, and in the evening consumed a standardised low-flavonoid meal provided 
by the research team.
During the run-in week and throughout the study, subjects were asked to avoid consumption 
of epicatechin- and quercetin-rich foods, such as cocoa-containing products, red wine, 
apples, and onion-rich foods, and to drink no more than one cup of tea per day. Subjects 
ingested 2 capsules/d, with a glass of water: one during breakfast and one during dinner. 
Subjects reported capsules that were not ingested and non-adherence to the dietary 
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FIGURE 1. Study design. Participants ingested 2 capsules/d, one during breakfast and one during 
dinner, for 4 wk. Measurements of blood pressure, vascular function, and insulin resistance were taken 
at the start and end of each intervention period. Additional FMD measurements were taken on the final day 
of each intervention period, 2 h after consumption of 2 capsules. Participants received interventions 
(epicatechin, quercetin-3-glucoside, and placebo) in random order. FMD, flow-mediated dilation.
guidelines in a diary. Compliance was checked by asking participants to return all unused 
capsules. In addition, plasma and urinary flavonoid concentrations were determined. 
The daily dosage of epicatechin used (100 mg = 345 µmol) was in line with the amount of 
epicatechin present in previous cocoa/chocolate intervention studies (46–107 mg) [25–28]. 
In contrast to epicatechin, quercetin is present in foods only as glycosides. Quercetin-
3-glucoside was chosen because of its superior bioavailability [29]. For quercetin-3-
glucoside, an equimolecular dose was used (160 mg quercetin-3-glucoside =345 µmol). 
A supplemental file (Supplemental Material 1) describes details on capsules and isolation 
and purification of the flavonoids.
Functional and Biochemical Markers of Vascular Function
Endothelial function (FMD) was measured non-invasively in the right brachial artery by 
the same researcher, who was blinded to treatment allocation. An ultrasound transducer 
(7.5 MHz) was positioned proximal to the antecubital fossa. Baseline arterial diameter was 
measured for 3 min. Subsequently, reactive hyperaemia was induced by 5 min of lower 
arm occlusion through inflation of a cuff to 200 mm Hg. FMD images were processed 
automatically using custom-written software (MyFMD; APG Hoeks, Department of 
Biomedical Engineering, Maastricht University). During analysis, 11% (34/309) of recordings 
were removed due to movement of arm after cuff release or unclear image of the arterial 
wall. FMD was calculated as peak change in arterial diameter following reactive hyperemia 
relative to baseline. Endothelium-independent vasodilation was calculated as peak change 
in arterial diameter over a 5-min period following sublingual administration of 400 mg 
glyceryl trinitrate.
Pulse wave analysis and pulse wave velocity were measured by applanation tonometry 
on the radial artery, in triplicate, with the SphygmoCor system (version 8; Atcor Medical). 
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Central aortic waveforms were derived using a validated transfer function [30, 31]. Sub-
sequently, central SBP, central DBP, subendocardial viability ratio and heart rate (HR)–
corrected central augmentation index were estimated using integrated software. Carotid-
femoral pulse wave velocity was calculated as the measured carotid-femoral distance 
divided by the pulse transit time between the 2 sites.
Office BP and HR (beats/min) were measured as the mean of the last 3 of 4 measurements 
using an automated oscillometric device (Dinamap Pro 100; KP Medical). Measurements 
were taken in a temperature-controlled room (20–248C), in the supine position, after 
10 min of rest. Twenty-four-hour ABPM was performed using Spacelabs 90217 devices 
(Spacelabs Medical Inc.). Daytime BP (07:00–23:00) was recorded every 30 min and night-
time BP (2300–07:00) every 60 min. Weighted 24-h mean ABPM and mean daytime (08:00–
22:00) and night-time (00:00–06:00) BP were calculated.
Plasma insulin concentrations were determined by ELISA from EDTA-plasma. Blood 
glucose, total and HDL cholesterol, and triglycerides were analysed with standard kits 
using an autoanalyzer (Hitachi 917; Roche Diagnostics). Insulin resistance was calculated 
by HOMA-IR, as described previously [32]. LDL cholesterol was calculated according to the 
Friedewald equation [33].
TABLE 1. Baseline characteristics of 37 healthy subjects randomised at the start of the study.
Mean ± SD
Age (yrs) 66.4 ± 7.9
BMI (kg/m²) 26.7 ± 3.3
Office SBP (mmHg) 129.3 ± 14.1
Office DBP (mmHg) 74.8 ± 9.8
Pulse Wave Velocity (m/s) 12.9 ± 1.9
AIx (%) 25.9 ± 7.6
Plasma glucose (mmol/L) 5.71 ± 0.65
Serum insulin (mU/L) 6.10 ± 3.77
HOMA-IR 1.57 ± 0.97
Fasting serum lipids (mmol/L)
Total cholesterol 5.63 ± 0.90
LDL cholesterol 3.49 ± 0.80
HDL cholesterol 1.54 ± 0.41
Triglycerides 1.29 ± 0.57
AIx, augmentation index corrected for a heart rate of 75 bpm; BMI, body mass index; DBP, diastolic 
blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin 
resistance; LDL,  low-density lipoprotein; SBP, systolic blood pressure.
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Heparin-plasma was used to determine the nitric oxide (NO) concentration by the 
estimation of NO by chemiluminescence formed after the release of NO from NO2, NO2─, 
and nitrosated and nitrosylated species. To minimize NOx contamination, measurements 
of NO were performed when air NOx concentrations were <40 mg/m3. Detection limit 
was 10 nmol/L [34]. Endothelin-1 was measured in EDTA-plasma by ELISA. Flavonoid 
concentrations were analysed in 24-hour urine and plasma samples after enzymatic 
hydrolysis of the conjugates by means of HPLC-electrochemical detection [35]. Detection 
limit for epicatechin and quercetin was 300 nmol/L.
Statistical Analysis
FMD was defined as the primary outcome. Because no previous studies have assessed 
the effects of pure flavonoids on FMD, the power calculation was based on results from 
cocoa studies [4]. Assuming an SD in absolute FMD change of 2.7%, 35 participants would 
provide sufficient power to detect an absolute change in FMD of 1.3% (2-sided α of 5%, 
power = 0.80). 
Data were analysed according to a pre-defined statistical analysis plan using SAS software 
version 9.2 (SAS Institute). Pre- and post-intervention data are shown in Supplemental 
Table 1. Treatment effects were calculated as the changes between values at the start and 
the end of each 4-week intervention period. Treatment effects were tested by comparing 
changes during epicatechin and quercetin supplementation with changes during placebo. 
Data were checked for normality of  distribution, and all variables were considered normally 
distributed. Using the SAS PROC MIXED statement, a linear mixed model for repeated 
measures with compound symmetry as covariant structure was used to compare changes. 
Treatment and period were set as fixed effects and subject as random effect. To test for 
a carryover effect, we also included previous treatment in the model. No carryover effect 
was apparent, however, and was therefore excluded from the final model. Numerical data 
are expressed as means ± SDs, medians with IQRs, or treatment effects (least squares 
means) with 95% CIs. Statistical significance was set at a 2-sided p-value of 0.05.
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RESULTS
Study Population
Of the 37 subjects (25 men, 12 women) who participated, 33 completed all interventions 
(Figure 2). Two subjects experienced an adverse event: one had a non-fatal acute myo-
cardial infarction, and another had a fatal stroke. Both events took place during washout 
periods. The Medical Ethics Committee judged that these events were unrelated to the 
intervention, and this was confirmed by an independent Data and Safety Monitoring Board 
of a previous study [36].
The age of the study population ranged from 48 to 79 years, and BMI was between 20 and 
35 (Table 1). Subjects had a mean SBP/DBP of 129/75 mm Hg, and 22% were hypertensive 
(SBP ≥140 and/or DBP ≥90 mm Hg). Missing treatments due to dropout did not affect 
baseline characteristics between the quercetin and epicatechin groups (Supplemental 
Table 2). Body weight remained stable throughout the study period, and no omission of 
capsule ingestion was reported.
Absorption and Compliance
Plasma epicatechin was not detectable in fasting samples at the start or end of all 
4-week interventions but was detectable 2 hours after acute-on-chronic epicatechin 
supplementation, with a mean concentration of 1950 ± 2070 nmol/L. At baseline, before 
each intervention, all urine samples were below the detection limit for epicatechin 
(300 nmol/L). After 4 weeks of epicatechin supplementation, 51% of urine samples had 
urinary epicatechin concentrations above the detection limit. After placebo and quercetin 
interventions, no urine samples had epicatechin concentrations above the detection limit.
Fasting plasma quercetin concentrations increased from a mean of 381 ± 205 nmol/L to 
707 ± 517 nmol/L (p<0.001) after 4 weeks of quercetin supplementation, with a further 
increase to 2060 ± 1370 nmol/L 2 hours after acute supplementation (p<0.001). Fasting 
plasma quercetin concentration in the placebo group was 393 ± 217 nmol/L at baseline and 
did not change during placebo intervention. At baseline, before each intervention, all urine 
samples but one were below the detection limit for quercetin (300 nmol/L). After 4 weeks 
of quercetin supplementation, 71% of urine samples had urinary quercetin concentrations 
above the detection limit. After placebo intervention, 12% of urine samples had urinary 
quercetin concentrations slightly above the detection limit. Based on returned capsules 
and diary entries, more than 98% of capsules distributed were ingested, and all subjects 
(excluding dropouts) ingested at least 80% during each intervention.
Flavonoid Supplementation
Epicatechin supplementation did not change FMD significantly (1.1% absolute; 95% CI: 
-0.1, 2.3; p=0.07) over the 4-week period, and no acute-on-chronic effects were seen (Table 
2). Endothelium-independent vasodilation did not change following acute or chronic 
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TABLE 2. Effects of (-)-epicatechin (100 mg, 345 µmol) and quercetin-3-glucoside (160 mg, 345 µmol) 
supplementation daily for 4 weeks on vascular function, BP and body weight in healthy subjects1.
(-)-Epicatechin (n=35) Quercetin-3-glucoside (n=35)
Treatment 
effect (95% CI) P-value
Treatment 
effect (95% CI) P-value
FMD chronic (%)2 1.08 (-0.09, 2.26) 0.07 0.33 (-0.79, 1.44) 0.56
FMD acute (%)2 -0.19 (-1.47, 1.10) 0.77 0.20 (-1.05, 1.45) 0.75
EID chronic (%)2 0.99 (-2.15, 4.13) 0.53 0.16 (-2.89, 3.22) 0.91
EID acute (%)2 -1.08 (-3.27, 1.11) 0.32 -1.53 (-3.63, 0.56) 0.15
Office BP (mmHg)
   SBP
   DBP  
 
-0.51
-0.06
 
(-5.38, 4.36) 
(-2.32, 2.20)
 
0.84 
0.96
 
1.77
0.78
 
(-3.12, 6.65) 
(-1.48, 3.05)
 
0.47 
0.49
Office HR (bpm) 0.05 (-3.18, 3.30) 0.97 0.14 (-3.10, 3.38) 0.93
24-hour BP (mmHg)
   SBP
   DBP
 
-2.37  
-1.49
 
(-5.95, 1.21) 
(-3.50, 0.38)
 
0.19 
0.12
 
0.67  
0.32
 
(-2.91, 4.25) 
(-1.54, 2.19)
 
0.71 
0.73
Daytime BP (mmHg)
   SBP
   DBP
 
-1.90 
-1.31
 
(-5.72, 1.92) 
(-3.56, 0.93)
 
0.32 
0.25
 
1.05 
0.68
 
(-2.77, 4.87) 
(-1.57, 2.93)
 
0.58 
0.55
Night-time BP (mmHg)
   SBP
   DBP
 
-3.77 
-1.90
 
(-8.87, 1.33) 
(-4.74, 0.94)
 
0.14 
0.19
 
-0.61
-0.34
 
(-5.70, 4.49) 
(-3.18, 2.49)
 
0.81 
0.81
Pulse Wave Velocity 
(m/s)
0.32 (-0.33, 0.96) 0.33 0.18 (-0.45, 0.82) 0.58
Pulse Wave Analysis
   Central SBP (mmHg) 1.23 (-3.22, 5.67) 0.58 2.10 (-2.33, 6.54) 0.35
   Central DBP (mmHg) -1.14 (-3.61, 1.34) 0.36 0.16 (-2.31, 2.63) 0.90
   AIx (%) -1.37 (-3.10, 0.37) 0.12 -0.70 (-2.43, 1.04) 0.43
   SEVR (%) 3.83 (-3.80, 11.50) 0.32 3.01 (-4.60, 10.60) 0.43
Body weight (kg) -0.21 (-0.90, 0.47) 0.54 -0.35 (-1.03, 0.33) 0.31
1 All values are least square means (95% CI) from linear mixed model for repeated measures with 
compound symmetry as covariant structure. ‘Treatment’ and ‘period’ were set as fixed effects and 
‘subject’ as random effect. P values were derived from this model.
2 Absolute difference.
Abbreviations: AIx, augmentation index corrected for heart rate of 75 bpm; DBP, diastolic blood 
pressure; EID, endothelium-independent dilation; FMD, flow-mediated dilation; HR, heart rate; SBP, 
systolic blood pressure; SEVR, subendocardial viability ratio.
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epicatechin supplementation. No changes were seen for plasma glucose concentrations. 
Mean plasma fasting insulin changed by -1.46 mU/ L (95% CI: -2.74, -0.18; p=0.03), resulting 
in a change in HOMA-IR of -0.38 (95% CI: -0.74, -0.01; p=0.04) (Table 3). Epicatechin 
supplementation had no effect on office BP or HR. Mean 24-h SBP (∆: -2.4 mm Hg; 95% 
CI: -5.95, 1.21; p=0.19) and DBP (∆: -1.5 mm Hg; 95% CI: -3.50, 0.38; p=0.12) did not change 
significantly after epicatechin supplementation (Table 2). No changes were seen for other 
markers of cardiometabolic health (Table 3).
Quercetin supplementation did not affect FMD, insulin resistance, or any other marker of 
cardiometabolic health (Tables 2 and 3).
TABLE 3. Effects of (-)-epicatechin (100 mg, 345 µmol) and quercetin-3-glucoside (160 mg, 345 µmol) 
supplementation daily for 4 weeks on biomarkers of cardiometabolic health in healthy subjects1.
(-)-Epicatechin (n=35) Quercetin-3-glucoside (n=35)
Treatment 
effect (95% CI) P-value
Treatment 
effect (95% CI) P-value
Glucose (mmol/L) -0.02 (-0.21, 0.18) 0.88 0.01 (-0.19, 0.21) 0.94
Insulin (mU/L) -1.46 (-2.74, -0.18) 0.03 -0.34 (-1.62, 0.94) 0.60
HOMA-IR -0.38 (-0.74, -0.01) 0.04 -0.07 (-0.44, 0.29) 0.68
Nitric oxide chronic 
(nmol/L)
-6.99 (-32.5, 18.5) 0.59 6.68 (-19.1, 32.4) 0.61
Nitric oxide acute 
(nmol/L)
-5.64 (-27.2, 15.9) 0.60 -13.1 (-34.7, 8.5) 0.23
Endothelin-1 (pg/ml) -0.03 (-0.20, 0.13) 0.68 0.04 (-0.13, 0.21) 0.65
Fasting serum lipids 
(mmol/L)
Total cholesterol -0.08 (-0.36, 0.19) 0.54 -0.001 (-0.28, 0.28) 0.99
HDL cholesterol -0.01 (-0.09, 0.07) 0.79 0.03 (-0.05, 0.11) 0.43
LDL cholesterol -0.02 (-0.25, 0.22) 0.90 -0.01 (-0.25, 0.23) 0.92
Triglycerides -0.13 (-0.35, 0.08) 0.22 -0.04 (-0.26, 0.17) 0.69
1 All values are least square means (95% CI) from linear mixed model for repeated measures with 
compound symmetry as covariant structure.  Treatment’ and ‘period’ were set as fixed effects and 
‘subject’ as random effect. P values were derived from this model.
HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, 
low-density lipoprotein.
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DISCUSSION
In this study of 37 healthy older adults, supplementation of pure epicatechin did not 
improve FMD but reduced insulin resistance. Epicatechin had no effect on any other 
marker of cardiometabolic health. Quercetin supplementation did not affect FMD, insulin 
resistance, or any other marker of cardiometabolic health. 
Increases in plasma flavonoid concentrations after active treatment but not after placebo 
showed that epicatechin and quercetin were absorbed. Because of the short elimination 
half-life of epicatechin (2 h) [37], plasma epicatechin concentrations remained below 
the detection limit in fasting blood after chronic supplementation. Plasma epicatechin 
concentrations did increase after acute supplementation (to 1950 nmol/L). This increase 
was considerably higher than in previous studies on acute cocoa consumption (±400 
nmol/L after 100 mg epicatechin) [25, 38]. Because of the longer plasma elimination half-
life of quercetin (17 h) [29], plasma quercetin concentrations increased both chronically 
(p<0.001) and acutely (p<0.001).
Flow-Mediated Dilation
On the basis of a meta-analysis of cocoa studies, we expected a mean absolute increase 
in FMD of 1.3%. However, we did not observe a significant effect of epicatechin on FMD 
(absolute ∆: +1.1%; 95% CI: -0.1, 2.3; p=0.07). Our intervention was sufficiently powered 
to detect an absolute change in FMD of 1.3%, indicating that the effect, if any, is expected 
to be smaller than 1.3%. A 1% increase in FMD would be clinically relevant, because at 
a population level, a 1% increase in FMD is associated with a 13% lower risk of a cardio-
vascular event [39].
We did not observe an acute-on-chronic effect of epicatechin supplementation on FMD. 
This is contrary to earlier data that showed the acute effect of cocoa to be larger than 
the chronic effect [4]. Previous studies, however, investigated the acute effects of cocoa 
consumption not in combination with chronic effects. Possibly in our study, a plateau in 
endothelial function was reached after 4 weeks, and an additional acute dose could not 
elicit more effect on FMD.
Quercetin supplementation did not affect FMD, suggesting that quercetin alone is not 
responsible for the changes in endothelial function observed after tea consumption [12]. 
The median daily dose of tea used in the tea interventions (500 mL) would provide just 8 
mg of quercetin [20], much lower than the dose of 100 mg used in the current study.
Insulin Resistance
Epidemiological studies have shown an association between HOMA-IR and CVD risk 
[42, 43]. In our study, the reduction in mean HOMA-IR of -0.38 following epicatechin 
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supplementation was smaller than that of the cocoa meta-analysis (-0.67), although it did 
fall within the 95% CI (-0.98, -0.36) of this meta-analysis [4]. Our study population had a 
mean HOMA-IR of 1.57, which is below the threshold of insulin resistance (<2.77) [44]. 
The response to epicatechin may be stronger in subjects with impaired fasting glucose 
concentrations and higher levels of insulin resistance [45]. The results of the present study 
suggest that epicatechin contributes to the favourable effects seen in cocoa trials [46, 47].
Insulin and HOMA-IR may influence vascular function through stimulation of the production 
of NO [40, 41]. Epicatechin did not affect plasma NO concentrations, which suggests no 
involvement of NO in this favourable response. Besides NO, improvements in pancreatic 
β-cell function as well as induction of the AKT/PI-3-kinase and ERK1/2 pathways have been 
suggested to play a role in effects on insulin resistance of cocoa flavan-3-ols [28, 48]. Future 
studies should explore these mechanisms.
In our study, quercetin supplementation did not affect HOMA-IR. Green tea contains almost 
3 times more epicatechin than does quercetin [49], suggesting that epicatechin rather than 
quercetin is responsible for the beneficial effects of green tea on insulin resistance [13].
Blood Pressure
The measurement of 24-h ABPM is a strength of our study because it is considered 
superior to office BP in predicting cardiovascular mortality [50]. In contrast to cocoa 
RCTs, epicatechin did not change office BP. Hooper et al. [4] deduced that improvements 
in BP occurred with cocoa/chocolate containing 50–100 mg epicatechin, with no further 
reductions above 100 mg. As we supplemented 100 mg epicatechin/d in our study, an 
effect on BP was expected. However, we did not observe a statistically significant effect. 
Quercetin had no effect on office BP or 24-h ABPM. This is in contrast to studies using 
pure quercetin aglycone. Egert et al. [22] noted a 2.6 mm Hg reduction of SBP compared 
with placebo in overweight weight-stable subjects following 6 weeks of quercetin 
supplementation (150 mg/d). Similarly, Edwards et al. [21] reported a reduction in SBP/
DBP of 7/5 mm Hg compared with placebo in untreated stage I weight-stable subjects with 
hypertension following 4 weeks of quercetin consumption (730 mg/d). Possibly, a higher 
quercetin intake is required, and/or the health state plays a role.
Other Vascular Function Markers
Endothelin-1 and NO - important mediators of vasoconstriction/vasodilation - were not 
affected by epicatechin or quercetin supplementation, consistent with the unchanged 
FMD. The beneficial effects of cocoa flavan-3-ols on FMD, BP, and insulin resistance are 
thought to be partly mediated through the release of NO [51]. Both epicatechin and 
quercetin in pure forms have been shown to increase NO products acutely at high doses 
of 200 mg [23]. The dose used in our study (100 mg) was possibly too small to elicit an 
effect on NO metabolism.
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Arterial stiffness was not affected by epicatechin or quercetin. Most RCTs that reported 
improvements in arterial stiffness following dietary interventions had durations between 
1.5 and 25 months [52]. The current study may have been too short to elicit structural 
vascular changes.
Results from cocoa studies show that cocoa reduced LDL and total cholesterol [11]. In 
our study, epicatechin supplementation had no effect on cholesterol, suggesting that 
epicatechin is not responsible for the observed effects of cocoa. Quercetin supplementation 
also did not affect cholesterol. This is in line with Conquer et al. [53], who did not find an 
effect of even a much higher dosage of quercetin (1000 mg) on serum cholesterol and 
triglyceride concentrations.
Study Limitations
In the present study, a number of markers of cardiometabolic health were assessed. We 
cannot, therefore, exclude the possibility of a false-positive finding. Nevertheless, we chose 
not to correct for multiple testing, based on the arguments of Rothman [54]. That said, for 
readers who wish to know which results would and would not be statistically significant 
if we did adjust for multiple testing, we note that we conducted 29 tests. Therefore, to 
maintain a family-wise type I error rate of 0.05, were one to use a Bonferroni correction, 
p-values would need to be <0.05/29 = 0.002. Readers may view our reported p-values 
in that context. To exclude the possibility of false positives, more studies are needed to 
confirm our results.
By studying pure flavonoids, we excluded potential interactions with other flavonoids and 
compounds in cocoa/tea. It is possible that such interactions play a role in the effects of 
cocoa and tea; however, to our knowledge, studies on such interactions have not been 
published.
The analytic method for plasma and urinary flavonoids was not sensitive enough to 
reliably determine concentrations smaller than 300 nmol/L. Although we were able to 
demonstrate differences between placebo and interventions and sufficient washout 
between interventions, comparison with cocoa/tea studies should be made cautiously.
CONCLUSIONS
Our findings suggest that epicatechin plays a role in the beneficial effects of cocoa and tea 
on insulin resistance. No effects of epicatechin were seen on endothelial function or other 
markers of cardiometabolic health. Quercetin, a major flavonol in tea, did not influence 
any of the markers of cardiometabolic health. It is unlikely, therefore, that quercetin plays 
a role in the cardioprotective effects of tea.
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SUPPLEMENTAL TABLE 2. Baseline characteristics of study population by treatment group. Of the 
37 subjects, 35 completed the epicatechin, 35 the quercetin and 35 the placebo intervention, due 
to dropouts.
Subjects in epicatechin 
group (n=35)
Subjects in quercetin group 
(n=35)
Men/women 23/12 23/12
Age (yrs) 65.9 ± 7.9 66.0 ±7.9
BMI (kg/m²) 26.6 ± 3.4 26.6 ± 3.3
Systolic BP (mmHg) 129.4 ± 14.5 129.2 ± 14.2
Diastolic BP (mmHg) 75.0 ± 9.8 74.7 ± 10.04
Pulse Wave Velocity (m/s) 12.8 ± 1.9 12.9 ± 1.9
Augmentation Index (%) 25.8 ± 7.9 26.0 ± 7.9
Plasma glucose (mmol/L) 5.70 ± 0.67 5.69 ± 0.66
Serum insulin (mU/L) 6.14 ± 3.85 6.09 ± 3.87
HOMA-IR 1.58 ± 0.99 1.56 ± 1.00
Fasting serum lipids (mmol/L)
Total cholesterol 5.65 ± 0.89 5.57 ± 0.85
LDL cholesterol 3.49 ± 0.79 3.43 ± 0.75
HDL cholesterol 1.57 ± 0.41 1.55 ± 0.42
Triglycerides 1.30 ± 0.57 1.29 ± 0.57
Data are given as mean ± SD. 
Abbreviations: BMI = body mass index; BP = blood pressure; HOMA-IR = homeostasis model assessment 
of insulin resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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SUPPLEMENTAL MATERIAL 1.  
Flavonoid isolation and purification process 
ChromaDex (Irvine, CA, USA) developed procedures to isolate and purify (-)-epicatechin 
and quercetin-3-glucoside. (-)-Epicatechin was extracted from Acacia heart wood with 
aqueous alcohol. The crude extract was purified by preparative chromatography, followed 
by repeated fractional crystallisation from water. Rutin was extracted from Uncaria elliptica 
leaves with aqueous alcohol, followed by partial acid hydrolysis to give quercetin-3-O-β-
D-glucoside, which was purified on activated charcoal. All solvents and equipment used 
were food grade. Identity was confirmed using NMR and MS. Purity was checked by HPLC, 
and was 96.2% for (-)-epicatechin (water 0.3%) and 93.2% for quercetin-3-O-β-D-glucoside 
(water 4.0%). Supplements were encapsulated in non-transparent capsules which were 
matched for size and colour, using microcrystalline cellulose as an excipient and 1% 
colloidal siliciumdioxide. Variation in contents was within 3.7% (SD/mean*100%) for 
epicatechin and 5.7% for quercetin. Placebo capsules contained microcrystalline cellulose. 
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SUPPLEMENTAL MATERIAL 2. 
Letter to the editor from Schroeter et al. and reply
Is this the end of (-)-epicatechin, or not? New study highlights the complex challen-
ges associated with research into the cardiovascular health benefits of bioactive 
food constituents 
Hagen Schroeter; Carl L Keen; Howard D Sesso; Joann E Manson; Joanne R Lupton
Dear Editor: 
A considerable body of evidence supports the beneficial effects of dietary flavanols in 
relation to cardiovascular health, and the data for cocoa flavanols are particularly extensive 
and consistent. In addition to the reported results of individual studies, cocoa flavanol–
related health benefits also have been substantiated by a Cochrane Review [1], as well as 
by a scientific consensus statement resulting in a European Food Safety Authority health 
claim [2]. However, it is important to consider that the compound classes of flavanols and 
procyanidins include a variety of chemically distinct bioactives, one of which, (-)-epicatechin, 
has been identified as one of the bioactive flavonoid constituents of cocoa [3]. Although 
food matrix properties and other constituents present in flavanol-containing foods are 
likely to contribute to, or modulate, the effects of (-)-epicatechin by affecting its bioactivity 
and/or bioavailability, we agree with Dower et al. [4] in a recent article in the Journal that it 
is important to investigate individual bioactives and to rigorously test on a larger scale the 
validity of previous findings. In their article, Dower et al. [4] investigated the effects of ‘‘pure 
epicatechin’’ in a controlled, double-masked, crossover study in humans and concluded 
that although (-)-epicatechin intake did not significantly increase flow-mediated arterial 
dilation (FMD; primary endpoint) or decrease blood pressure, it did have a significant 
beneficial effect on insulin resistance (secondary endpoint). 
In an Editorial in the Journal that accompanied the Dower et al. article, Scalbert and 
Zamoras-Ros [5] emphasized that, ‘‘In contrast to the negative results observed on CVD 
[cardiovascular disease] markers, Dower et al. also observed a decrease in fasting plasma 
insulin….’’ We are concerned that the authors represent effects that are not statistically 
significant as ‘‘negative results’’ and that their interpretation does not distinguish 
between the primary endpoint the study was prospectively powered for, from outcomes 
representing secondary endpoints. So should the data by Dower et al. put to rest the idea 
that (-)-epicatechin represents a bioactive food constituent with cardiovascular health 
benefits? In other words, how rigorous are the data, what are the limitations of their 
interpretation, and how high is the risk of a false negative result? According to Dower et 
al. [4], ‘‘A 1% increase in FMD would be clinically relevant, because at a population level, 
a 1% increase in FMD is associated with a 13% lower risk of a cardiovascular event.’’ We 
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fully agree with the statement and the reference provided in its support. Dower et al. 
reported that they observed an (-)-epicatechin intake-related increase in FMD of 1.1%, an 
outcome that did not reach statistical significance (p=0.07; Table 2 in their article), because 
a hypothesized 1.3% change in FMD was the basis for their power calculation. Although 
we agree with the conclusion by Dower et al. that the statistical evaluation of their data 
disproves their hypothesis, we submit that drawing general conclusions from this work 
requires a careful consideration of all study limitations, including the question of sufficient 
statistical power in the context of a diverse study population. We appreciate the technical 
challenges of detecting a comparatively small change in FMD in healthy individuals in the 
context of a dietary intervention study of this scale. Although technical considerations are 
often overlooked and unappreciated, they can have a considerable impact on outcomes 
and final interpretations. One of the challenges encountered by Dower et al. [4] was 
the relatively large heterogeneity of their study population, especially considering the 
small total number of participants. The study population ranged in age from 48 to 79 y 
and in BMI (in kg/m2 ) from 20 to 35, and although the average systolic/diastolic blood 
pressure was 129/75 mm Hg, 22% of participants would be considered as hypertensive. 
These characteristics, which will very likely also result in a high inter-individual variability 
in the primary endpoint of FMD, can represent a considerable challenge with regard to 
detecting small effect sizes. Moreover, the overall health status of the study population is 
an important consideration, especially when investigating the effects of a bioactive such 
as (-)-epicatechin in the context of health and nutrition. Although Dower et al. aimed at 
recruiting healthy individuals, the reported intervention-independent occurrence of 1 
myocardial infarction and 1 fatal stroke, as well as the 22% prevalence of hypertension 
in the overall study population, indicates significant heterogeneity in vascular disease risk 
factor status. Further complicating the interpretation of the study, the primary endpoint 
of FMD was assessed with the use of a less-than-ideal methodology. Harris et al. [6], 
among others, demonstrated that an ultrasound transducer of 10–14 MHz is needed to 
optimally image superficial vessels. Dower et al. [4] used a 7.5 MHz transducer, which can 
result in significant interassay variations that may have contributed to the 2.7% SD of FMD 
measurements observed in their study. This may also explain why 11% of FMD recordings 
were removed from the analysis. We also have some concerns regarding the level of 
compliance in the study by Dower et al. Assuming that 5–20% of dietary (-)-epicatechin is 
thought to be excreted in urine over 24 h [7], 5–20 mg of (-)-epicatechin equivalents should 
have been detected in urine. Conservatively assuming a diuresis of 3 L/d, the concentration 
of (-)-epicatechin equivalents detected in urine should have been between 5 and 20 M, 
i.e., between 20 and 80 times higher than the limit of detection reported by Dower et al. 
Because 49% of urine samples were reported below the limit of detection, these results 
would suggest an analytic problem, or a problem with compliance, which would greatly 
affect any outcomes assessment. 
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Taken together, the low statistical power, heterogeneity of the study population—
particularly with respect to cardiovascular disease risk factor status—questions regarding 
compliance, and the proficiency in assessing the primary endpoint of FMD each represent 
limitations that need to be taken into account when interpreting the final outcomes 
presented by Dower et al., and, more generally, when investigating clinically meaningful 
effect sizes in small study populations. Consequently, although important and timely, we 
submit that the data by Dower et al. do not represent strong evidence for or against the 
bioactivity of (-)-epicatechin in the context of cardiovascular health. Further research in 
this area, including large-scale randomized trials with clinical event outcomes, is needed to 
better define the potential health benefits of (-)-epicatechin. 
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REPLY TO H SCHROETER ET AL.
James I Dower; Johanna M Geleijnse; Daan Kromhout and  Peter CH Hollman
Dear Editor:
In their letter, Schroeter et al. raise a number of interesting issues on which we would 
like to comment. In our study, we found that daily supplementation with 100 mg of ‘‘pure 
epicatechin’’ (quotes by Schroeter et al., but purity was >96%!) increased flow-mediated 
dilation (FMD) by 1.1%. Although this effect was not statistically significant, we agree with 
Schroeter et al. that this effect, judged in the context of the total evidence, is of clinical 
interest. 
Schroeter et al. suggest that the variation in age, BMI, and blood pressure in our study 
population contributes to a large inter-individual variability in FMD, thereby reducing 
statistical power. However, the effects of cocoa consumption on FMD have been reported 
in studies with similar populations, often with smaller sample sizes. For example, Grassi et 
al. [1] showed that cocoa dose-dependently improved FMD in 20 participants (crossover 
design) aged 18–70 y with a BMI (in kg/m²) between 19 and 30 and blood pressure,140/90 
mm Hg. Similar results were obtained by Davison et al. [2] with 25 overweight/obese 
participants (parallel design) with a blood pressure ,160/100 mm Hg. In addition, the effects 
of high flavan-3-ol cocoa extracts on FMD were similar in young (<35 y) and elderly (50–80 
y) men [3]. Furthermore, we are not aware of published data reporting that health status 
modifies the vascular effects of cocoa. We therefore do not consider the heterogeneity of 
our study population to be a major problem. 
Schroeter et al. also pointed out that an ultrasound transducer of 10–14 MHz is required 
to adequately measure FMD, whereas we used an ultrasound transducer of 7.5 MHz. Two 
commonly used guidelines state that a linear array transducer with a minimum frequency 
of 7–7.5 MHz is required for FMD measurement [4, 5]. Furthermore, previous studies 
with the use of a 7.0-MHz transducer have shown improvements in FMD after cocoa 
consumption [6, 7]. 
In their letter, Schroeter et al. also raised concerns about compliance. We checked 
compliance based on diary entries and returned capsules, as well as biomarkers. More 
than 98% of capsules distributed were ingested, and all subjects (excluding dropouts) 
ingested at least 80% during each intervention, which proves adequate compliance. Urine 
samples were collected as an additional objective measure of compliance. The low urinary 
epicatechin excretion is very likely caused by poor deconjugation of the aryl-sulfatases 
used in the analysis [8], which will have a high impact because epicatechin sulfates account 
for >90% of urinary metabolites [9]. Nevertheless, differences between epicatechin and 
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placebo support compliance. Taken as a whole, based on returned capsules, diary entries, 
and an increase in urinary epicatechin, we are confident that we achieved a high level of 
compliance. 
In conclusion, we thank Schroeter et al. for their comments and agree that evidence of the 
effects of epicatechin on vascular function is still limited. More and larger trials with pure 
epicatechin are needed to unravel the potential role of epicatechin on the cardiometabolic 
effects of cocoa. None of the authors had a conflict of interest with the content of this 
letter. 
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ABSTRACT
Background
Consumption of flavonoid-rich foods such as cocoa and tea may reduce cardiovascular 
disease risk. The flavonoids epicatechin (in cocoa and tea) and quercetin (in tea) probably 
play a role by reducing endothelial dysfunction and inflammation, two main determinants 
of atherosclerosis. We aimed to study the effects of supplementation of pure epicatechin 
and quercetin on biomarkers of endothelial dysfunction and inflammation.
Methods
Thirty-seven apparently healthy (pre)hypertensive men and women (40–80 years) parti-
cipated in a randomised, double-blind, placebo-controlled crossover trial. Participants 
ingested (-)-epicatechin (100 mg/d), quercetin-3-glucoside (160 mg/d), or placebo capsules 
for a period of four weeks, in random order. Plasma biomarkers of endothelial dysfunction 
and inflammation were measured at the start and end of each four-week intervention 
period. The differences in changes over time between the intervention and placebo 
periods (∆intervention - ∆placebo) were calculated and tested with a linear mixed model 
for repeated measures.
Results
Epicatechin supplementation decreased soluble endothelial selectin (sE-selectin) by 7.7 
ng/mL (95% CI: 14.5, 0.83; P=0.03), when compared to placebo (∆epicatechin - ∆placebo). 
Epicatechin did not significantly change the z-score for endothelial dysfunction (-0.30; 
95% CI: -0.61, 0.01; P = 0.06). Quercetin lowered sE-selectin by -7.4 ng/mL (95% CI: -14.3, 
-0.56; P = 0.03), IL-1β by -0.23 pg/mL (95% CI: -0.40, -0.06; P = 0.009), and the z-score for 
inflammation by -0.33 (95% CI: -0.60, -0.05; P = 0.02), when compared to placebo.
Conclusions
In (pre)hypertensive men and women, epicatechin may contribute to the cardioprotective 
effects of cocoa and tea through improvements in endothelial function. Quercetin may 
contribute to the cardioprotective effects of tea by improving endothelial function and 
reducing inflammation. This trial was registered at clinicaltrials.gov as NCT01691404.
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INTRODUCTION
Flavonoids (a subclass of polyphenols) are structurally related secondary metabolites that 
are ubiquitous in plant foods. Consumption of flavonoid-rich foods such as cocoa and tea 
are associated with a lower risk of cardiovascular disease (CVD). Data from 7 studies (n = 
114,009) showed that the risk of CVD was 37% lower in subjects with the highest amount 
of chocolate consumption [1]. Likewise, data from 9 studies (n = 194,965) showed a 21% 
lower risk of stroke for subjects who consumed 3 cups/d of tea than for subjects who 
consumed <1 cup/d [2]. It is suggested that the beneficial effects of flavonoid-rich foods 
are mediated through reduction of endothelial dysfunction and inflammation which are 
important early steps in the pathogenesis of atherosclerosis [3–5].
Atherosclerosis is characterised by the accumulation of lipids and fibrous elements in 
large arteries and is one of the main contributors to CVD [6]. At sites of inflammation, 
activated endothelial cells release cytokines such as TNF-α, C-reactive protein (CRP), and 
IL-1β, IL-6, and IL-8. In response to these cytokines, adhesion molecules such as soluble 
endothelial selectin (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), 
soluble intercellular adhesion molecule-1 (sICAM-1), and von Willebrand factor (vWf) are 
synthesized by endothelial cells and induce adhesion of leukocytes to the endothelium. 
After adhesion, monocyte chemoattractant protein-1 (MCP-1) induces the transendothelial 
migration of monocytes into the intima [7]. Once in the intima, monocytes take on the role 
and properties of macrophages as they scavenge oxidized LDL, form foam cells, and cause 
fatty streaks and fibrous plaques, leading to atherosclerosis. Indeed, studies have shown 
that biomarkers of inflammation (e.g. CRP, TNF-α, and IL-6) and endothelial dysfunction 
(e.g. sVCAM-1, sICAM-1, and sE-selectin) are predictors of CVD risk [8–10]. 
A limited number of human intervention studies with a duration of 2–6 weeks investi- 
gated the effects of flavonoid-rich foods, such as cocoa and tea, on biomarkers of 
endothelial dysfunction and inflammation. Consuming a high flavan-3-ol (the flavonoid 
subclass of epicatechin) cocoa beverage decreased plasma concentrations of sVCAM-1 by 
11% [11] but did not change sICAM-1. In contrast, consuming 40 g of cocoa decreased 
serum concentrations of sICAM-1 by 10% but did not change sVCAM-1 or markers of 
inflammation, including IL-6 and high-sensitivity CRP [12]. Similarly, consumption of dark 
chocolate and a cocoa drink had no effect on IL-1β, IL-6, high-sensitivity CRP, and TNF-α 
[13]. For black tea, Hodgson et al. [14] found that consumption of 5 cups/d (1 cup = 250 
mL) had no effect on the adhesion molecules E-selectin, P-selectin, sICAM-1, and sVCAM-1, 
which was confirmed by Steptoe et al. [15] for P-selectin. Only one tea intervention studied 
the effect on MCP-1 and found a decrease of 19% [16]. A reduction in CRP of 27%–47% was 
found in two tea interventions [15, 16], whereas another did not find an effect on CRP, IL-
1β, IL-6, or TNF-α [17]. 
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Until now, human intervention studies have only investigated the effects of flavonoid-
rich foods such as cocoa and tea on a limited number of biomarkers of inflammation 
and endothelial dysfunction. These foods are complex mixtures of flavonoids and other 
substances. To unravel the role of individual flavonoids, pure flavonoids should be 
studied. Cocoa and tea are rich dietary sources of epicatechin, whereas tea is the main 
dietary source of quercetin [18, 19]. For this reason, we hypothesised that epicatechin and 
quercetin are responsible for the cardioprotective effects of cocoa and tea. The aim of the 
present study was to investigate whether pure (-)-epicatechin and quercetin could account 
for the beneficial effects of cocoa/chocolate and tea on inflammation and endothelial 
function. This was done for the first time, by measuring a comprehensive set of biomarkers 
of these two functions in a double-blind, placebo-controlled, crossover study in 37 healthy 
(pre)hypertensive adults who ingested supplements with pure isolated (-)-epicatechin, 
quercetin-3-glucoside, or placebo daily for periods of 4 weeks.
METHODS
Study Design
The study was conducted as a 3-armed, randomised, double-blind, placebo-controlled, 
crossover study as described previously [20]. In brief, 37 apparently healthy non-smoking 
men and women between the ages of 40 and 80 years with a BMI (in kg/m2) between 20 
and 40 and systolic blood pressure between 125 and 160 mm Hg took part in the study. 
Excluded from participation were subjects with chronic diseases, users of medication, 
users of prescribed diet, and pregnant or lactating women [20].
Participants ingested equimolecular amounts of (-)-epicatechin (100 mg/d = 345 µmol/d) 
and quercetin-3-glucoside (160 mg/d = 345 µmol/d) and placebo capsules for periods of 4 
weeks, in random order, separated by 4-week washout periods. The dosage of epicatechin 
chosen was in line with the amount of epicatechin present in previous cocoa/chocolate 
intervention studies (46–107 mg/d) [21–24]. For quercetin an equimolecular dose was 
chosen. In The Netherlands, the habitual intake of epicatechin is 11 mg/d and of quercetin 
is 16 mg/d [20]. Subjects were asked to avoid consumption of flavonoid-rich foods (cocoa, 
tea, apples, onion, and red wine) during the study. They consumed a standardised low-
flavonoid meal (boiled potato with a meatball and spinach) the evening before each 
measurement day. Fasted blood samples were collected at the research centre at the start 
and end of each intervention period. All participants provided written consent before the 
start of the study. The study was approved by the Medical Ethics Committee of Wageningen 
University (NL 40772.081.12), and informed consent of all participants was obtained. The 
trial was registered at clinicaltrials.gov as NCT01691404.
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Biomarkers of Endothelial Dysfunction and Inflammation
Serum biomarkers of endothelial dysfunction (sICAM-1, sVCAM-1, sE-selectin, and MCP-1) 
and  inflammation [CRP, serum amyloid A (SAA), TNF-α, IL-1β, IL-6, IL-8, and sICAM-1] were 
assessed by an electrochemiluminescence detection system and vWf by ELISA, as described 
previously [25]. The interassay CVs ranged from 1.8% to 11.1% for all biomarkers. 
Individual z-scores were calculated for each biomarker using the following formula: 
(individual value - population mean)/population SD. Overall z-scores were calculated 
by averaging the individual z-scores according to clusters of biomarkers for endothelial 
dysfunction and inflammation [26, 27]. The endothelial dysfunction cluster consisted of 
sICAM-1, sVCAM-1, sE-selectin, vWf, and MCP-1. The inflammation cluster consisted of 
TNF-α, CRP, SAA, IL-1β, IL-6, IL-8, and sICAM-1. 
Statistical Analysis 
Statistical analyses were performed according to a pre-defined analysis plan using SAS 
9.2 (SAS Institute). Baseline variables were checked for normality of distribution and 
were expressed as mean ± SD for normally distributed variables and median with IQRs 
for skewed variables. The difference between the change during each 4-week treatment 
period and the change during the 4-week placebo period was calculated. This difference 
(∆treatment - ∆placebo) was defined as the treatment effect of epicatechin and quercetin, 
and was statistically tested. Treatment effects were checked for normality of distribution, 
and all variables were considered to be normally distributed. A linear mixed model for 
repeated measures (SAS, PROC MIXED) was used to test the treatment effects. Treatment 
and period were set as fixed effects and subject was set as random effect. Compound 
symmetry was used as covariant structure because this resulted in the best fit according 
to a likelihood ratio test. No clear carryover effect was apparent; therefore, previous 
treatment was not included in the model. Treatment effects are expressed as least squares 
mean with 95% CIs. Statistical significance was set at a 2-sided α-level of 0.05. Effects of 
outliers were checked by performing additional analyses after removal of outliers >5 times 
the SD from the mean. This resulted in the removal of one outlier for MCP-1, vWf, IL-1β, 
IL-6, IL-8, TNF-α, and CRP and two outliers for SAA, distributed over 7 subjects.
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RESULTS
Of the 37 subjects who participated in the study, 4 subjects did not complete all 3 inter-
ventions [20]. These dropouts occurred at different points in the study, meaning that 35 
completed the epicatechin intervention, 35 the quercetin intervention, and 35 the placebo 
intervention. At the start of the study, the mean age of the study population was 66.4 ± 
7.9 years. The average blood pressure (systolic blood pressure/diastolic blood pressure) 
was 129/75 mm Hg, and 23 subjects (62%) had a BMI > 25 kg/m² (Table 1). Body weight 
remained stable throughout the study period (mean change body weight: 0.2 ± 1.3 kg).
The treatment effect of epicatechin supplementation (∆epicatechin - ∆placebo) was a 
significant decrease of plasma sE-selectin by 7.7 ng/mL (95% CI: 14.5, 0.83; p=0.03) (Table 2). 
The magnitude of this effect equalled 10% of the baseline value (Table 1). All other markers 
of endothelial dysfunction did not change significantly. Epicatechin supplementation did 
not significantly change the z-score for endothelial dysfunction biomarkers (Δ = -0.30; 95% 
CI: -0.61, 0.01; p=0.06). Epicatechin had no significant effect on markers of inflammation or 
the z-score for inflammation.
The treatment effect of quercetin supplementation (∆quercetin - ∆placebo) was a 
significant decrease of plasma sE-selectin by 7.4 ng/mL (95% CI: 14.3, 0.56; p=0.03) (Table 
2). The magnitude of this effect equalled 10% of the baseline value (Table 1). No other 
changes in markers of endothelial dysfunction or the z-score for endothelial dysfunction 
were seen. Quercetin significantly decreased (∆quercetin - ∆placebo) IL-1β by 0.23 pg/mL 
(95% CI: 0.40, 0.06; p=0.009) (Table 2). The magnitude of this effect equalled 29% of the 
baseline value (Table 1). All other markers of inflammation did not change significantly. 
However, quercetin supplementation significantly lowered the z-score for biomarkers of 
inflammation (Δ = 0.33; 95% CI: 0.60, 0.05; p=0.02), when compared to placebo. Removal of 
outliers did not change these effects, with the exception of vWf that decreased by 22.6% 
absolute (95% CI: 40.1, 5.0; p=0.01) after epicatechin supplementation once the outlier was 
removed.
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TABLE 1. Baseline characteristics of study population1
Characteristic Value
n, male/female 37, 25/12
Age, yrs 66.4 ± 7.9
Body mass index, kg/m² 26.7 ± 3.3
Systolic blood pressure, mmHg 129.3 ± 14.1
Diastolic blood pressure, mmHg 74.8 ± 9.8
IL-1β, pg/mL 0.78 (0.50 - 1.26)
IL-6, pg/mL 2.5 (1.8 – 4.7)
IL-8, pg/mL 5.3 (4.7 – 6.8)
TNF-α, pg/mL 7.1 (6.5 – 9.1)
CRP, µg/mL 0.97 (0.52 – 2.32)
SAA, µg/mL 2.4 (1.6 – 5.4)
sVCAM-1, ng/mL 427 (359 – 477)
sICAM-1, ng/mL 264 (242 – 291)
sE-selectin, ng/mL 73.6 (60.3– 119)
vWf, % 144 (105 – 181)
MCP-1, pg/mL 284 (247 – 327)
1 Data are given as mean ± SD and median (IQR).
Biomarkers of endothelial dysfunction and inflammation were determined in fasting plasma samples. 
Abbreviations:  CRP = C-reactive protein; IL = interleukin;  MCP-1 = monocyte chemotactic protein-1; 
SAA = serum amyloid A;  sICAM-1 =soluble intercellular adhesion molecule-1;  sE-selectin = soluble 
endothelial selectin; sVCAM-1 = soluble vascular cell adhesion molecule-1; TNF-α = tumor necrosis 
factor-α;  vWf = von Willebrand factor.
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TABLE 2. Effects of (-)-epicatechin (100mg, 345µmol) and quercetin-3-glucoside (160mg, 345µmol) 
supplementation on markers of endothelial dysfunction and inflammation in (pre)hypertensive 
subjects (n=35).1
(-)-Epicatechin Quercetin-3-glucoside
Treatment effect 
(95% CI)2 P-value3
Treatment effect 
(95% CI)2 P-value3
Markers of endothelial 
dysfunction
   sVCAM-1, ng/mL -10 (-58, 37) 0.66  5 (-42, 52) 0.84
   sICAM-1, ng/mL -11 (-28, 4.7) 0.16 -6 (-22, 10) 0.47
   sE-selectin, ng/mL -7.7 (-14.5, -0.83) 0.03 -7.4 (-14.3, -0.56) 0.03
   vWf, % -15 (-37, 8) 0.19 -2 (-25, 20) 0.84
   MCP-1, pg/mL -28 (-77, 22) 0.27 -39 (-88, 11) 0.12
   Z-score -0.30 (-0.61, 0.01) 0.06 -0.20 (-0.52, 0.11) 0.20
Markers of inflammation
   IL-1β, pg/mL -0.07 (-0.24, 0.10) 0.42 -0.23 (-0.40, -0.06) 0.009
   IL-6, pg/mL 0.13 (-0.92, 1.17) 0.81 -0.31 (-1.35, 0.74) 0.56
   IL-8, pg/mL -1.1 (-3.4, 1.2) 0.35 -1.5 (-3.8, 0.8) 0.19
   TNF-α, pg/mL -0.09 (-0.84, 0.66) 0.81 -0.48 (-1.23, 0.27) 0.20
   CRP, µg/mL -1.3 (-6.0, 3.3) 0.57 -0.90 (-5.5, 3.7) 0.70
   SAA, µg/mL -6.4 (-21.1, 8.2) 0.38 -8.7 (-23.4, 6.0) 0.24
   Z-score -0.12 (-0.39, 0.16) 0.40 -0.33 (-0.60, -0.05) 0.02
1 All biomarkers were determined in fasting plasma samples.
2 Data are least square means (95% CI) from linear mixed model for repeated measures with compound 
symmetry as covariant structure. Treatment effect = (∆treatment) – (∆placebo).
3 P-value for treatment effect. 
Abbreviations:  CRP = C-reactive protein; IL = interleukin;  MCP-1 = monocyte chemotactic protein-1; 
SAA = serum amyloid A;  sICAM-1 =soluble intercellular adhesion molecule-1;  sE-selectin = soluble 
endothelial selectin; sVCAM-1 = soluble vascular cell adhesion molecule-1; TNF-α = tumor necrosis 
factor-α;  vWf = von Willebrand factor. 
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DISCUSSION
In this randomised crossover study of 37 healthy (pre)hypertensive adults, supplementation 
of pure epicatechin decreased sE-selectin. All other markers for endothelial dysfunction, 
including the z-score, did not change significantly. Supplementation of pure quercetin 
significantly decreased sE-selectin and IL-1β and the z-score for inflammation. These data 
suggest that the cardiometabolic effects of quercetin and epicatechin only partly overlap, 
which may distinguish the effects of cocoa and tea.
When assessing markers of inflammation and endothelial dysfunction, it is important 
to consider within-subject biological variation [28]. To minimize within-subject variation, 
we designed a crossover study that used a rather strict study protocol. Subjects avoided 
consumption of flavonoid-rich foods throughout the study and also consumed a 
standardised low-flavonoid meal the evening before each measurement day. To reduce 
diurnal variation [29], blood samples were taken at the same time of day. Despite these 
precautions, a large biological variation in markers of inflammation and endothelial 
dysfunction is evident from wide confidence intervals. Baseline values and variation of 
markers of inflammation and endothelial dysfunction were, however, similar to values 
reported in a study with younger Dutch adults (n = 293) that used the same analytical 
methods [30]. Another strength of our study was the high compliance, because >98% of 
capsules distributed were consumed. In addition, increases in plasma epicatechin and 
quercetin concentrations due to supplementation also showed that the flavonoids in the 
capsules were absorbed [20].
Because of the number of biomarkers (n = 11) measured, we cannot exclude the possibility 
of a false-positive finding. Nevertheless, we did not correct for multiple testing because 
these markers are mutually dependent, and correction may hide a true effect. With the use 
of a Bonferroni correction for multiple testing, p-values would need to be <0.005 (0.05/11) 
to be considered statistically significant. After this correction, the changes found would no 
longer be statistically significant. The z-scores for biomarkers of endothelial dysfunction 
and inflammation were calculated because the pathogenesis of atherosclerosis is a 
complex process, involving numerous cytokines and adhesion molecules. As mentioned 
by van Bussel et al. [31], the calculation of a z-score does hold some limitations because its 
calculation is based on the assumption that each biomarker carries a similar weight. This 
may not be the case because some biomarkers may outweigh others. As such, the z-scores 
calculated here do provide pooled measures of endothelial dysfunction and inflammation 
biomarkers, but may not optimally reflect the pathophysiology of endothelial dysfunction 
and inflammation.
To our knowledge, the present study is the first to assess the effects of pure flavonoids on 
a comprehensive set (n = 11) of biomarkers of endothelial dysfunction and inflammation. 
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Only a limited number of interventions with cocoa and tea were published, which all 
addressed only a few of these biomarkers at the same time. Interventions with cocoa and 
tea did not find effects on E-selectin [11, 12, 14]. The magnitude of the effect on E-selectin 
of ~7% found in the present study is similar to the effect of ~10% found for other adhesion 
molecules in some of the cocoa and tea interventions [11, 12]. E-selectin is involved in the 
adhesion of leukocytes to the endothelium [32]. A previous study showed that E-selectin 
concentrations in patients with carotid artery atherosclerosis were 15% higher than in 
control subjects [33]. Furthermore, E-selectin was inversely associated to flow-mediated 
dilation (FMD), a functional marker of endothelial function [28]. This suggests that the 
reductions in sE-selectin of 7% found after both epicatechin and quercetin supplementation 
could beneficially affect endothelial function and the development of atherosclerosis. 
However, we previously published that in this study FMD did not change significantly after 
epicatechin or quercetin supplementation [20]. Endothelial function is a complex process 
that involves numerous molecules and pathways and also pathologic conditions. The lack 
of an effect on FMD of our supplementations, despite a decrease in sE-selectin, suggests 
that other molecules besides sE-selectin and other factors may play a role.
The lack of an effect of epicatechin on markers of inflammation is in line with previous 
chocolate and cocoa intervention studies that showed no effects on markers of inflam-
mation [12, 13]. In contrast to epicatechin, we found that quercetin supplementation 
decreased IL-1β and the z-score for inflammation. To our knowledge, no studies have 
investigated the effects of pure quercetin on inflammation. Only a limited number of 
studies with tea, the main dietary source of quercetin, were reported. Two of 3 of these tea 
interventions found that tea suppressed CRP [15, 16]. However, only one tea intervention 
measured IL-1β, IL-6, and TNF-α, which did not change [17]. These results should be 
compared cautiously, because the dosage of pure quercetin used in the present study 
(100 mg/d) is notably higher than the amount of quercetin present in 4 cups (1 cup = 250 
mL) of black tea (19 mg) [34].
In this intervention study, we previously reported improvements in insulin resistance after 
epicatechin supplementation only [20]. It was suggested that endothelial dysfunction is 
closely related to the pathogenesis of insulin resistance and impaired glucose metabolism 
[5]. Higher concentrations of sE-selectin and, to a lesser extent, sICAM-1 were associated 
with an increased risk of developing diabetes [35]. Similarly, studies have shown higher 
concentrations of sE-selectin and sICAM-1 in subjects with insulin resistance [36–38]. In 
the present study, the decrease in sE-selectin after epicatechin supplementation may 
have contributed to the improvements in insulin resistance reported previously. However, 
quercetin also decreased sE-selectin but did not affect insulin resistance, suggesting that 
other markers are also involved. 
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In conclusion, in (pre)hypertensive men and women, epicatechin supplementation re-
duced sE-selectin, a marker of endothelial dysfunction, but did not significantly change 
other markers of endothelial dysfunction when compared to placebo. This suggests that 
epicatechin may contribute to the cardioprotective effects of epicatechin-rich foods such as 
cocoa and tea. Similarly, quercetin supplementation reduced sE-selectin but also reduced 
IL-1β and the z-score for inflammation. This suggests that quercetin may contribute to 
the cardioprotective effects of quercetin-rich foods such as tea by improving endothelial 
function and reducing inflammation. Further long-term studies are needed to confirm 
these results and to gain more insight into the potential mechanisms behind the proposed 
effects of both epicatechin and quercetin.
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ABSTRACT
Background
There is increasing evidence that consumption of cocoa products have a beneficial 
effect on cardiometabolic health, but the underlying mechanisms remain unclear. Cocoa 
contains a complex mixture of flavan-3-ols. Epicatechin, a major monomeric flavan-3-ol, 
is considered to contribute to the cardioprotective effects of cocoa. We investigated the 
effects of pure epicatechin supplementation on whole genome gene expression profiles of 
circulating immune cells.  
Methods
In a randomised, double blind, placebo-controlled, cross-over trial, 37 (pre)hypertensive 
(40-80 years) subjects received two 4-week interventions; epicatechin (100mg/day) or 
placebo with a washout period of 4 weeks between both interventions. Whole genome 
gene expression profiles of peripheral blood mononuclear cells were determined before 
and after both interventions.
Results
After epicatechin supplementation 1180 genes were significantly regulated, of which 234 
were also significantly regulated compared to placebo. Epicatechin supplementation up-
regulated gene sets involved in transcription/translation and tubulin folding and down-
regulated gene sets involved in inflammation. Only a few genes within these regulated gene 
sets were actually significantly changed upon epicatechin supplementation. Upstream 
regulators that were shown to be inhibited were classified as cytokine or inflammatory 
type molecules. 
Conclusions
Pure epicatechin supplementation modestly reduced gene expression related to inflam-
mation signalling routes in circulating immune cells. These routes are known to play a role 
in cardiovascular health. 
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INTRODUCTION
Prospective cohort studies showed that higher levels of chocolate or cocoa consumption 
are associated with a lower risk of cardiometabolic disorders [1]. In addition, several 
randomised controlled intervention studies showed beneficial effects on intermediate 
markers of CVD, especially on blood pressure, flow mediated dilation (FMD) [a marker 
of endothelial function], but also on insulin resistance [2-4]. Based on this evidence, the 
European Food and Safety Authority (EFSA) approved a health claim that cocoa flavan-
3-ols help maintain normal endothelium-dependent vasodilation [5]. Although a cause-
and-effect relationship has been established between cocoa/chocolate consumption 
and these cardiometabolic health markers, the underlying mechanisms remain largely 
unknown. Recently, we demonstrated in a human intervention study that dark chocolate 
consumption improved FMD and also lowered adhesion molecules on leukocytes in the 
circulation [6]. These findings may suggest a role of immune cells in the cardioprotective 
effects of dark chocolate. 
Cocoa is rich in flavan-3-ols. Epicatechin, its major monomeric flavan-3-ol, may be responsible 
for the beneficial effect of cocoa on FMD [7]. However, cocoa contains a complex mixture 
of many flavan-3-ols and other substances, and the specific role of epicatechin is less well 
studied in isolation. For this reason, we recently conducted a human intervention study to 
determine the effects of pure epicatechin supplementation on markers of cardiometabolic 
health [8, 9]. Findings from that study suggested that epicatechin may, in part, contribute 
to the cardioprotective effects of cocoa by lowering sE-selectin, a leukocyte adhesion 
molecule and marker of endothelial function, and improving fasting insulin and insulin 
resistance [8, 9]. This hypothesis is in line with a cocoa intervention study which showed 
that an improvement in endothelial function after 15 days of dark chocolate consumption 
was paralleled by a decrease in insulin resistance [3].
However, the underlying mechanisms by which epicatechin may affect endothelial function 
in humans remain largely unclear. Several in vitro experiments in human endothelial 
cells demonstrated that epicatechin stimulated the synthesis of nitric oxide (NO), an 
important mediator of vasodilation, and prevented the superoxide-mediated loss of NO 
[10, 11]. Other factors known to be important in endothelial health, such as inflammation, 
leukocyte adhesion and coagulation, might also be affected by epicatechin, but are less 
extensively studied in vivo [6, 12]. Peripheral blood mononuclear cells (PBMC) are immune 
cells which are easy to collect in human intervention studies. These cells play an important 
role in inflammation and endothelial function and react to changes in nutrient levels 
and inflammatory agents in blood. They are, therefore, valuable to study the potential 
cardioprotective effects of epicatechin in vivo [13, 14]. A powerful and largely unbiased 
strategy to understand how nutrients and bioactive compounds may affect cellular 
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processes is by using whole genome wide screening techniques, such as transcriptomics. 
We demonstrated that atherosclerotic-related gene expression changes can be detected 
in PBMCs in vivo upon consumption of different types of fatty acids [13, 14]. Applying such 
high throughput screening tools may increase our understanding of how epicatechin may 
affect immune cells and thereby might exert its cardioprotective effects. For this reason, 
we aimed to investigate the effects of 4-week supplementation of pure epicatechin on 
whole genome gene expression profiles of PBMCs using a randomised, double-blind, 
placebo-controlled, crossover trial. 
MATERIALS AND METHODS
Subjects
We included 37 (pre-)hypertensive subjects (25 men, 12 women) between 40-80 years 
old from a previously reported study [8]. All subjects were non-smoking and free of 
chronic diseases. All subjects gave written informed consent and the study was approved 
by the local Medical Ethics Committee. The study was registered at clinicaltrials.gov as 
NCT01691404. 
Study Design
The original study [8, 9] investigated the effects of epicatechin and quercetin-3-glucoside 
on markers of cardiometabolic health. Because epicatechin had more pronounced effects 
on these markers than quercetin, we selected only the epicatechin treatment for PBMC 
transcriptome analysis and compared these effects with the placebo group. 
The study was a randomised, double blind, placebo-controlled, cross-over trial in 
which subjects received two 4-week interventions; epicatechin (100mg/day) or placebo 
(microcrystalline cellulose). Details of the study have been described previously [8]. In brief, 
subjects received both interventions in random order with a washout period of 4 weeks 
between both interventions. Subjects consumed 2 capsules per day with a glass of water: 
one during breakfast and one during dinner. Subjects were asked to avoid consumption of 
epicatechin-rich foods throughout the study period. Fasting PBMCs were collected before 
(T0) and after each intervention period (T4). On the day prior to each study day, subjects 
received a standardised evening meal, refrained from alcohol consumption and strenuous 
exercise, and were not allowed to eat or drink anything except water after 22:00. 
PBMC and RNA isolation
Fasting PBMCs were isolated before and after both intervention arms using BD Vacutainer 
Cell Preparation Tubes. RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), 
quantified (Nanodrop ND 1000, Nanodrop technologies, Wilmington, Delaware USA) and 
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integrity was checked by an Agilent 2100 Bioanalyser with RNA 6000 microchips (Agilent 
Technologies, South Queensferry, UK). Samples were included for microarray analysis if 
the RNA integrity number (RIN) was > 7.  
Microarray Processing 
PBMC samples from 32 subjects yielded enough RNA of sufficient quality at all collection 
points to perform microarray analysis. Microarray analysis was performed for each 
individual before and after 4 weeks supplementation of placebo and epicatechin, resulting 
in a total of 128 microarrays, which all passed the RNA quality control (RIN>7). Total RNA 
was labelled using a one-cycle cDNA labelling kit (MessageAmp™ II-Biotin Enhanced Kit; 
Ambion Inc, Nieuwekerk a/d IJssel, Netherlands) and hybridised to GeneChip® Human 
Gene 1.1 ST Array targeting 19,738 unique gene identifiers (Affymetrix Inc. Santa Clara, CA). 
Sample labelling, hybridization to chips and image scanning were performed according to 
the manufacturers’ instructions.
Microarray Analysis
MADMAX pipeline was used for statistical analysis of microarray data [15]. Microarrays 
were analysed using the reorganised oligonucleotide probes, which combine all individual 
probes for a gene [16]. Expression values were calculated using the robust multichip 
average (RMA) method and normalised by quantile normalisation [17, 18]. Genes with 
normalised signals >20 on >10 arrays were defined as expressed and selected for further 
analysis. Microarray data are registered as GSEXXXX in the Gene Expression Omnibus. 
Differences in gene expression changes between intervention groups were calculated 
from the individual signal-to-log ratios (SLR). The change over time in gene expression due 
to the intervention (Δ epicatechin or Δ placebo) was considered significant if the p-value in 
a paired t-test with Bayesian correction was <0.05 (Limma) [19]. The difference between 
the change during the epicatechin intervention and the placebo intervention (Δ epicatechin 
vs. Δ placebo) was analysed in the same way. Data was further analysed with gene set 
enrichment analysis (GSEA) [20] to identify regulated gene sets and QIAGEN’s Ingenuity 
Pathway Analysis (IPA®,QIAGEN Redwood City) to identify transcriptional regulators. Gene 
sets with a false discovery rate (FDR) Q-value <0.25 were defined as significantly regulated 
and further analysed in Cytoscape (Cytoscape 2.8.3) to visualise clusters of the most 
significantly changed gene sets. 
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RESULTS
The mean age of the 32 subjects included in the analysis was 65.8 ± 7.9 years and the mean 
BMI was  26.7 ± 3.5 kg/m² (Table 1). Epicatechin supplementation changed the expression 
of 1180 genes (Δ epicatechin), and placebo changed the expression of 500 genes (∆placebo) 
(Figure 1). Expression of 465 genes changed significantly between the epicatechin and the 
placebo intervention (Δ epicatechin vs. Δ placebo). Of these 465 genes, 234 genes also 
changed in expression upon epicatechin intervention (Δ epicatechin) with an up-regulated 
expression of 95 genes and a down-regulated expression of 139 genes. To obtain a 
selection of robust responding genes upon epicatechin consumption (Δ epicatechin), we 
selected the 20 genes with the lowest p-value. These selected genes ranked based upon 
SLR are visualised in an expression heatmap (Figure 2).
Gene Set Enrichment Analysis
To elucidate which gene sets were regulated by epicatechin supplementation we performed 
a GSEA. Significantly regulated gene sets between intervention arms (Δ epicatechin vs. Δ 
placebo) and within epicatechin intervention(Δ epicatechin) included 35 upregulated gene 
sets and 21 down–regulated gene sets (FDRQ<0.25) (Supplemental Table 1 and 2). High 
ranking gene sets (ranked on normalised enrichment score (NES), FDR Q< 0.1) that were 
affected after the epicatechin intervention and were also significantly changed between
TABLE 1. Baseline characteristics of 32 healthy subjects included in the analysis.
N = 32
Male/female 20/12
Age (yrs) 65.8 ± 7.9
BMI (kg/m²) 26.7 ± 3.52
Office SBP (mmHg) 128.2 ± 13.0 
Office DBP (mmHg) 74.3 ± 9.3
Plasma glucose (mmol/L) 5.72 ± 0.57
Serum insulin (mU/L) 6.76 ± 4.49
HOMA-IR 1.74 ± 1.16
Fasting serum lipids (mmol/L)
Total cholesterol 5.62 ± 0.75
LDL cholesterol 3.46 ± 0.65
HDL cholesterol 1.56 ± 0.44
Triglycerides 1.32 ± 0.51
Values are mean ± SD. 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; 
HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; SBP, 
systolic blood pressure.
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the epicatechin and the placebo intervention (Δ epicatechin vs. Δ placebo) are visualised 
in Figure 3. A cluster of gene sets with genes involved in transcription/translation was 
upregulated. Gene sets in this cluster largely included zinc finger proteins and ribosomal 
proteins. Other upregulated gene sets included genes involved in ‘tubulin folding’. Changes 
of individual genes within these above described up-regulated gene sets showed a relatively 
large variation in response (Supplemental Figure 1). A down-regulated cluster included 
inflammatory gene clusters IL8–CXCR1/2 pathways and AMB2_neutrophil pathway, which 
are related to vascular health (Figure  3). Only a few genes within these significantly down-
regulated gene sets were changed significantly after the epicatechin intervention and 
between intervention arms (Δ epicatechin vs. Δ placebo) (Supplemental Figure 1). In the 
current study we observed that epicatechin supplementation resulted in improved fasting 
insulin and insulin resistance [8]. We therefore specifically investigated if related pathways 
were affected. The insulin synthesis and processing pathway was upregulated (FDR q= 
0.11, supplemental table 1)  but no genes within this gene set were changed significantly 
after the epicatechin intervention and between intervention arms (Δ epicatechin vs. Δ 
placebo). The AMPK signalling pathway was down regulated (FDR q= 0.17, supplemental 
table 1), but only the PLCB1 gene changed significantly after the epicatechin intervention 
and between intervention arms within this pathway. 
FIGURE 1. Flow diagram showing the number of genes of which the expression was changed after 
4-week epicatechin or placebo supplementation and the number of genes that significantly changed 
in expression between the epicatechin or placebo intervention. A change was considered significant 
if P<0.05.
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Upstream Regulator Analysis
In order to identify common upstream regulators of the affected genes we performed 
an upstream regulator analysis using Ingenuity Pathway Analysis. No significant potential 
upstream regulators were identified if we compared the epicatechin and the placebo 
intervention (Δ epicatechin vs. Δ placebo).  However, when analysing the effects upon 
epicatechin supplementation only, we identified 3 activated and 16 inhibited potential 
upstream regulators (Table 2). No significant upstream regulators were identified upon 
placebo supplementation. Upregulated upstream regulators were Hdac, miR-155-5p and 
JAG2. The majority of the inhibited upstream regulators upon epicatechin supplementation 
were classified as platelet-derived growth factor complex (PDGF BB), or as a cytokine (TNF, 
CCL5, IL1β, IL1A, IL17A and IFNG) or other inflammatory type molecules (NF-kB, RELA (NF-
kB p65 subunit) and TLR7). 
FIGURE 3. Enrichment map of gene sets (FDR Q< 0.25) that changed significantly after 4-week pure 
epicatechin supplementation (Δ epicatechin ) and between the epicatechin and the placebo intervention 
(Δ epicatechin vs. Δ placebo). Nodes represent gene sets, whereas lines indicate overlapping genes 
between the gene sets (overlap cut-off: 0.5). Colours in the nodes indicate if the gene set was up-
regulated (red), down-regulated (blue) after pure epicatechin supplementation. Abbreviations: BIOC, 
BioCarta Pathway Diagrams; KEGG, Kyoto Encyclopedia of Genes and Genomes database; NCI, Nature 
Pathway Interaction database; REACT, Reactome knowledgebase; WIP_HS, WikiPathways Homo 
Sapiens.
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TABLE 2. Predicted upstream regulators upon epicatechin supplementation (Δ epicatechin)*.
Upstream Regulator Molecule Type
Predicted 
Activation 
State
Activation 
z-score
p-value of 
overlap
NUPR1 transcription regulator Inhibited -4,343 0.000
TNF cytokine Inhibited -3,664 0.013
PDGF BB complex Inhibited -3,606 0.000
NFkB (complex) complex Inhibited -3,328 0.045
RELA transcription regulator Inhibited -3,207 0.007
STAT3 transcription regulator Inhibited -3,112 0.006
SYVN1 transporter Inhibited -3,051 0.035
TGM2 enzyme Inhibited -3,031 0.019
CCL5 cytokine Inhibited -2,646 0.007
IL1B cytokine Inhibited -2,589 0.003
FOXL2 transcription regulator Inhibited -2,435 0.002
EGFR kinase Inhibited -2,413 0.003
IL1A cytokine Inhibited -2,394 0.027
NCR2 transmembrane receptor Inhibited -2,213 0.002
IL17A cytokine Inhibited -2,156 0.040
ID1 transcription regulator Inhibited -2,000 0.006
Hdac group Activated 2,378 0.039
miR-155-5p mature micro-rna Activated 2,425 0.004
JAG2 growth factor Activated 2,804 0.000
*No significant upstream regulators were identified upon placebo supplementation (Δ placebo), or 
between the placebo or epicatechin intervention (Δ epicatechin vs Δ placebo). (P value <0.05 and 
activation z-score > 2 or <-2). 
DISCUSSION
In a 4-week randomised, double-blind, placebo-controlled, crossover trial we demonstrated 
that epicatechin supplementation modestly affected PBMC gene expression profiles. 
Compared to placebo, epicatechin up-regulated gene sets involved in transcription/
translation and tubulin folding, and down-regulated gene sets involved in inflammation. 
However, within these regulated gene sets, expression of only a few genes was significantly 
changed upon epicatechin supplementation and significantly changed between the 
epicatechin and the placebo intervention (Δ epicatechin vs. Δ placebo). 
Processed on: 9-6-2016
503508-L-bw-Dower
101
 
5
Ep
ic
at
ec
hi
n 
an
d 
ge
ne
 e
xp
re
ss
io
n
The down-regulation of the clusters IL8 –CXCR1/2 and AMB2_neutrophil pathway points 
in the direction of an anti-inflammatory effect by epicatechin. Furthermore, a number of 
potential upstream regulators, including  NF-κB, TNF and IL1β that have been classified 
as cytokine or inflammatory type molecules were inhibited upon epicatechin sup-
plementation. These differences did not remain, however, when compared to placebo. If 
epicatechin does exert anti-inflammatory effects, we hypothesise that these effects may 
be mediated via the inhibition of MAPKs and the subsequent inhibition of inflammatory 
transcription factors such as NF-κB and AP-1 [21]. This hypothesis is supported  by a 
previously published human intervention trial which showed that cocoa powder (28.2mg 
epicatechin) significantly decreased NF-κB activation in PBMCs compared to baseline [22]. 
Similarly, Morrison et al. showed that pure epicatechin supplementation prevented diet-
induced activation of aortic NF-κB in ApoE*3-Leiden mice fed an atherogenic diet [23]. The 
reduction in expression of genes involved in inflammation by epicatechin may be one of 
the contributing factors to the cardioprotective effects of cocoa [24]. However, it must be 
noted that the effects of epicatechin supplementation on plasma markers of endothelial 
dysfunction or inflammation in this intervention study were relatively mild; out of 11 
plasma markers of inflammation or endothelial dysfunction, only sE-selectin was changed 
by epicatechin supplementation when compared to placebo [9]. Plasma markers reflect 
a systemic response coming from several organs. Because the current analysis focused 
specifically on the effects in circulating immune cells, comparisons with plasma markers 
should be made cautiously.
We previously reported in this intervention study that epicatechin supplementation 
improved insulin resistance [8]. Although an up-regulation of the insulin synthesis and 
processing pathway was observed, no genes within this gene set changed significantly 
between intervention arms. The current observed effects on gene expression in PBMCs are 
too variable between individuals to draw conclusions with respect to changes in glucose/
insulin regulatory pathways. As insulin signalling is especially of relevance in metabolically 
active organs, such as muscle, immune cells may not be the optimal cell-type to study the 
observed effects of epicatechin on insulin resistance. In addition, many changes in insulin 
signalling are regulated on the protein level by, for instance, phosphorylation [25]. 
Cardiometabolic health effects of pure epicatechin may also work via an increased NO 
bioavailability [26]. A hypothesised mechanism through which epicatechin may increase 
the bioavailability of NO is by protecting against oxidative damage via the transcription 
factor Nrf2 [27]. However, our results do not point towards this hypothesis. With our 
non-targeted approach, we identified up-regulated gene sets involved in transcription/
translation and tubulin folding upon epicatechin supplementation. These gene sets are 
involved in basic cellular functions. How epicatechin may affect these pathways in PBMCs 
is so far unclear. 
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In the current study, 1180 genes were significantly regulated (p<0.05) after epicatechin 
supplementation. However, after comparison to the placebo intervention we identified 
465 genes to be significantly regulated. Only 234 of these genes were overlapping and 
were considered to be significantly regulated by epicatechin supplementation compared 
to the placebo. This number of genes and the magnitude of change were smaller than 
previously found for various fatty acids, also in PBMCs [14]. The small effect sizes and the 
large variation in individual responses may explain the relatively low number of genes 
significantly regulated. As a consequence, pure epicatechin, in concentrations achievable 
with dietary exposure , did not show consistent and robust effects on gene expression in 
immune cells. The molecular effects of (-)-epicatechin on immune cells will depend on the 
concentrations of epicatechin metabolites in the circulation available for  interaction with 
membranes or inside cells [28]. In humans, epicatechin is absorbed by epithelial cells in 
the jejunum and completely metabolised upon absorption to (-)-epicatechin glucuronides, 
sulfates, and O-methyl sulfates [29]. The absorption and conjugation patterns may differ 
substantially between subjects [7] and may, therefore, affect receptors and nuclear factors 
differently. This could explain the large variation in gene expression response. Previous 
studies in our group on the effects of isoflavones demonstrated that the effects of 
isoflavones on whole-genome wide expression are more pronounced in adipose tissue [30] 
compared to PBMCs [31]. Similarly, the effect of epicatechin might be more pronounced in 
other cells, such as endothelial cells, adipose or muscle tissue and effects on PBMCs might 
be relatively modest [28].
The compliance in this relatively large cross-over study (n=32) was high; >98% of the 
distributed supplements were consumed, causing a marked increase in plasma epi-
catechin concentrations upon acute consumption of the capsules [8]. In the current 
design we compared the changes induced by 4-week supplementation of epicatechin to 
those induced by placebo supplementation. Only 234 of these genes were significantly 
regulated, even without false discovery rate controlling procedures. We considered genes 
changed if they were significantly changed after both the epicatechin intervention and 
between the epicatechin and the placebo intervention (Δ epicatechin vs. Δ placebo). Such 
an approach is rather strict, but in our opinion it is also the most valid way of performing 
such analysis. Especially when considering that 500 genes were significantly changed by 
the placebo treatment. 
In conclusion, pure epicatechin supplementation in (pre)hypertensive men and women 
affected gene expression profiles in PBMCs, but the effects were relatively small and the 
variation in individual responses was large. Results from this gene expression analysis, 
suggest that epicatechin may inhibit inflammation signalling routes which are known to 
play a role in cardiovascular health. 
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SUPPLEMENTAL TABLE 1: Significantly up–regulated gene sets in both within the epicatechin inter-
vention (Δ epicatechin) and between intervention arms (Δ epicatechin vs. Δ placebo).
NAME
SIZE
(# genes) NES
FDR
q-value
KEGG_RIBOSOME 74 2 0.14
REACT_FORMATION OF A POOL OF FREE 40S SUBUNITS 79 1.9 0.15
REACT_FORMATION OF THE TERNARY COMPLEX, AND 
SUBSEQUENTLY, THE 43S COMPLEX
41 1.9 0.12
REACT_INSULIN SYNTHESIS AND PROCESSING 109 1.9 0.11
REACT_POST-ELONGATION PROCESSING OF INTRONLESS PRE-
MRNA
22 1.9 0.1
REACT_VIRAL MRNA TRANSLATION 68 1.9 0.09
REACT_EUKARYOTIC TRANSLATION TERMINATION 70 1.9 0.08
REACT_INFLUENZA VIRAL RNA TRANSCRIPTION AND 
REPLICATION
68 1.9 0.07
REACT_NONSENSE MEDIATED DECAY INDEPENDENT OF THE 
EXON JUNCTION COMPLEX
75 1.9 0.07
REACT_PROCESSING OF CAPPED INTRONLESS PRE-MRNA 22 1.9 0.06
WIP_HS_CYTOPLASMIC_RIBOSOMAL_PROTEINS 74 1.9 0.07
REACT_RNA POLYMERASE II TRANSCRIPTION TERMINATION 40 1.9 0.06
REACT_CLEAVAGE OF GROWING TRANSCRIPT IN THE 
TERMINATION REGION
40 1.8 0.06
REACT_POST-ELONGATION PROCESSING OF THE TRANSCRIPT 40 1.8 0.06
REACT_GENE EXPRESSION 492 1.8 0.06
REACT_FORMATION OF TUBULIN FOLDING INTERMEDIATES BY 
CCT_TRIC
19 1.8 0.06
REACT_COOPERATION OF PREFOLDIN AND TRIC_CCT  IN ACTIN 
AND TUBULIN FOLDING
26 1.8 0.06
REACT_GENERIC TRANSCRIPTION PATHWAY 204 1.8 0.08
REACT_POST-ELONGATION PROCESSING OF INTRON-
CONTAINING PRE-MRNA
31 1.8 0.08
REACT_MRNA 3-END PROCESSING 31 1.8 0.08
REACT_3 -UTR-MEDIATED TRANSLATIONAL REGULATION 88 1.7 0.08
REACT_PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE  TO 
CCT_TRIC
25 1.7 0.07
REACT_RNA POLYMERASE II TRANSCRIPTION 92 1.7 0.08
REACT_PD-1 SIGNALING 25 1.6 0.13
KEGG_ASTHMA 19 1.6 0.13
REACT_NONSENSE MEDIATED DECAY ENHANCED BY THE EXON 
JUNCTION COMPLEX
92 1.6 0.13
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NAME
SIZE
(# genes) NES
FDR
q-value
REACT_NONSENSE-MEDIATED DECAY 92 1.6 0.15
REACT_PHOSPHORYLATION OF CD3 AND TCR ZETA CHAINS 22 1.6 0.16
REACT_INTERACTIONS OF REV WITH HOST CELLULAR PROTEINS 32 1.6 0.16
REACT_FORMATION AND MATURATION OF MRNA TRANSCRIPT 146 1.5 0.17
REACT_TRANSCRIPTION 131 1.5 0.18
REACT_NUCLEAR IMPORT OF REV PROTEIN 31 1.5 0.18
REACT_TRANSLOCATION OF ZAP-70 TO IMMUNOLOGICAL 
SYNAPSE
20 1.5 0.2
NCI_DNAPK_PATHWAY 15 1.5 0.2
REACT_METABOLISM OF NON-CODING RNA 21 1.5 0.2
Ranking based on normalised enrichment score (NES). Abbreviations: KEGG, Kyoto Encyclopedia 
of Genes and Genomes database; NCI, Nature Pathway Interaction database; REACT, Reactome 
knowledgebase; WIP_HS, WikiPathways Homo Sapiens.
SUPPLEMENTAL TABLE 1. Continued
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SUPPLEMENTAL TABLE 2. Significantly down–regulated gene sets within the epicatechin intervention 
(Δ epicatechin) and between intervention arms (Δ epicatechin vs. Δ placebo)
NAME
SIZE
(# genes) NES
FDR        
q-value
WIP_HS_NOTCH_SIGNALING_PATHWAY 42 -2.3 0.00
NCI_RETINOIC_ACID_PATHWAY 23 -2.2 0.01
NCI_AURORA_A_PATHWAY 29 -2.0 0.05
REACT_SIGNALING BY RHO GTPASES 102 -2.0 0.06
NCI_IL8CXCR2_PATHWAY 31 -1.9 0.05
REACT_RHO GTPASE CYCLE 102 -1.9 0.04
NCI_IL8CXCR1_PATHWAY 25 -1.9 0.04
NCI_RAC1_REG_PATHWAY 32 -1.9 0.06
WIP_HS_ADIPOGENESIS 103 -1.9 0.06
NCI_AMB2_NEUTROPHILS_PATHWAY 30 -1.8 0.06
WIP_HS_FOLATE_METABOLISM 44 -1.8 0.09
NCI_HES_HEYPATHWAY 40 -1.7 0.13
KEGG_PPAR SIGNALING PATHWAY 41 -1.6 0.15
NCI_AP1_PATHWAY 55 -1.6 0.16
WIP_HS_ANGIOGENESIS 17 -1.6 0.16
WIP_HS_AMPK_SIGNALING 54 -1.6 0.17
REACT_REGULATION OF LIPID METABOLISM BY PPAR 41 -1.5 0.21
REACT_TRANSMISSION ACROSS CHEMICAL SYNAPSES 103 -1.5 0.20
REACT_SYNAPTIC TRANSMISSION 143 -1.5 0.20
NCI_CDC42_REG_PATHWAY 26 -1.5 0.24
REACT_G ALPHA (Q) SIGNALLING EVENTS 106 -1.4 0.25
Ranking based on normalised enrichment score (NES). Abbreviations: KEGG, Kyoto Encyclopedia 
of Genes and Genomes database; NCI, Nature Pathway Interaction database; REACT, Reactome 
knowledgebase; WIP_HS, WikiPathways Homo Sapiens.
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ABSTRACT
Background
Cocoa, rich in flavan-3-ols, improves vascular function, but the contribution of specific 
flavan-3-ols is unknown. Epicatechin, a major flavan-3-ol in cocoa, may play an important 
role. We compared the effects of pure epicatechin and chocolate in a randomised cross-
over study.
Methods
Twenty apparently healthy men aged 40-80 years completed the study. Treatments were: 1) 
70g dark chocolate (150 mg epicatechin) with two placebo capsules; 2) two pure epicatechin 
capsules (100 mg epicatechin) with 75g white chocolate and 3) two placebo capsules with 
75g white chocolate (0 mg epicatechin). Flow-mediated dilation (FMD), augmentation 
index (AIx) and additional markers of vascular function were measured before and 2 hours 
after interventions. These changes were compared between intervention and placebo 
(∆intervention-∆placebo) with linear mixed models for repeated measures. Epicatechin 
metabolites were measured in blood samples taken repeatedly, and the area under the 
concentration-time curve (AUC) was calculated to determine bioavailability.
Results
There was no significant difference in improvement in FMD (∆0.21%; p=0.65) or AIx (∆-
2.4%; p=0.20) between pure epicatechin and dark chocolate. The absolute changes in FMD 
(+0.75%; p=0.10) and AIx (-2.2%; p=0.23) after pure epicatechin were not significant. Dark 
chocolate improved FMD (+0.96%; p=0.04) and AIx (-4.6%; p=0.02). Standardised per 100mg 
of epicatechin, the AUC did not differ (p=0.14) between pure epicatechin (18.9 µM.h) and 
dark chocolate (16.2 µM.h).
Conclusion
The acute improvements in FMD and AIx after pure epicatechin and dark chocolate were 
similar and the bioavailability of epicatechin did not differ. This suggests that epicatechin 
may contribute to the vascular effects of cocoa. 
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INTRODUCTION
Cocoa consumption is associated with a lower risk of cardiovascular disease (CVD). In a 
meta-analysis of prospective cohort studies, subjects (n=114,009) with the highest level 
of chocolate consumption had a 37% lower risk of CVD, compared to the lowest level [1]. 
Human randomised controlled  trials (RCTs) showed that consumption of flavonoid-rich 
cocoa/chocolate improved risk factors of CVD, such as blood pressure [2] and insulin 
resistance (HOMA-IR) [3], as well as flow-mediated dilation (FMD) - a measure of endothelial 
function. RCTs showed that acute cocoa/chocolate consumption increased FMD by 3.2% 
[3]. In addition, chocolate consumption improved vascular function by reducing arterial 
stiffness acutely (2-3 hours), as measured by augmentation index (AIx) [4, 5]. Potential 
mechanisms point to an increase in nitric oxide (NO), a vasodilator, after chocolate 
consumption and a decrease in endothelin-1, a vasoconstrictor [6]. 
Cocoa is notably rich in flavan-3-ols, and contains a mixture of monomers and oligomers 
(up to 10 units). Ottaviani et al. showed that only monomeric flavan-3-ols, but not 
oligomers contributed to the plasma pool of flavan-3-ols in humans [7]. Cocoa contains two 
monomeric flavan-3-ols; epicatechin and catechin. The content of epicatechin in cocoa is 
approximately three times higher than that of catechins [8]. A study in rats also showed that 
epicatechin was more bioavailable than catechins [9]. The relatively high bioavailability and 
high natural occurrence of epicatechin in cocoa suggests that epicatechin may contribute 
directly to the cardioprotective effects of cocoa. In a study with 10 subjects, Schroeter et 
al. showed that changes in FMD after acute cocoa consumption correlated with changes in 
plasma epicatechin concentrations [10]. Furthermore, Loke et al. showed that 200 mg of 
pure epicatechin increased NO and decreased endothelin-1 concentrations acutely [11]. 
Effects of other compounds in cocoa such as theobromine and magnesium on vascular 
function have not yet been studied [12], and to our knowledge, the bioavailability of pure 
epicatechin and epicatechin from chocolate has also not yet been compared. As such, the 
contribution of epicatechin to the vascular effects of cocoa is still unclear. In the present 
study we aimed to compare the acute effects of pure epicatechin (in supplement form) 
and dark chocolate on vascular function in a randomised, assessor-blind, crossover study. 
In addition, we compared the bioavailability of pure epicatechin and epicatechin in dark 
chocolate.
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METHODS
Subjects 
Apparently healthy, non-smoking, men aged 40 to 80 years and with a BMI between 20 and 
30 kg/m2 were recruited from the area of Wageningen and surroundings, in the Netherlands. 
Exclusion criteria included presence of diabetes mellitus, cardiovascular, gastrointestinal 
or liver diseases as well as usage of anti-hypertensive or cholesterol-lowering medication, 
adherence to a prescribed diet, unstable weight in the last two months and high levels of 
moderate physical activity (>10hrs/week). All participants (Table 1) gave written informed 
consent and the study was approved by the Medical Ethics Committee of Wageningen 
University (NL 4843308114). The trial was registered at ClinicalTrials.gov (registration no: 
NCT02221791).
Study Design
The study was conducted as an acute randomised, placebo-controlled, crossover inter-
vention in September and October 2014. Subjects received three treatments, encoded 
A, B, and C. Subjects were allocated to one of six possible intervention sequences using 
computer-generated block randomization. The three treatments were: 1) 70g of dark 
chocolate (150 mg epicatechin) with two placebo capsules; 2) pure epicatechin (100mg) in 
two capsules with 75g of white chocolate and 3) two placebo capsules with 75g of white 
chocolate (0 mg epicatechin). Epicatechin capsules contained 50 mg of (-)-epicatechin 
(purity 96.2%) and microcrystalline cellulose as an excipient. Placebo capsules contained 
only microcrystalline cellulose [13]. Treatments were provided in sealed envelopes by a 
member of staff not involved in the study, leaving researchers blind to treatment allocation. 
Subjects were blinded to the type of capsule (A,B, or C) but not to the type of chocolate.
TABLE 1. Composition of the chocolates.
Dark chocolate (70g) White chocolate (75g)
(-)-Epicatechin (mg)
(+)-Catechin (mg)
150 
42
0
0
Energy (kcal) 397 415
Total fat (g) 30 25
Saturated fat (g) 18 16
Carbohydrates (g) 22 42
Sugars (g) 19 42
Protein (g) 5 6
Magnesium (mg) 114 5
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Participants visited the university on three measurement days, which were each separated 
by a two-week washout period. For the 24-hours prior to each measurement day, subjects 
were asked to avoid physical activity and alcohol consumption and in the evening 
consumed a standardised low-flavonoid meal provided by the research team. One week 
prior to the start of the study and throughout the study period, subjects were asked to 
avoid consumption of flavonoid-rich foods (cocoa products, red wine and apples) and to 
drink no more than one cup of tea per day. 
Baseline vascular function (FMD and AIx) was measured in a fasting state (T=0), at the 
beginning of each measurement day (Figure 1). Immediately after baseline measurements, 
subjects consumed the chocolate and capsules with a glass of water. Vascular function 
measurements were repeated two hours after chocolate consumption (T=2). To determine 
bioavailability, blood samples were taken by means of an intravenous catheter (venflon) 
at baseline (T=0) as well as 1 hour, 2, 3, 4, 6 and 8 hours after chocolate consumption. 
Participants received a flavonoid-free breakfast consisting of bread, cheese, honey, water 
and milk after all vascular function measurements were completed (after T=2).
Chocolate Composition
The dark and  white chocolate were matched for energy, fat, saturated fat and protein 
(Table 1). The dark chocolate was obtained from Barry Callebaut® (CHD-070-ACTICOA--558) 
and the white chocolate was a commercially available brand (Verkade). The flavan-3-ol 
monomer concentrations of the two types of chocolate were determined by means of 
reversed phase HPLC with fluorescence detection [14]. Samples of NIST Baking Chocolate 
(NIST2384) were analysed as a certified reference sample, and the estimated epicatechin 
content for the NIST Baking Chocolate was close to the certified value and within the 
certified range. The daily dose of dark chocolate contained 150 mg of (-)-epicatechin and 
42 mg of (+)-catechin. The white chocolate contained no (-)-epicatechin or (+)-catechin. The 
dark chocolate provided 19 g of sugar and 114 mg of magnesium, compared to 42 g of 
sugar and 5 mg of magnesium for the white chocolate. 
FIGURE 1. Timeline of intervention study. Participants received interventions (dark chocolate, 
epicatechin and placebo) in random order. The chocolate was consumed immediately after the 
baseline measurements (T = 0 hrs) were completed. Each intervention was separated by a 2-week 
washout period. Vascular function measurements included flow-mediated dilation and pulse wave 
analysis. 
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Vascular Function
Endothelial function (FMD) was measured non-invasively in the right brachial artery by 
the same researcher, who was blinded to treatment allocation. An ultrasound transducer 
(7.5 MHz) was positioned proximal to the antecubital fossa. Baseline arterial diameter 
was measured for 3 mins. Subsequently, reactive hyperaemia was induced by 5 mins of 
lower arm occlusion through inflation of a cuff to 200mmHg. FMD-images were processed 
automatically using custom-written software (MyFMD, Prof. A.P.G. Hoeks, Department 
of Biomedical Engineering, Maastricht University). FMD was calculated as peak change 
in arterial diameter following reactive hyperaemia relative to baseline. Endothelium-
independent vasodilation was calculated as peak change in arterial diameter over a 5 
minute period following sublingual administration of 400 µg of glyceryl trinitrate (GTN) 
and did not differ between the interventions. 
Arterial stiffness was measured  as AIx corrected for a heart rate of 75 bpm. Measurements 
were taken in triplicate by means of applanation tonometry using the SphygmoCor system 
(version 8: Atcor Medical, Sydney, Australia). Central aortic waveforms were derived using a 
validated transfer function [15, 16]. Subsequently, HR-corrected central AIx, subendocardial 
viability ratio (SEVR) and ejection duration were estimated using integrated software. Office 
BP was measured as the mean of the last three of four measurements using an automated 
oscillometric device (Dinamap Pro 100). All measurements were taken in a temperature-
controlled room (20-24°C), in the supine position, after 10 minutes of rest.
Blood Parameters
Heparin-plasma samples were taken at baseline (T=0) and two hours after chocolate 
consumption (T=2) to determine plasma NOx concentrations by chemiluminescence of 
NO formed after release from NO2, NO2- and nitrosated and nitrosylated species [17]. 
To minimize NOx contamination, measurements of NOx were performed only when 
atmospheric NOx concentrations were below 40 µg/m3. Detection limit was 10 nmol/L 
and the intra-assay coefficient of variation was 8.3%. Endothelin-1 was measured by an 
electrochemiluminescence detection system using multiarray technology (SECTOR Imager 
2400, Meso Scale Discovery) in EDTA-plasma.
To determine epicatechin bioavailability, EDTA-plasma samples were taken at all 7 time-
points throughout the day. Monomeric (epi)catechin metabolites were determined using 
a slightly modified procedure as described previously [18]. In brief, after centrifugation, 
plasma samples were mixed with a storage solution of 0.4M NaH2PO4 buffer containing 
20% ascorbic acid and 0.1% EDTA, and stored at -80°C until further analysis. For analysis, 
plasma samples were thawed and mixed with taxifolin as internal standard. Proteins were 
precipated with trichloroacetic acid and dimethylformadide. UPLC-MS/MS analysis was 
used to determine sulfated, glucuronidated and methylated metabolites of (-)-epicatechin 
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and (+)-catechin including di-conjugated metabolites. For each type of (epi)catechin 
metabolite (e.g. monosulfate, monoglucuronide, etc.), a number of isomers with distinct 
retention times were observed, and the peak areas of all isomers were summed for the 
purposes of calculating total (epi)catechin metabolites.  
Statistical Analysis
FMD was defined as the primary outcome and the power calculation was based on previous 
cocoa studies3. Assuming an SD in absolute FMD change of 2.5%, 16 participants would 
provide sufficient power to detect an absolute change of 2.1% (2-sided α  of 5%, power = 
80%). All analyses were performed according to a pre-defined statistical analysis plan using 
SAS software version 9.3 (SAS Institute, Cary, NC) prior to de-blinding. The change over 
time from baseline to 2-hour post intervention was calculated for each vascular function 
parameter. Treatment effect was defined as the difference between the change over time 
after each intervention compared to placebo (∆ intervention - ∆ placebo). Histograms of 
treatment effects were visually inspected and all treatment effects were judged to be 
normally distributed. Linear mixed models for repeated measures (SAS, PROC MIXED) 
were used to test the treatment effects. ‘Treatment’ and ‘period’ were set as fixed effects 
and ‘subject’ as random effect. Compound symmetry was used as covariant structure as 
this resulted in the best fit according to a likelihood ratio test. Treatment effects were 
expressed as least squares mean with 95% confidence intervals (95% CI). Statistical 
significance was set at a two-sided α-level of 0.05. Bioavailability was calculated as the area 
under the curve (AUC) for total (epi)catechin metabolites over the 8-hour period, and was 
calculated according to the trapezoidal rule.
RESULTS
Study Population
The mean age of the 20 randomised men who all completed the study was 61.8 ± 9.3 years. 
The mean baseline BMI was 25.1 ± 2.1 kg/m² and the mean SBP/DBP was 121/74 mm Hg 
(Table 2). Body weight remained stable throughout the study period and subjects did not 
report adverse events. 
Vascular Function
The change in FMD was not different between dark chocolate and pure epicatechin (∆ 0.21%; 
p=0.65). Pure epicatechin supplementation increased FMD by 0.75% (95% CI: -0.18,1.69; 
p=0.10) when compared to placebo, but the effect was not statistically significant. Dark 
chocolate significantly increased FMD by 0.96% (95% CI: 0.02-1.90; p=0.04) when compared 
to placebo (Table 3). 
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TABLE 2. Baseline characteristics of 20 subjects randomised at the start of the study.
Mean ± SD
Age (yrs) 61.8 ± 9.3
BMI (kg/m²) 25.1 ± 2.1
Office SBP (mmHg) 121.5 ± 15.1
Office DBP (mmHg) 74.0 ± 6.3
FMD (%) 3.0 ± 1.6
AIx (%) 19.3 ± 11.9
Nitric oxide (nmol/L) 79.0 ± 23.2
Endothelin-1 (pg/ml) 1.46 ± 0.30
Data are given as mean ± SD. 
Abbreviations: AIx, augmentation index corrected for heart rate of 75 bpm; BMI, body mass index, DBP, 
diastolic blood pressure; FMD, flow-mediated dilation; SBP, systolic blood pressure. 
TABLE 3. Treatment effects of pure epicatechin (100mg) and dark chocolate (150mg epicatechin) sup-
plementation on markers of vascular function in healthy subjects.
Pure epicatechin (n=20) Dark chocolate (n=20) Difference†
Treatment effect*
(95% CI)
p- 
value
Treatment effect* 
(95% CI)
p- 
value
Difference       
(95% CI)
p- 
value
FMD (%)‡ 0.75 (-0.18, 
1.69) 
0.10 0.96 (0.02, 
1.90)
0.04 0.21 (-0.72, 
1.13)
0.65
Pulse Wave Analysis‡
AIx (%) -2.2 (-5.9, 1.5) 0.23 -4.6 (-8.2, -0.9) 0.02 -2.4 (-6.1, 1.3) 0.20
SEVR (%) -0.4 (-9.7, 8.8) 0.92 -1.5 (-10.8, 7.8) 0.74 -1.1 (-10.4, 8.2) 0.81
Ejection duration 
(ms)
5.2 (-8.9, 19.3) 0.46 5.5 (-8.6, 19.6) 0.43 0.4 (-12.7, 
13.4)
0.96
Systolic BP (mmHg) 1.3 (-3.6, 6.2) 0.84 -0.5 (-5.4, 4.4) 0.60 -1.8 (-6.7, 3.1) 0.47
Diastolic BP (mmHg) 0.3 (-2.8, 3.5) 0.94 0.1 (-3.0, 3.3) 0.82 -0.2 (-3.4, 2.9) 0.88
Nitric oxide (nmol/L) -8.7 (-21.7, 4.3) 0.18 18.1 (5.1, 31.1) 0.008 26.8 (13.8, 39.7) <0.001
Endothelin-1 (pg/ml) 0.07 (-0.14, 0.29) 0.50 0.45 (0.24, 0.67) <0.001 0.38 (0.16, 0.60) 0.001
* Treatment effect , Δintervention – Δplacebo = (value parameter at end treatment – value at start treatment) – 
(value parameter at end placebo – value at start placebo)
† Difference in treatment effect between dark chocolate and pure epicatechin (∆chocolate - ∆epicatechin).
‡ Absolute difference.
Abbreviations: AIx, augmentation index corrected for a heart rate of 75 bpm; DBP, diastolic blood 
pressure; FMD, Flow-mediated dilation; BP, blood pressure; SEVR = subendocardial viability ratio.
Data are least square means (95% CI) from linear mixed model for repeated measures with compound 
symmetry as covariant structure.
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The change in AIx was not different between dark chocolate and pure epicatechin (∆-2.4%; 
p=0.20). Pure epicatechin lowered AIx by 2.2% (95% CI: -5.9, 1.5; p=0.23), but the effect was 
not statistically significant. Dark chocolate lowered AIx by 4.6% (95% CI: -8.2,-0.9; p<0.05) 
when compared to placebo. Ejection duration and SEVR did not change following either 
pure epicatechin or dark chocolate supplementation. 
The increase in plasma NO was higher after dark chocolate than after pure epicatechin 
(∆26.8 nmol/L; p<0.001). Pure epicatechin did not change plasma NO levels when 
compared to placebo. Dark chocolate increased plasma NO when compared to placebo 
(∆ 18.1 nmol/L; 95% CI: 5.1,31.1; p<0.01). The increase in plasma endothelin-1 was higher 
after dark chocolate than after pure epicatechin (∆ 0.38 pg/ml; p=0.001). Pure epicatechin 
had no effect on endothelin-1, however, dark chocolate increased endothelin-1 by 0.45 pg/
ml (95% CI: 0.24,0.67; p<0.01) compared to placebo. 
FIGURE 2. Time course of plasma (epi)catechin metabolite concentrations following consumption of 
1) 70g dark chocolate (150 mg epicatechin) + 2 placebo capsules); 2) pure epicatechin (100mg) in 2 
capsules + 75g of white chocolate) and; 3) placebo (75g of white chocolate + 2 placebo capsules). Data 
are mean ± SEM.
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Bioavailability
Both epicatechin and dark chocolate increased (epi)catechin metabolite concentrations, 
with a peak seen after 2 hours (Figure 2). The placebo intervention did not increase (epi)
catechin metabolite concentrations at any time point (total AUC = 0.03 µM.h). After pure 
epicatechin supplementation the AUC  was 18.9 µM.h, and higher after dark chocolate 
consumption: 24.4 µM.h. This difference was statistically significant (p=0.03). Taking 
into account the difference in epicatechin dosage between the dark chocolate and the 
epicatechin supplement, the AUC after dark chocolate was 16.2 µM.h, per 100 mg of 
epicatechin. This was not significantly lower than the AUC for pure epicatechin of 18. 9 
µM.h  (∆2.8 µM.h ; p=0.14).
DISCUSSION
In this acute study of 20 healthy adult men, the increase of FMD after pure epicatechin and 
dark chocolate was similar, but not statistically significant for pure epicatechin. In contrast 
to dark chocolate, pure epicatechin did not significantly affect  AIx, NO, or endothelin-1. 
The bioavailability of pure epicatechin and epicatechin from chocolate was similar.
Pure epicatechin increased FMD and decreased AIx, however, in both cases the effect 
was not significant. In contrast, dark chocolate increased FMD and decreased AIx. There 
was no significant difference, however, between the effects of pure epicatechin and dark 
chocolate on FMD and AIx. The increase in FMD of 0.96% (absolute) after dark chocolate 
consumption is lower than the increase of 3.2% (95% CI: 2.04, 4.33) reported in a meta-
analysis of acute cocoa RCTs which used similar dosages of about 100 mg of epicatechin 
[3]. Our study population was, on average, older than the majority of study populations 
included in the meta-analysis. Because FMD is known to decrease with age [19], this could 
have influenced the results of our study. Whether age also plays a role in the improvement 
of FMD has not been sufficiently studied. Recently, Heiss et al. showed, however, that 
improvements in FMD (absolute) were similar in young and elderly healthy men [20]. 
Besides FMD, dark chocolate also decreased Aix by 4.6%, which is in line with previous 
acute RCTs which showed decreases of 5% 4 and 7.8% [5].
The fact that dark chocolate significantly improved FMD and AIx while pure epicatechin 
did not, could be explained by differences in dosage. The chocolate used in the present 
study had a certified minimum flavan-3-ol content of 1%.  The content of epicatechin 
was not, however, specified. In a previous study, this chocolate had a reported content 
of 96-119 mg of epicatechin [4]. When designing the trial we, therefore, decided to use 
this chocolate. Unfortunately, after chemical analysis, we found that the batch used in our 
study had a higher epicatechin content (150 mg), and thus the comparison between the 
chocolate and the pure epicatechin was less well-balanced concerning dosage. Possibly the 
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100mg in the epicatechin supplements was not high enough to elicit significant changes 
in vascular function. Standardised for the epicatechin content of the dark chocolate, 
there was no significant difference in the AUC for (epi)catechin metabolites between pure 
epicatechin and dark chocolate. Besides (-)-epicatechin, the dark chocolate also contained 
(+)-catechin. Because metabolites of (+)-catechin and (-)-epicatechin cannot be separated 
in the chromatographic system, both (-)-epicatechin and (+)-catechin are likely to have 
contributed to the (epi)catechin metabolites of the AUC. A study in rats showed that the 
bioavailability of (+)-catechin is approximately 40% lower than that of (-)-epicatechin [9]. 
Nevertheless,  (+)-catechin will also have contributed to the AUC of dark chocolate. This 
suggests that epicatechin from dark chocolate is less bioavailable than pure epicatechin, 
and dismisses a bioavailability issue of the pure epicatechin supplement. 
To match for the energy and fat content of the dark chocolate, which otherwise would 
have affected vascular function [21, 22], we used white chocolate during the epicatechin 
and placebo interventions. This introduced imbalance in other nutrients and bioactive 
compounds. The higher sugar content of the white chocolate (42g vs. 19g) may have 
suppressed the effects of pure epicatechin on FMD, as a previous study showed that sugar 
consumption (≤75g glucose) reduced FMD acutely [22]. The effects of theobromine (which 
is present in dark chocolate) on FMD and AIx are unknown [12]. Besides theobromine, 
the dark chocolate also contained 114mg of Mg - almost one half of the recommended 
daily allowance of 300mg/day for male adults. The white chocolate only contained a minor 
quantity of Mg. To our knowledge, acute effects of Mg have not been studied. Previous 
RCTs reported that chronic supplementation of about 350 mg of Mg increased FMD by 
5.1% [23] and 11.1% [24] in cardiometabolic patients, but not in a healthy population [25]. 
It is possible, therefore, that sugar and Mg could play a role in the effects of chocolate on 
endothelial function.  
The improvements in vascular function are thought to be mediated through changes 
in vasoactive compounds such as NO (vasodilator) and endothelin-1 (vasoconstrictor). 
Results from RCTs showed that cocoa consumption increased NO acutely [10, 26]. In our 
acute study, dark chocolate also increased NO, which confirms the established beneficial 
effects of dark chocolate on vascular function. A recent study showed that cocoa flavan-3-
ols dose-dependently decreased endothelin-1 production in healthy volunteers6. To our 
knowledge, our study is the first to show an increase in endothelin-1 after dark chocolate 
consumption, which could be a chance finding. Previously, Loke et al. showed that 
acute consumption of 200mg of epicatechin dissolved in water increased plasma nitrite 
concentrations and decreased plasma endothelin-1 [11].  In our study, pure epicatechin 
supplementation had no effect on NO or endothelin-1. This again suggests that a higher 
dosage may be required to elicit changes in NO and endothelin-1. Thus, dose-response 
relations should be studied.  
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To conclude, there was no difference in FMD or AIx between pure epicatechin and dark 
chocolate. The bioavailability of epicatechin did not differ between pure epicatechin  dark 
chocolate. This suggests that epicatechin may contribute to the vascular effects of cocoa.
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Cocoa and tea intake are associated with a lower risk of cardiovascular disease (CVD) [1, 
2]. This may be due to the high intake of flavonoids from cocoa and tea. In this thesis, the 
effects of epicatechin (the main flavan-3-ol in cocoa, but also substantially present in tea) 
and quercetin (the main flavonol in tea) on cardiovascular health were investigated. This 
was done by means of an epidemiological analysis, randomised-controlled trials (RCTs) in 
humans, and gene expression analyses. 
The association between epicatechin intake and CVD mortality was studied using data 
from the Zutphen Elderly Study, a cohort of elderly Dutch men who were followed for a 
period of 25-years. Men in the highest tertile of epicatechin intake had a 38% lower risk 
of coronary heart disease (CHD) mortality compared to men in the lowest tertile. For men 
with prevalent CVD, the risk of CVD mortality was 46% lower for men in the highest tertile 
of intake, compared to men in the lowest tertile. 
In a chronic randomised-controlled trial (RCT) we showed that 4-week supplementation 
of pure epicatechin improved insulin resistance, sE-selectin (a biomarker of endothelial 
function), and had a borderline significant effect on endothelial function. Epicatechin 
did not improve blood pressure, arterial stiffness or biomarkers of inflammation. Pure 
quercetin supplementation (4 weeks) did not improve endothelial function, blood pressure 
or insulin resistance but did improve IL-1β (a biomarker of inflammation) and sE-selectin. 
To investigate the effects of epicatechin on gene expression, we carried out whole genome 
analyses of peripheral blood mononuclear cells which were collected in the chronic RCT. 
Expression of 465 genes changed significantly between the epicatechin and the placebo 
intervention. Epicatechin down-regulated gene sets involved in inflammation. Only 
a few genes within these regulated gene sets were actually significantly changed upon 
epicatechin supplementation. Upstream regulators that were inhibited were classified as 
cytokine or inflammatory-type molecules.
In an acute RCT, we showed that there was no difference in response of endothelial function 
(FMD and AIx) between epicatechin (100 mg) and dark chocolate (150 mg epicatechin). 
Only dark chocolate significantly improved FMD and AIx. The bioavailability of epicatechin 
did not differ between the supplement of pure epicatechin and the dark chocolate. 
These results will be interpreted and methodological issues will be considered. Lastly, 
the main findings from the studies will be integrated so that a final conclusion about the 
cardioprotective effects of epicatechin and quercetin can be made. 
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INTERPTREATION OF MAIN FINDINGS
Epicatechin, quercetin and cardiovascular disease mortality
To investigate the association between epicatechin intake and CVD mortality, we conduc-
ted a prospective cohort analysis. In the Zutphen Elderly Study we found that the risk of 
CHD mortality was inversely associated with epicatechin intake. Elderly men who consumed 
more than 18 mg/d of epicatechin had 38% lower risk of CHD mortality compared to 
men who consumed less than 11 mg/d (Chapter 2). Higher epicatechin intake was also 
associated with a 46% lower risk of CVD mortality in men with prevalent CVD. 
The association of quercetin intake with CHD mortality has already been studied in a 
number of prospective cohort studies, and the results were inconclusive. In the Finnish 
Mobile Clinic Health Examination Survey, subjects in the highest quartile of quercetin 
intake had a 21% lower risk of CHD mortality compared to the lowest quartile [3]. In 
two other cohort studies quercetin intake was also associated with a lower risk of CHD 
mortality, however, the associations were not statistically significant [4, 5]. In the Health 
Professionals Follow-up Study, quercetin intake was not associated with nonfatal CHD [6]. 
In Europe in general, tea contributes more than 20% of quercetin intake [7]. In the Zutphen 
Elderly Study, tea contributed 50% of epicatechin intake (Chapter 2). As a result, strong 
correlations between epicatechin, quercetin and tea intake will be present. This makes 
it difficult to separate the effects of epicatechin and quercetin from those of tea. For 
this reason, RCTs are critical for unravelling the roles of epicatechin and quercetin in the 
aetiology of CVD. 
Chronic effects of pure epicatechin and quercetin on markers of cardiometabolic 
health
To establish a cause-effect relationship of epicatechin and quercetin with CVD risk, two RCTs 
were carried out. In the first RCT, the daily consumption of pure epicatechin (100mg) for 
4 weeks improved flow mediated dilation (FMD) by 1.1% (95% CI: -0.1, 2.3; p=0.07) in (pre)
hypertensive adults, when compared to placebo. The effect was, however, only borderline 
statistically significant, but was supported by the effect of pure epicatechin on sE-selectin, 
a biomarker of endothelial function. To our knowledge, this is the first human RCT to 
investigate the chronic effects of pure epicatechin on FMD, using an upper dietary dose 
of 100 mg. A meta-analysis of cocoa RCTs reported that the chronic daily consumption of 
epicatechin-rich cocoa (46 - 203 mg epicatechin) improved FMD by 1.3% [8]. This suggests 
that the magnitude of the effect of pure epicatechin in our study was comparable with that 
of epicatechin-rich cocoa. 
In our RCT, epicatechin did not change arterial stiffness, which was assessed by measuring 
the augmentation index (AIx) and pulse wave velocity (PWV). No previous RCTs have 
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investigated the effects of pure epicatechin on AIx or PWV, and results from chronic cocoa 
RCTs are limited. One trial reported that consuming a cocoa drink (25 mg epicatechin) 
for 3 weeks had no effect on AIx and increased PWV [9]. In contrast, however, Grassi et 
al. reported that cocoa dose-dependently (42-168 mg epicatechin) decreased PWV when 
consumed for 1 week [10]. 
Vascular function markers such as arterial stiffness and FMD are indicators of the proper 
functioning of blood vessels, and both are closely linked to blood pressure [11-14]. In our 
trial, pure epicatechin did not significantly lower 24-hour blood pressure, which is consistent 
with the fact that pure epicatechin did not change arterial stiffness, NO (vasodilator) or 
endothelin-1 (vasoconstrictor). This is, however, in contrast to results from cocoa RCTs. 
A meta-analysis of 13 RCTs showed that cocoa/chocolate consumption decreased blood 
pressure [15]. Other chronic RCTs reported that cocoa/chocolate increased NO [16, 17], 
and decreased endothelin-1 [10]. Of the cocoa RCTs which reported the epicatechin 
content of the cocoa/chocolate used, most had an epicatechin content between 46 and 
107 mg/d [18-21]. This suggests that the dose of epicatechin used in our RCT (100 mg/d) 
probably was sufficient. An alternative explanation could be that the bioavailability of pure 
epicatechin is less than that of epicatechin from cocoa/chocolate. However, this was not 
evident when we compared the bioavailability of the pure epicatechin in the capsules 
and the epicatechin from dark chocolate (Chapter 6). Possibly other flavan-3-ols or other 
bioactive compounds in cocoa also contribute to the vascular effects of cocoa. As will 
be discussed in more detail later on, cocoa contains many more flavan-3-ols, especially 
oligomeric flavan-3-ol. Oligomeric flavan-3-ols cannot be absorbed from the cocoa as 
such, but first have to be converted into smaller molecules by the microbiota of the colon. 
A potentially interesting group of colonic metabolites are the valerolactons [22], which 
inhibited angiotensin 1-converting enzyme (ACE) and reduced blood pressure in rats [23].
Results from our trial did show that pure epicatechin improved insulin resistance, 
as measured by the homeostatic model assessment of insulin resistance (HOMA-IR). 
This is in line with a meta-analysis of cocoa RCTs which found that chronic cocoa con-
sumption improved HOMA-IR [8]. With the exception of a positive effect on sE-selectin, 
pure epicatechin did not significantly change other biomarkers of endothelial function 
or inflammation. 
Pure quercetin supplementation did not affect FMD, blood pressure, arterial stiffness, 
insulin resistance, NO or endothelin-1. Previous chronic RCTs have reported that pure 
quercetin improved blood pressure [24-27], however, these RCTs have used very high 
doses (150-730 mg aglycone/d) of quercetin. If a dose-response relationship exists, then 
possibly the dose used in our study (100 mg aglycone/d) was not high enough to elicit 
significant changes in blood pressure and other markers of cardiometabolic health. In 
our study, we chose to use quercetin-3-glucoside because of its superior bioavailability in 
Processed on: 9-6-2016
503508-L-bw-Dower
131
 
7General di
sc
us
si
on
comparison to quercetin aglycone [28]. It is unlikely, therefore, that poor bioavailability of 
the supplement is an explanation for the lack of an effect seen in our trial.
Pure quercetin did significantly lower sE-selectin and IL-1β (a biomarker of inflammation) 
when compared to placebo. The few published tea trials on inflammation or endothelial 
dysfunction markers have reported inconclusive results. One RCT reported that consuming 
4 cups/day of black tea for 6 weeks decreased plasma CRP [29], while other trials reported 
that consuming tea (polyphenols) for 4 weeks had no effect on biomarkers of inflammation 
[30] or endothelial dysfunction [31].
Chronic effects of pure epicatechin on gene expression
Advances in technologies and reductions in costs have made gene expression analyses 
more feasible. Although often labour intensive and statistically complex, a comprehensive 
nutrigenomics approach may be useful in defining more subtle intervention-related changes 
in cardiometabolic health [32]. In our chronic RCT, pure epicatechin supplementation for 
4-weeks down-regulated gene sets involved in inflammation in circulating immune cells 
(Chapter 5). NF-κB was identified as a possible upstream regulator to be inhibited upon 
epicatechin supplementation. In a previous RCT, cocoa powder significantly decreased 
NF-κB activation compared to baseline [33]. Similarly, pure epicatechin supplementation 
prevented diet-induced activation of NF- κB in ApoE*3-Leiden mice fed an atherogenic diet 
[34]. Also the inflammatory gene clusters IL8 –CXCR1/2 pathways and AMB2_neutrophil 
pathway were down-regulated upon epicatechin supplementation. 
It has also been suggested that flavonoids may exert cardioprotective effects by increasing 
NO bioavailability through the regulation of oxidative damage via the transcription factor 
Nrf2 [35]. This was not, however, evident in our analysis of PBMC whole gene expression. 
Taken together, the effects of pure epicatechin on gene expression were modest compared 
to other nutritional interventions such as fatty acids. Previous analyses suggested that the 
effects of isoflavones on whole-genome wide expression are more pronounced in adipose 
tissue [36] than in PBMCs [37]. Possibly PBMCs are less adequate for investigating the 
effects of epicatechin on cardiometabolic health compared to other cell types such as 
endothelial cells and adipose tissue [38]. 
Acute effects of pure epicatechin compared to chocolate 
Because of the consistent vascular effects of cocoa in RCTs and the modest effects of pure 
epicatechin found in our trial, we directly compared the effects of pure epicatechin and 
dark chocolate on vascular function in an acute RCT. There was no statistically significant 
difference in FMD or arterial stiffness between pure epicatechin and dark chocolate. 
Compared to placebo (white chocolate), pure epicatechin supplementation (in capsule 
form) did not significantly change FMD, arterial stiffness (AIx) and nitric oxide (NO), 
whereas dark chocolate did have a beneficial effect. To rule out differences in bioavailability 
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between epicatechin in the chocolate and the epicatechin supplement, we measured 
plasma (epi)catechin metabolite concentrations over a period of 8 hours. Unexpectedly, 
the dark chocolate used in this study contained more epicatechin than in the capsules 
(150mg vs. 100mg). After adjustment for the difference in epicatechin content, there was 
no statistically significant difference between the bioavailability of epicatechin from dark 
chocolate and the pure epicatechin in the capsules. Possibly the dose of epicatechin in the 
capsules was not high enough to elicit significant changes in vascular function. 
Conclusions of the main findings
Combining our results from the epidemiological analysis as well as from the RCTs and gene 
expression analyses, it appears that epicatechin contributes to the cardioprotective effects 
of cocoa and tea. Epicatechin intake was associated with a 38% lower risk of CHD mortality 
in elderly Dutch men and with a 46% lower risk of CVD mortality in men with prevalent 
CVD. Results from the chronic RCT using pure epicatechin pointed towards improvements 
in insulin resistance and endothelial function. However, the effects of pure epicatechin 
on PBMC gene expression profiles were modest, with only a few changes seen in genes 
related to inflammation. The acute effects of pure epicatechin (100 mg/d) were also less 
pronounced than the effects of cocoa (150 mg/d epicatechin), suggesting that the dose 
may play an important role in the cardioprotective effects of epicatechin. Quercetin, on the 
other hand, does not appear to contribute to the cardioprotective effects of tea. Results 
from the chronic RCT showed that pure quercetin did not beneficially affect markers of 
endothelial function, or insulin resistance but may have a minor effect on inflammation. 
METHODOLOGICAL CONSIDERATIONS
Assessment of the intake of flavonoids
Accurate dietary assessment is critical in nutritional epidemiology. A major strength of 
the Zutphen Elderly Study is the use of a cross check dietary history method as a dietary 
assessment tool. This method assesses the habitual dietary intake and has been shown 
to be a reproducible and valid dietary assessment tool [39]. It should be noted, however, 
that no dietary assessment tool currently exists that has been validated to assess the 
intake of flavonoids. For this reason, we cannot exclude the possibility of misclassification 
of epicatechin intake which could influence the results. Ideally, future studies should aim 
to validate tools for assessing the intake of flavonoids, however, this does pose a great 
challenge. 
Firstly, it is important to note that the reported flavonoid content of foods can vary between 
studies due to the use of different flavonoid databases. For example, two commonly 
used flavonoid databases are the USDA Database [40] and the PhenolExplorer Database 
[41]. The average (-)-epicatechin content of black tea is 2.13 mg/100mL according to the 
Processed on: 9-6-2016
503508-L-bw-Dower
133
 
7General di
sc
us
si
on
USDA database, compared to 3.94 mg/100mL according to the PhenolExplorer database. 
These differences reflect variation in tea cultivars, growth conditions (climate and soil), 
crop management (irrigation, fertilisation, pest management), post-harvest handling, 
storage, and preparation of the tea infusion, and to a lesser extent also differences in 
analytical methods . With the exception of flavan-3-ols, it is also important to realise that 
PhenolExplorer reports flavonoids as the original glycosides present in the foods, whereas 
USDA only reports aglycone values. A failure to recognise this, may lead to different and 
incomparable flavonoid intakes. This means that when assessing flavonoid intake, it is 
important to use the flavonoid contents of foods consumed in the local area whenever 
possible. In our cohort study we used data of foods sampled in the Netherlands from at 
least three selling locations or three major brands, which were combined per product to a 
composite reflecting sales [42]. For example, the flavonoid content of black tea used in our 
studies was based on a weighted average of the most common brands of tea consumed 
in the Netherlands.
Ideally, dietary assessment methods should be validated against objective biomarkers. 
Analysing flavonoid concentrations in body fluids like plasma and urine is a complex 
process since most flavonoids are metabolised into glucuronides, sulfates, and O-methyl 
sulfates, resulting in a variety of circulating metabolites. For this reason, valid biomarkers 
do not currently exist for assessing flavonoid intake. Moreover, flavonoids are rapidly 
excreted after ingestion, which results in highly fluctuating plasma concentrations that 
only postprandially relate to intake. Measuring 24-h urine samples would be the best 
choice, but these kind of samples are often not available in cohort studies. For this reason, 
using biomarkers to validate the intake of individual flavonoids is currently unfeasible. The 
best available measure of validity for flavonoid intake is to determine the reproducibility 
of repeated measurements. In the Zutphen Elderly Study we used repeated assessments 
of epicatechin intake and the 5-year repeated estimate of epicatechin intake was strongly 
correlated (r=0.59). This suggests that the method used to determine epicatechin intake was 
reproducible. Advances in metabolomics may, however, offer new validation opportunities 
in the future [43].
Residual confounding in cohort studies
Another important point to consider in cohort studies is the possibility of residual con-
founding. Residual confounding is a result of inadequate adjustment for confounders, 
which can lead to distortion of the observed association between an exposure and 
outcome. Adequate adjustment for confounders is especially important in nutritional 
research since (un)healthy habits tend to correlate. For example, smokers generally have 
a lower intake of β-carotene which is a marker of fruit and vegetable consumption [44]. 
Also, sedentary behaviour is associated with a less healthy diet [45]. In our cohort studies, 
subjects with a higher epicatechin intake also had a higher intake of protein, calcium and 
fibre and were generally more physically active and less likely to smoke. To minimise the 
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potential confounding of other dietary components or lifestyle factors on the outcome, it 
is important to adjust for these potential confounders. Although we adjusted for a wide 
range of potential confounders, we cannot exclude the possibility of residual confounding 
– either due to missing confounders or due to measurement error of the confoun- 
ders included. 
Epicatechin and other dietary components in cohort studies
In the Zutphen Elderly Study, the main dietary source of epicatechin was tea, followed by 
apples and cocoa. Tea contributed 50% of epicatechin intake and hence there was a high 
correlation between tea consumption and total epicatechin intake. This makes it difficult 
to separate the effects of epicatechin from that of tea. Besides epicatechin, tea contains a 
wide range of other compounds including other flavonoids as well as theaflavins, caffeine 
and potassium. Hence, we cannot exclude the possibility that compounds in tea other 
than epicatechin also contribute to the cardioprotective effects of tea, and that epicatechin 
intake acts as a surrogate marker of tea intake.
Relevance of cardiometabolic markers
Effects of dietary interventions on cardiometabolic health should ideally be assessed 
by means of an RCT using clinical endpoints such as CVD morbidity and/or mortality. 
However, due to the large sample sizes and long durations required, such interventions 
would be prohibitively expensive. Therefore, surrogate markers of cardiometabolic health 
have to be used.
In both RCTs that we conducted, the primary outcome was the change in FMD – which is 
considered the best available measure of endothelial function [46]. Studies showed that 
FMD is reduced in subjects with CVD risk factors and that FMD acts as an independent 
predictor of CVD events - every 1% increase in FMD is associated with an 8-13% lower risk 
of future CVD events [47, 48]. It has also been suggested that the prognostic value of FMD 
is stronger in patients with established CVD and more modest in asymptomatic subjects 
[49]. 
It is important to note that FMD is a sensitive measurement which can be influenced 
by minor changes in methodology (Chapter 3, supplemental material 2). For example, it 
has been shown that there is a diurnal variation in FMD, with higher values seen in the 
afternoon than in the morning [50, 51]. Also the placement of the cuff/probe (distal or 
proximal to the antecubital fossa) [52], as well as duration of cuff inflation can influence 
the magnitude of FMD [53]. Differences in ultrasound transducer could influence the 
measurement of FMD [49, 54]. In our studies we used an ultrasound transducer of 7.5 MHz 
which is in line with two commonly used guidelines which state that a minimum frequency 
of 7-7.5 MHz is required [49, 54]. As a consequence of advances in technology, however, 
transducers with a higher frequency (10-14 MHz) are now often used. Other external 
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factors such as exercise [55], caffeine consumption, and tobacco use can also influence 
the accuracy of FMD [56]. These differences could explain why studies have reported 
varying degrees of within-subject variability, between 7% and 50% [32]. In our study, we 
followed a strict protocol, adhering to two commonly used guidelines for FMD measure- 
ments [49, 54]. Nevertheless, there still often exists variation in methodology and apparatus 
between studies. 
Differences in study population could also influence the observed effects. Our study popu-
lation was fairly heterogeneous with large differences in age, BMI, and blood pressure. 
Nevertheless, the effects of cocoa consumption on FMD have been reported in studies 
with similar populations, even when using smaller sample sizes. For example, Grassi et al. 
showed that cocoa dose-dependently improved FMD in only 20 participants aged 18-70, 
with a BMI between 19 and 30 kg/m² [10]. Similar results were obtained by Davison et al. 
with 16 participants [57]. The aforementioned differences in methodology and differences 
in study population could, however, partly explain the variation in FMD response between 
cocoa RCTs, with studies reporting a change in FMD of between 0.4 and 7.1% (absolute) 
after acute cocoa consumption [8]. Indeed, in our study, FMD increased by 1.0% after acute 
cocoa consumption, which is lower than the 3.2% reported in a meta-analysis of acute 
cocoa RCTs [8]. For this reason, caution should be taken when comparing the magnitude 
of effect sizes of FMD between studies. 
Besides FMD, we also measured blood pressure, arterial stiffness and a comprehensive 
set of biomarkers for endothelial function and inflammation. The measurement of 24-hour 
blood pressure was a major strength of our study (Chapter 3) as 24-hour blood pressure 
has been shown to hold a greater prognostic value than office blood pressure [58]. In 
our study, we did not see an effect of epicatechin or quercetin supplementation on 24-
hour blood pressure. Epicatechin supplementation did reduce 24-hour SBP by 2.4 mmHg 
and DBP by 1.5 mmHg, however, the effects were not statistically significant. Based on a 
power calculation to detect a change in the primary outcome (FMD) of 1.5%, we included 
37 subjects in the study. To detect a significant change in SBP of 3 mmHg we would have 
needed to include 88 subjects. In addition, the mean baseline SBP of the 37 subjects 
included in the study was 129 mmHg which may have been too low to warrant a significant 
decrease in blood pressure. 
Advances in computer technology have made it possible to quickly and accurately measure 
arterial stiffness in a non-invasive manner. In our studies, we measured pulse wave velocity 
(PWV) and augmentation index (AIx), two separate methods for measuring arterial stiffness. 
Despite the fact that blood pressure and arterial stiffness are closely linked, indices of 
arterial stiffness do have additional predictive value [59]. Cohort studies showed that 
PWV is a strong predictor of future CVD events – every 1m/s increase in PWV is associated 
with a 14% higher risk of CVD mortality [60]. Likewise, a 10% (absolute) increase in central 
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AIx is associated with a 32% higher risk of cardiovascular events [61]. Importantly, these 
measurements can be considered diet-sensitive markers of arterial stiffness as studies 
have shown that nutritional interventions using omega-3 fatty acids and soy isoflavone 
supplements are able to improve both PWV and AIx [62]. 
The duration of a study may play an important role in the effect of a dietary intervention 
on arterial stiffness. It is thought that PWV may represent more long-term changes in 
vascular function. In contrast, studies have shown that cocoa intake improves AIx acutely 
by approximately 5% [63, 64], which we confirmed for chocolate in our acute intervention 
study (Chapter 6). It has been suggested that acute changes in arterial stiffness are likely 
to be a result of changes in functional mechanisms that regulate arterial stiffness, such as 
changes in the bioavailability of NO or reductions in inflammation [62]. 
In chapter 4 we investigated the effects of pure epicatechin and quercetin on a compre-
hensive set of biomarkers of endothelial dysfunction and inflammation. The assessment 
of these biomarkers can be useful in nutritional research as they are relatively easily 
accessible and are closely associated with CVD [65-68]. Based on pre-defined clusters 
we calculated Z-scores for markers of endothelial dysfunction and inflammation. We 
found that epicatechin had a borderline significant effect on the z-score for endothelial 
dysfunction. The calculation of a z-score can be useful for calculating the effects on a group 
of biomarkers, however, the assumption that all biomarkers carry the same weight may 
not be valid. As such, we consider the calculation of the z-scores a useful indication but 
are apprehensive about drawing firm conclusions about the effects of pure flavonoids on 
endothelial dysfunction and inflammation based on the z-scores. 
In Chapter 3, we found that epicatechin supplementation improved fasting insulin and 
insulin resistance. This is in line with the meta-analysis of Hooper et al. which showed 
that flavonoid-rich cocoa improved insulin resistance [8]. However, based on results of 
the gene expression analysis, there was no apparent effect of epicatechin on mechanisms 
involved in insulin resistance. Since PBMCs are immune cells, they may not be the optimal 
cell-type for investigating changes in gene expression profiles related to insulin signalling. 
Other metabolically active tissues such as adipose or muscle tissue, or endothelial cells 
may be more relevant. We cannot, however, exclude the possibility that the effect of 
epicatechin supplementation on insulin resistance was a chance finding. It should also 
be noted that the measurement of insulin resistance based on fasting glucose and insulin 
concentrations is an indirect measure of insulin resistance and may not optimally reflect 
glucose and insulin metabolism. To get a more accurate view, future studies should look to 
investigate the effects of pure epicatechin on more direct markers of glucose and insulin 
metabolism such as a hyperglycemic clamp. 
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Cocoa flavan-3-ol bioavailability, and potential additional bioactive compounds  
of cocoa
Cocoa contains many flavan-3-ols including monomers such as epicatechin and catechin, 
as well as oligomers called procyanidins. As an example, a cocoa extract used in an 
intervention study contained 64 mg of epicatechin, 7 mg of catechin and 377 mg of 
procyanidins [69]. In this thesis, we chose epicatechin as a flavan-3-ol of interest due to its 
high natural occurrence in cocoa, its relatively high bioavailability as a monomer as opposed 
to procyanidins, and its relatively high bioactivity (see Chapter 1). Ottaviani et al. showed 
that the vasodilatory effect of (-)-epicatechin was 5 times higher than that of (+)-catechin 
in rats [70]. In the same study, they showed that the bioavailability of epicatechin was 
approximately 25% higher than that of catechin [70]. Another rat study showed that the 
bioavailability of a procyanidin dimer tested was only 1% that of epicatechin, whereas 
trimers were not absorbed [71]. This shows that direct effects of procyanidins on vascular 
function can be neglected. Although minor, we cannot, however, completely exclude the 
possibility that catechin contributes to the cardioprotective effects of cocoa. 
Besides flavan-3-ols, cocoa also contains a number of other bioactive compounds such 
as magnesium and theobromine. Effects of magnesium on vascular function are unclear 
with two RCTs reporting that magnesium improved FMD [72, 73], and another reporting 
no change [74]. Theobromine could contribute to the cardioprotective effects of cocoa by 
reducing arterial stiffness and central blood pressure [9]. The effects of theobromine on 
FMD are currently unknown. Future studies should establish the effects of magnesium and 
theobromine on vascular function.
In our two RCTs we provided pure epicatechin in capsule form. In reality, however, flavo-
noids are not consumed in pure form but enclosed within a food matrix. Possibly the 
bioavailability of flavonoids could be influenced by fats, sugars and protein, which raises 
questions about the bioavailability of the pure flavonoid supplements. In Chapter 6 we 
compared the bioavailability of epicatechin from dark chocolate and pure epicatechin. 
To match for energy, fat and protein we provided white chocolate with the epicatechin 
supplements. We did not observe a difference in bioavailability of epicatechin from the dark 
chocolate or the pure epicatechin supplement, when consumed in combination with white 
chocolate. This suggests that the chocolate matrix itself did not influence bioavailability.
Because we used white chocolate, we cannot exclude the possibility that the bioavailability 
of epicatechin was influenced by the sugar, fat or protein content of white chocolate. 
The effects of such nutrients on flavan-3-ol bioavailability are, however, unclear. For 
example, cocoa powder dissolved in milk had no significant effect on plasma epicatechin 
concentrations when compared to a water-based cocoa drink [75, 76]. On the other hand, 
Serafini et al. showed that consuming milk with chocolate inhibited the absorption of 
epicatechin [77]. Ideally we would have included an additional intervention arm in our 
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study with only pure epicatechin (no white chocolate), however, logistically this was not 
feasible. Future studies should consider using a sugar-free, water-based cocoa drink as 
an alternative to chocolate as this would eliminate the potential effects of sugar and fats 
which are present in chocolate.   
The effect of epicatechin dose and duration
Chronic cocoa RCTs have consistently shown improvements in blood pressure, endothelial 
function and insulin resistance after the daily consumption of cocoa typically containing 
between 46 and 107 mg of epicatechin [18-21]. In the meta-analysis of Hooper et al. cocoa 
containing >50mg/d of epicatechin resulted in the greatest improvements in systolic and 
diastolic blood pressure [8]. This is almost three times as high as the highest category of 
epicatechin intake in the epidemiological study - the highest category of intake corres-
ponded to a median epicatechin intake of approximately 20mg/d.
Besides a difference in dose, epidemiological studies and RCTs also inevitably differ in the 
duration of exposure. Most chronic cocoa RCTs lasted between 2 and 18 weeks. In contrast, 
the median follow-up time in the Zutphen Elderly Study was 10.7 years. This suggests that 
the beneficial effects of epicatechin may be achieved from relatively low levels of intake, 
which can be attained from a normal diet, when consumed over a sufficiently long period 
of time. Currently, there are no studies that systematically explored this dose-duration 
effect. Remarkably, in the cocoa RCT with the longest duration of 18 weeks, a relatively 
low habitual intake of dark chocolate (6.3g/d chocolate; 5.1mg/d epicatechin) resulted in 
significant reductions in systolic and diastolic blood pressure as well as an increase in NO 
bioavailability [17]. More long-term RCTs are required in order to investigate the effects of 
habitual intake of low levels of dark chocolate and epicatechin on cardiometabolic health.  
FINAL CONCLUSIONS AND FUTURE DIRECTIONS
In this thesis we aimed to investigate the effects of epicatechin and quercetin on cardio-
vascular health by means of epidemiological analysis, human intervention studies and 
whole genome analyses. 
In the Zutphen Elderly Study we found that a higher epicatechin intake was associated with 
a lower risk of CHD mortality in a population of elderly Dutch men, and with CVD mortality 
in men with prevalent CVD. More and larger cohort studies are required to confirm the 
association of epicatechin intake with CVD mortality, possibly with a focus on populations 
with a high risk of CVD. 
In the chronic RCT that we conducted, we found that pure epicatechin improved insulin 
resistance and sE-selectin, and had a borderline significant effect on FMD when compared 
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to placebo. This suggested that epicatechin contributes to the cardioprotective effects 
of cocoa and tea. Larger long-term RCTs are required to confirm the effects of pure 
epicatechin on insulin resistance and to further investigate the effects on endothelial 
function and inflammation. To investigate the effects of pure epicatechin on glucose 
and insulin metabolism, more established methods such as a hyperglycemic clamp are 
also needed. With the exception of sE-selectin, IL-1β and the z-score for inflammation, 
quercetin did not beneficially affect any marker of cardiometabolic health. This suggests 
that quercetin is unlikely to play a major role in the cardioprotective effects of tea but may 
help to lower inflammation. 
In the acute RCT, we found that the cardioprotective effects of dark chocolate were 
higher than that of pure epicatechin, which could be explained by differences in the 
dose of epicatechin. Alternatively, other compounds in chocolate could also contribute 
to the cardioprotective effects of dark chocolate. Future studies should look to assess the 
cardioprotective effects of other compounds in chocolate such as colonic metabolites of 
procyanidins, magnesium and theobromine. More studies are needed to compare the 
cardioprotective effects of pure epicatechin and cocoa, with a focus on the effects of dose-
response and duration of epicatechin. Future studies could also consider using a cocoa 
drink instead of chocolate, as this would exclude the effects of sugar and fat which are also 
present in chocolate. 
TABLE 1. Summary of effects of epicatechin, quercetin and dark chocolate/cocoa on cardiovascular 
mortality and cardiometabolic risk factors, based on results from this thesis.
Mortality Functional Markers Biomarkers
CVD1 CHD Stroke FMD AIx BP
HOMA-
IR
Inflam-
mation
Endothelial  
function2
Epicatechin ++ ++ ↔ + ↔ ↔ ++ ↔ +
Quercetin N/D N/D N/D ↔ ↔ ↔ ↔ + ↔
Dark Chocolate/
Cocoa
↔ ↔ ↔ ++ ++ N/D N/D N/D ++
++ Significant improvement (p<0.05)
+ Borderline improvement (0.05< p ≤0.10)
↔ No significant change (p > 0.10)
N/D Not determined
1 Epicatechin intake associated with a lower risk of CVD mortality in subjects with prevalent  CVD.
2 Endothelial function for dark chocolate/cocoa based only on nitric oxide.
Abbreviations: AIx: augmentation index; BP: blood pressure; CHD: coronary heart disease; CVD: 
cardiovascular disease; FMD: flow-mediated dilation; HOMA-IR: homeostatic model assessment of 
insulin resistance.
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To conclude, based on the results of this thesis, we can say that epicatechin contributes 
to the cardioprotective effects of cocoa and tea (Table 1). The cardioprotective effects 
of epicatechin are likely mediated through improvements in insulin resistance and 
possibly endothelial function. In contrast, quercetin is unlikely to play a major role in the 
cardioprotective effects of tea. Results from cohort studies on quercetin are inconclusive, 
and based on the results of our chronic RCT, quercetin does not appear to contribute to 
the effects of tea on vascular function or insulin resistance, but may have a beneficial 
effect on inflammation. Evidence of the role that individual flavonoids play in the aetiology 
of CVD is, however, still limited and more studies with pure flavonoids are required to 
elucidate their role. 
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Epidemiological studies showed that the consumption of flavonoid-rich foods such as 
cocoa and tea is associated with a lower risk of cardiovascular disease (CVD). Randomised 
controlled trials (RCTs) showed that cocoa and tea improved markers of cardiometabolic 
health including blood pressure, endothelial function, insulin resistance, arterial stiffness 
and inflammation. 
Cocoa is particularly rich in the flavan-3-ol epicatechin and tea is the main dietary source 
of epicatechin and of the major flavonol quercetin. However, evidence on the individual 
roles of epicatechin and quercetin in the health effects of cocoa and tea is still scarce. 
Therefore, we estimated the strength of the association between epicatechin intake and 
CVD mortality in a prospective cohort study. Furthermore, we also investigated the effects 
of epicatechin and quercetin on markers of cardiometabolic health and gene expression, 
by means of two RCTs. 
In Chapter 2, the association between epicatechin intake and CVD mortality was studied 
using data from the Zutphen Elderly Study, a cohort of 744 elderly Dutch men. During 25 
years of follow-up, 329 men died from CVD and 148 from coronary heart disease (CHD). 
Results from this study showed that men in the highest tertile of epicatechin intake had 
a 38% lower risk of CHD mortality compared to men in the lowest tertile. For men with 
prevalent CVD, the risk of CVD mortality was 46% lower for men in the highest tertile of 
intake, compared to men in the lowest tertile. This is the first epidemiological study to have 
investigated the association between epicatechin intake and CVD mortality. Hence, more 
and larger cohort studies are required to confirm this association, possibly with a focus on 
populations with a high risk of CVD.
In Chapter 3, the chronic effects of pure epicatechin and quercetin on markers of 
cardiometabolic health were investigated by means of a RCT. Thirty-seven apparently 
healthy men and women aged 40–80 years consumed (-)-epicatechin (100 mg/d), quercetin-
3-glucoside (160 mg/d), or placebo capsules for 4 weeks, in random order. Markers of 
cardiometabolic health were measured before and after each 4-week intervention. 
The results of this study showed that epicatechin improved insulin resistance and had 
a borderline significant effect on endothelial function. This suggests that epicatechin 
contributes to the cardioprotective effects of cocoa and tea, however, larger long-term 
RCTs are required to confirm these effects. Pure quercetin supplementation did not affect 
any of these markers of cardiometabolic health.
Using data from the same study, we investigated the effects of supplementation of 
pure epicatechin and quercetin on a comprehensive set of biomarkers of endothelial 
dysfunction and inflammation (Chapter 4). With the exception of sE-selectin (a biomarker 
of endothelial dysfunction), epicatechin supplementation did not beneficially influence 
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any of the biomarkers, suggesting a lack of evidence for a role of epicatechin in inflam-
mation. Quercetin also lowered sE-selectin as well as the inflammatory biomarker IL-1β 
and the overall z-score for inflammation. This suggests that quercetin may contribute to 
the cardioprotective effects of tea by reducing inflammation and possibly by improving 
endothelial function. 
In the same study, the effects of pure epicatechin supplementation on whole genome 
gene expression profiles of circulating immune cells were also assessed (Chapter 5). Pure 
epicatechin supplementation modestly reduced gene expression related to inflammation 
signalling routes in circulating immune cells – routes which are known to play a role in 
cardiovascular health. However, there was no evidence that epicatechin affected pathways 
related to insulin resistance or endothelial function.
To directly compare the acute effects of pure epicatechin and epicatechin from dark 
chocolate on vascular function, we carried out an acute RCT in 20 apparently healthy men 
aged 40-80 years (Chapter 6). On three separate occasions, subjects consumed: 1) 70g dark 
chocolate (150 mg epicatechin) with two placebo capsules; 2) two pure epicatechin capsules 
(100 mg epicatechin) with 75g white chocolate and 3) two placebo capsules with 75g white 
chocolate (0 mg epicatechin). Endothelial function and arterial stiffness were measured 
before and two hours after each intervention. To determine epicatechin bioavailability, 
epicatechin metabolites were measured in blood samples taken at repeated intervals over 
a period of 8 hours. There was no significant difference in improvement in endothelial 
function or arterial stiffness between pure epicatechin and dark chocolate. There was also 
no difference in bioavailability of pure epicatechin and epicatechin from dark chocolate, 
when standardised per 100 mg of epicatechin. This suggests that epicatechin may contri-
bute to the vascular effects of cocoa and that the bioavailability of pure epicatechin and 
epicatechin from dark chocolate is similar.
In the general discussion (Chapter 7), the main findings of this thesis were first sum-
marised. Methodological considerations related to cohort studies, such as the assess-
ment of flavonoid intake and the possibility of residual confounding were also discussed. 
Issues related to the relevance of cardiometabolic markers in RCTs and the effect of cocoa 
flavan-3-ol bioavailability were addressed. Finally, suggestions for future research were 
put forward. 
In conclusion, the results of this thesis suggest that epicatechin contributes to the car-
dioprotective effects of cocoa and tea. Epicatechin intake was inversely related to CHD 
mortality in elderly men, and to CVD mortality in men with prevalent CVD. The cardio-
protective effects of epicatechin are likely mediated through improvements in insulin 
resistance and possibly endothelial function. In contrast, quercetin is unlikely to play a 
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major role in the cardioprotective effects of tea. Results for quercetin from cohort studies 
are inconclusive, and based on the results of our chronic RCT, quercetin did not affect 
vascular function or insulin resistance, but may help to lower inflammation. Evidence of 
the role that individual flavonoids play in the aetiology of CVD is still limited. More studies 
with pure flavonoids are required to elucidate their role.
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En nu tijd voor het meest belangrijke (en waarschijnlijk meest gelezen) stuk – het dank-
woord! Want één ding is zeker, alleen was dit zeker nooit gelukt. Het is niet altijd even 
makkelijk geweest, en daarom ben ik een aantal mensen enorm dankbaar voor alle steun 
die ik de afgelopen jaren heb gekregen.
Om te beginnen, mijn promotors – Daan en Marianne. Ik zou niet weten hoeveel meetings 
we door de jaren heen hebben gehad. Soms waren dat nogal pittige bijeenkomsten, maar 
de mix van inhoudelijke discussies en leuke verhalen en anekdotes (want die waren er 
genoeg!) maakte deze meetings niet alleen leerzaam, maar ook erg plezierig. En wie had 
gedacht dat ik ooit een epidemiologisch onderzoek zou doen? Ik in ieder geval niet! Het zal 
geen verassing zijn als ik zeg dat epidemiologisch onderzoek niet mijn passie is, maar met 
jullie begeleiding ben ik er doorheen gekomen en daarvoor ben ik jullie enorm dankbaar. 
En Marianne, wat leuk dat we je sinds kort ook Professor mogen noemen en dat je 27 juni 
mijn promotor mag zijn!
Eén van de meest belangrijke personen in dit proces was natuurlijk onze flavo-expert. 
Peter, ik vond het erg fijn om met jou samen te werken, vooral omdat ik altijd met mijn 
vragen bij jou terecht kon. Je hebt er van begin af aan veel tijd en energie in gestoken en 
dat waardeer ik zeer. Ik vermoed dat het flavo-verhaal nog niet helemaal af is, maar later 
dit jaar neem je in ieder geval wel een stapje terug. Ik wens je alvast een hele fijne tijd na 
je pensionering!
Twee mensen die ik ook nog in het bijzonder wil bedanken zijn Sabita en Janette. Op ver-
schillende momenten tijdens mijn PhD-project heb ik het genoegen gehad om met jullie 
samen te mogen werken. Jullie hebben mij allebei goed geholpen met de epi-analyses en 
ik heb met plezier met jullie samen gewerkt tijdens het begeleiden van MSc-studenten. 
En Janette, je bent nog niet helemaal van me af – ik zie je over een paar maanden weer 
bij Nutricia! 
Talking about MSc-students… Morgan and Mia, thank you for all the hard work you put in 
during your thesis. Mia, I know it couldn’t have been easy put up with us (Harry, Fabian, 
Christoph and myself), especially so early in the morning. But you were always there every 
morning and I really appreciate that. I hope you’ve managed to recover from the trauma 
by now! 
Eén van de eerste dingen die ik heb geleerd tijdens mijn PhD-project was hoeveel werk het 
uitvoeren van een interventiestudie inhield. Gelukkig waren er veel mensen die hebben 
geholpen tijdens de interventiestudies. Ik ben iedereen dankbaar voor hun inzet en 
ondersteuning. Als eerste Harry en Fabian, bedankt voor alle hulp tijdens de FLAVO-1 (en 
Harry ook tijdens de FLAVO-2). Het was echt lachen om samen met jullie te werken!
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Ook iedereen van het bloedprikteam: Anita, Henriette, Jantien, Diana en Christoph, 
bedankt voor alle hulp en ook begeleiding tijdens de interventiestudies. Ik heb veel 
geleerd tijdens het uitvoeren van deze studies en dat kwam mede door jullie begelei-
ding. Daarnaast vond ik het ook een erg plezierig team om in te werken. Na het bloed- 
prikken komen natuurlijk de analyses. Dini, bedankt voor alle tijd en moeite die je hieraan 
hebt besteed! 
Een speciale plek wil ik bewaren voor alle deelnemers die hebben deelgenomen aan beide 
interventiestudies. Zonder jullie was dit allemaal niet mogelijk geweest en hiermee hebben 
jullie een belangrijke bijdrage geleverd aan dit proefschrift. 
Op 27 juni mag ik op het podium staan, in de Aula in Wageningen, om dit proefschrift 
te verdedigen. Dit zou uiteraard niet mogelijk zijn zonder de opponenten. Ilja Arts, Aalt 
Bast en Jaap Keijer - bedankt voor het lezen en beoordelen van dit manuscript en voor 
het optreden als opponent. A special word of thanks also needs to be reserved for Aiden 
Cassidy – thank you so much that you were willing to make the journey from England to 
act as opponent for my PhD-defence. 
Naast de opponenten staan er ook twee bijzondere mensen op het podium. Rob en Femke, 
wat fijn dat jullie mijn paranimfen wilden zijn. Rob, je hebt door de jaren heen aardig wat 
meegekregen van alles en je had altijd een goed luisterend oor. Meestal wel met een koud 
biertje in de hand en een voetbalwedstrijd op de achtergrond, dat helpt altijd! Het is voor 
mij een beetje afkicken geweest sinds ik in Hoorn woon, zo weinig voetbal – daar moeten 
we maar eens verandering in zien te brengen!  
En Femke, wat was je een top roomy – ik had echt niet beter kunnen wensen! Het was altijd 
gezellig op het werk en je was er ook altijd om te praten – of het nou was om bij te kletsen 
na het weekend, of om alle frustraties te uiten – het maakte niet uit. Onze werkplek was ook 
regelmatig versierd, dat is iets wat me altijd zal bijblijven. Uiteraard niet alleen als roomy 
heb je het geweldig gedaan, maar ook als voorzitter van de kamer 116-feestcommissie ;) Ik 
heb echt genoten van alle uitjes en tripjes die we gezamenlijk hebben gemaakt. 
Kamer 116 is door de jaren heen steeds iets veranderd, maar de harde kern kregen ze 
niet zomaar weg – zelfs niet toen ze een nieuw gebouw wilden bouwen ;) Lieke, Susanne, 
Eveline en Harry – samen met Femke hebben we veel mooie momenten meegemaakt en 
ik hoop dat we elkaar nog regelmatig zullen zien. Susanne onze reis door Australië, samen 
met Femke, was voor mij echt één van de hoogtepunten van mijn PhD-tijd. Lieke, mijn 
TIFN-buddy -  ik vond het erg leuk om samen met jou de interventiestudies uit te voeren en 
wie weet, misschien dat we binnenkort weer collega’s worden! Eveline, bedankt voor alle 
gezelligheid en ook alle data ;) Ik beloof je dat ik je nooit meer zal vragen om een nieuwe 
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flavo-tabel. And Harry…..what can I say….? You pikey, je was echt geweldig! Soms leek het 
voor anderen misschien een beetje chaotisch, maar je kreeg altijd alles voor elkaar. Ik heb 
echt van je geleerd dat hoe dan ook, altijd alles goed komt. Wat ik niet van je heb geleerd 
is….hoe je worcestershiresaus uitspreekt ;)
Naast de harde kern, zijn er door de jaren heen veel mensen die (tijdelijk) in kamer 116 
hebben gebivakkeerd. Jaike, Sabine, Sifra, Danielle, Rianne, Claudia, Laura - bedankt 
voor alle gezelligheid en gekkigheid in kamer 116! 
Buiten Wageningen om zijn er ook een aantal mensen die hebben bijgedragen aan het 
project. Iedereen vanuit TIFN die heeft meegeholpen aan het project – Ronald, Peter, 
Arno, Richard, Casper, Peter, Yvo en Jos bedankt voor jullie inzet en levendige discussies 
die we door de jaren heen hebben gehad. Diederik, thanks voor alle geduld met het 
uitleggen van de genexpressie data! 
Als laatste wil ik een plek reserveren voor een aantal belangrijke mensen die misschien 
niet direct betrokken waren bij het project, maar veel steun hebben geboden tijdens de 
afgelopen jaren. Mum, Dad, Steve, Myriam en Yuhwi - het was misschien niet altijd even 
duidelijk wat ik allemaal aan het doen was in Wageningen, maar het feit dat ik altijd zo een 
fijne thuisbasis had om op terug te vallen heeft me door de jaren heen enorm geholpen. 
En natuurlijk hoort de schoonfamilie daar ook bij – Martje, Johan, Jaap, Sylvia, Sanne 
en Hein bedankt voor alle interesse en betrokkenheid vanaf de zijlijn de afgelopen jaren! 
Tot slot, een paar woorden voor het homefront. Lieve Lotte, je bent echt een rots voor me 
geweest! Toen het even zwaar was, wist je me altijd op de juiste manier te steunen – soms 
met wat goedgekozen wijze woorden, soms met een echte kick-up-the-backside…. Op een 
bepaalde manier wist je altijd wat ik nodig had. Sinds kort heeft onze leven samen een 
nieuwe, spannende wending gekregen. Lotte en Sebas, ik ben zeer trots op jullie allebei 
en ik weet zeker dat we een mooie toekomst tegemoet gaan! 
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